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Crohn’s disease (CD) is a chronic disease characterized by idiopathic inflammation of the 
gastrointestinal tract. An inappropriate immune response to extracellular pathogens in the 
gut in a genetically predisposed host, e.g., NOD2/CARD15 gene-associated, is thought to be 
the cause of CD.1, 2 However, the exact etiology remains unclear. The incidence of CD has 
classically been higher in developed countries; however, urbanization and modernization of 
undeveloped countries seem to increase the incidence of CD to a similar level as the 
developed countries.3 The peak age of onset for CD is 15 – 30 years, with a second peak 
between the ages of 50 to 80.4 There is no gender specificity. A systematic review of 
population-based cohorts estimated the prevalence of CD to be 26.0 to 198.5 cases per 
100,000 persons and the incidence to be 3.1 to 14.6 cases per 100,000 persons/years in North 
America.5 In Europe the incidence of CD is 6.0 to 15.0 cases per 100,000 persons/years and 
the prevalence 50.0 to 200.0 cases per 100,000 persons.6
CD can affect any part of the intestine, from mouth to anus, but preferentially involves the 
ileum and colon. Characteristic for CD are skip lesions; inflamed parts of the intestine 
interspersed by apparent normal healthy tissue. Patients with CD can suffer from diarrhea 
(with blood or mucus), abdominal pain, fever, weight loss, nausea, vomiting and fatigue.7 
The diagnosis of CD is established by the clinical features confirmed by endoscopy. Biopsy 
specimens from inflamed gut mucosa typically show transmural inflammation, including 
submucosal oedema, ulcerations and fibrosis. 
PERIANAL FISTULAS 
Frequent manifestations of CD are the development of abscesses, stricture formation, 
intestinal obstruction, and fistulas.1-3, 7, 8 Fistulas are abnormal connective passages from the 
epithelial lining of the intestines to another organ or to the skin caused by inflammation. 
Fistulas in CD are a major problem which can result in considerable morbidity. Approximately 
35% of all CD patients have at least one fistula episode. A quarter of the fistulas is between 
two parts of intestine, 9% is rectovaginal and 13% is different, including fistulas between the 
intestine and bladder and around a stoma.9 In case of an enterovesical fistula there may be 
recurrent polymicrobial urinary tract infections, pneumaturia and fecaluria. When a 
rectovaginal fistula develops, dyspareunia, malodorous vaginal discharge and recurring 
episodes of vaginitis can occur. Perianal fistulas are the most common type of fistulas in 
fistulizing CD. The cumulative incidence of perianal fistulas was estimated at 23%-26% after 
20 years of CD.9, 10 Patients with perianal fistulas can present with symptoms such as 
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constant anal pain or pain after defecation, (painful) swelling around the anus, continuous 
(malodourous) discharge of pus and/or blood from the external opening with skin irritation 
around the anus, fever and even incontinence.11 In 20-45% of the CD patients a perianal fistula 
developed before or at the time of diagnosis CD.9, 10 Patients with colonic and active rectal 
disease have more frequently perianal fistulas compared to patients with isolated ileal or 
ileocolonic disease.9, 10, 12-14 Male gender, age at diagnosis of CD and smoking are other risk 
factors, although data are conflicting.9, 10, 13, 15-17 The formation of perianal fistulas in CD is 
based on the presence of a penetrating ulcer in the rectal or anal mucosa resulting in an 
abnormal granulating connection between the epithelial lining of the rectum or anal canal 
and the perianal skin.18, 19 However, most perianal fistulas are cryptoglandular fistulas (90%) 
and are not associated with CD. They originate from the intersphincteric anal glands due to 
a local infection with abscess formation.20 Normally the internal sphincter is a barrier for 
bacterial overgrowth, only chronic infection, CD inflammation or local trauma can cause 
abscesses beyond this barrier in the intersphincteric space. When such an abscess increases 
it will usually drain in two ways: it can either drain through the intersphincteric space 
downwards to form an intersphincteric fistula erupting into the perianal skin or it can 
overcome the external sphincteric plane into the ischiorectal fossa resulting in a 
transsphincteric perianal fistula. In CD these abscesses are often a complex delta of channels 
and patients might present with large or multiple abscesses.  
The exact etiology of perianal fistulizing CD remains unclear. However, genetic, 
microbiological and immunological factors seem to play important roles. The risk haplotype 
of the carnitine/organic cation transporter (OCTN) on the IBD5 locus (5q31) is associated with 
penetrating and perianal CD due to altered bacteria killing resulting in inflammation.21 
Furthermore, diminished clearance of intracellular pathogens by autophagy caused by a 
specific polymorphism in the immunity-related GTPase family M (IRGM) gives an increased 
risk of penetrating and perianal CD.22 It is hypothesized that microbiota also contribute to 
the development of perianal fistulas as fecal diversion leads to long-term improvement.23 
Especially gram-positive microorganisms are present in CD perianal fistulas.24  
Diagnosis of perianal fistulas 
Knowledge about the exact route and internal opening of the fistula, its relation to the 
sphincters and the presence of abscesses, is crucial in the management of perianal fistulizing 
CD. Inspection of the perianal area is the first step in this process. The fistula disease activity 
can be quantified with the Perianal Disease Activity Index (PDAI)25 and comprises five 
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perianal disease and the degree of induration (all 0 – 4 points). Pelvic magnetic resonance 
imaging (MRI; figure 1) is accurate in determining the exact route of the fistula, 
differentiating between a fibrotic and septic fistula and locating abscesses.26-29 Introducing 
an endoanal coil receiver results in more detailed images of the location of the internal 
opening, the extent of the fistula tract and its relation with the sphincters.30, 31 Anorectal 
endoscopic ultrasound (EUS) requires expertise, but can be equivalent to pelvic MRI and is  
FIGURE 1 Pelvic magnetic resonance imaging (MRI) of a perianal fistula. Left: Transversal image of a perianal 
fistula (arrow) after introduction of an endoanal coil receiver. Right: A coronal image of a perianal fistula 
(arrows). The fistula tract shows a high signal intensity indicating active disease. 
less expensive and time consuming.32, 33 Examination under anaesthesia (EUA) has the 
advantage of the possibility of concomitant drainage of abscesses and placement of non-
cutting setons. The presence of related abnormalities are not detectable with digital 
examination (e.g., high abscesses and sinuses). In addition, MRI predicts patient outcome 
better than solely EUA.34, 35 The random combination of two of three methods (MRI, EUS 
and EUA) resulted in a 100% correct classification of perianal fistulizing CD.36 Independent of 
the diagnostic method used, proctosigmoidoscopy should be performed to assess whether 
the rectum and/or sigmoid is inflamed since active inflammation influences therapy choice 






extrasphincteric (figure 2B)] is
often used to describe a
perianal fistula. This Parks 
classification is also useful for
CD, although more
(complicated) tracts can occur
in a CD patient. Furthermore,
this system does not include
other perianal manifestations
of CD (e.g. abscesses or
strictures). In clinical practice
the ‘simple’ or ‘complex’
classification combining
physical inspection of the
perianal area and endoscopy to 
determine rectal inflame-
mation, is mostly used.14, 19 A 
simple fistula has its origin low
in the anal canal (superficial,
low intersphincteric or low
transsphincteric) and has a
single external opening
without evidence of a perianal
abscess, a recto-vaginal fistula
FIGURE 2 Parks classification of perianal fistulas. (A): An intersphincteric fistula situated between the internal
and external sphincter and a transsphincteric fistula passing the internal and external sphincter into the 
ischiorectal fossa. (B): A suprasphincteric fistula passing through the external sphincter above the puborectalis 
muscle into the ischiorectal fossa and an extrasphincteric fistula with its origin above the puborectalis draining
through the pelvic floor into the ischorectal fossa without passing the internal or external sphincter. Figure
reproduced with permission from Schouten et al.38
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or an anorectal stricture. A complex fistula is high intersphincteric, high trans-sphincteric, 
extrasphincteric or suprasphincteric and may have multiple external openings. They may be 
associated with a rectovaginal fistula, an anorectal stricture, active rectal disease at 
endoscopy and pain or fluctuation suggesting a perianal abscess. 
Treatment of perianal fistulas 
Treatment of perianal fistula is often indicated. Apart from the inconvenience of discharge 
from an untreated fistula, development of abscesses, sepsis, incontinence and carcinoma39, 
40 have been described. Both medical and surgical treatments are available. 
Medical treatment 
Antibiotics 
Antibiotics such as ciprofloxacin and metronidazole are broadly used as first-line treatment 
of perianal fistulas; however, only one randomized, double-blind, placebo-controlled pilot 
study was published to evaluate the safety and efficacy of ciprofloxacin and metronidazole 
as a treatment for active perianal fistulizing CD. No significant differences were found after 
10 weeks of treatment.41 In addition, re-exacerbations were common after discontinuation 
of these treatments.41, 42 Monotherapy with antibiotics is therefore not considered to induce 
complete healing of perianal fistulas.  
Immunosuppressants 
An open-label study from 2003 showed that perianal fistulas treated with the 
immunosuppressant azathioprine in combination with 8 weeks of antibiotics responded 
significantly more often than fistulas treated with antibiotics alone.43 In addition, 
immunosuppression with azathioprine and 6-mercaptopurine solely has been shown to be 
effective in the treatment of perianal fistulas (54% response in comparison to 21% in placebo 
group).44 In patients with previous failure or intolerance to 6-mercaptopurine methotrexate 
seemed an effective option with a 44 - 56% response rate.45, 46 However, the recurrence rate 
was high when the dose of methotrexate was tapered or changed to oral administration. 
Anti-TNFα agents 
Several trials clearly demonstrated the benefit of the anti-tumor necrosis factor alpha (anti-
TNFα) agents infliximab, adalimumab and certolizumab pegol for the induction and 
maintenance of remission in perianal fistulizing disease.47-50 However, a meta-analysis 
reported no statistically significant difference in the relative risk of fistulas remaining 
unhealed with anti-TNFα agents versus placebo.51 On exclusion of short-term follow-up 
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results, the effect of anti-TNFα on fistula healing became significant. Unfortunately, in a 
retrospective analysis the 5-year probability of recurrence of a perianal fistula that was 
initially healed with infliximab therapy, was estimated at 40.1%.52 When infliximab was 
combined with ciprofloxacin a trend to higher response compared to infliximab alone was 
observed.53 In the ADAFI trial54 patients with perianal fistulizing CD were treated with 
adalimumab monotherapy or adalimumab plus ciprofloxacin. After 12 weeks, the treatment 
with ciprofloxacin was stopped. At that point, a significant higher response and remission 
rate was reported in the combination group. However, at week 24 no significant difference 
in fistula healing between the two treatment groups was found. Another possibility is to 
inject anti-TNFα locally in the fistula tract. In three studies a small number of patients were 
open-label treated with multiple local injections of infliximab without any reported adverse 
events of the treatment.55-57 The remission rate varied among the studies with a sustained 
remission between 36.4%56 and 87.5%57 after approximately 1 year. However, in the latter 
study, local injection of infliximab was combined with fistulectomy. Local injections with 
adalimumab as a treatment for perianal fistulizing CD also appeared to be safe58, 59 with 
remission rates of 75 – 77.8%.59, 60 No relapse was observed after a mean follow-up time of 
17.5 months in one study.59 Because the results of locally injected anti-TNFα agents are 
encouraging, it would be worth it to set up randomized controlled studies to evaluate the 
efficacy of these local treatments for perianal fistulizing CD. 
Vedolizumab 
Recently Sandborn et al.61 reported the results of the first induction and maintenance trials 
of vedolizumab, an α4β7-integrin antibody. Although the number of patients with fistulas at 
baseline in this trial was quite low (165/1115; 14.8%) and the number of patients available for 
evaluation at week 52 even lower (n = 57), vedolizumab every 8 weeks resulted in a 
significant higher closure rate (41.2%) compared to placebo (11.1%) (p = 0.03).61  
Surgical treatment 
Before elaborating on the optimal surgical treatment technique, it has to be stated that a 
conservative surgical approach is warranted in most cases: aggressive surgery may result in 
outcomes that are worse than the CD itself. Fecal incontinence is a feared complication and 
may occur even after partial sphincter division. Concomitant proctitis has to be taken into 
account, and therefore, optimal medical therapy to control disease activity is paramount 
before embarking on surgery. 
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results, the effect of anti-TNFα on fistula healing became significant. Unfortunately, in a 
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FIGURE 3 Fistulotomy of a superficial perianal fistula. (A): The fistula is explored with a probe to find both 
openings and (B): is opened to heal by granulation. Figure reproduced with permission from Bemelman from 
van Koperen et al.62  
FIGURE 4 Non-cutting seton in a perianal fistula to assure drainage and to promote fibrosis of the fistula tract. 
          A.        B.
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Fistulotomy and non-cutting setons 
The most simple and classical surgical treatment for perianal fistulas is to open the fistula 
tract widely by fistulotomy and to let the wound heal by granulation (figure 3). Fistulotomy 
in case of simple superficial fistula is successful in up to 80-100% of the cases.19 Fistulotomy 
is not preferred in case of a trans- and extrasphincteric fistula as a part of the sphincters are 
cut during surgery. For these fistulas a non-cutting seton for initial drainage can best be 
placed (figure 4). This seton will drain the fistula tract and reduce the local inflammation. If 
the inflammation has diminished, the seton can be removed. However, the majority of the 
patients need additional surgical therapy, especially when optimal medical treatment does 
not appear to prevent disease recurrence. Therefore, seton drainage is often a bridge to a 
more definite surgical treatment.  
Mucosal advancement flap (MAF) 
When rectal inflammation is limited, the creation of a MAF to cover the internal opening is 
a good option. This technique can also be applied in case of a rectovaginal fistula with 
success rates of 54% to 71% in two retrospective series.63, 64 The mucosa and submucosa and 
even sometimes the muscle is mobilized and then advanced over the internal opening. This 
technically demanding procedure is known be successful in experienced hands in even up 
to 71% of CD patients.65 The majority of the MAF-reports are, however, limited to patients 
with cryptoglandular disease, obscuring its clinical value in CD patients. Incontinence may 
occur in 13% and 9%, respectively.66 
Fibrin glue 
The success rates of sealing the fistula tract with a mix of both fibrin and thrombin are 
varying. Fibrin can be retrieved from autologous blood but commercial fibrin adhesives are 
available as well. Optimistic reports on patients with cryptoglandular disease disclose 
success rates from 68% to 85% at one year.67, 68 Results in CD are less favourable: a 
randomised trial including 77 patients with moderate disease were randomised between 
observation after seton removal and fibrin glue administration.69 After 8 weeks, 38% of the 
glue patients experienced disease remission whereas only 16% did in the observation group. 
Fistula plug 
Fistula plugs consist of inert porcine intestinal submucosa that is known to avoid 
inflammatory reaction after implantation due to its inert nature. After 3 months the plug is 
populated with patient’s endogenous cells.70, 71 In patients with CD healing rates were 54%72 
without affecting fecal continence.73 A prospective study was conducted on 73 patients with 
CHAPTER 1 
16 
FIGURE 3 Fistulotomy of a superficial perianal fistula. (A): The fistula is explored with a probe to find both 
openings and (B): is opened to heal by granulation. Figure reproduced with permission from Bemelman from 
van Koperen et al.62  
FIGURE 4 Non-cutting seton in a perianal fistula to assure drainage and to promote fibrosis of the fistula tract. 
          A.        B.
INTRODUCTION 
17 
Fistulotomy and non-cutting setons 
The most simple and classical surgical treatment for perianal fistulas is to open the fistula 
tract widely by fistulotomy and to let the wound heal by granulation (figure 3). Fistulotomy 
in case of simple superficial fistula is successful in up to 80-100% of the cases.19 Fistulotomy 
is not preferred in case of a trans- and extrasphincteric fistula as a part of the sphincters are 
cut during surgery. For these fistulas a non-cutting seton for initial drainage can best be 
placed (figure 4). This seton will drain the fistula tract and reduce the local inflammation. If 
the inflammation has diminished, the seton can be removed. However, the majority of the 
patients need additional surgical therapy, especially when optimal medical treatment does 
not appear to prevent disease recurrence. Therefore, seton drainage is often a bridge to a 
more definite surgical treatment.  
Mucosal advancement flap (MAF) 
When rectal inflammation is limited, the creation of a MAF to cover the internal opening is 
a good option. This technique can also be applied in case of a rectovaginal fistula with 
success rates of 54% to 71% in two retrospective series.63, 64 The mucosa and submucosa and 
even sometimes the muscle is mobilized and then advanced over the internal opening. This 
technically demanding procedure is known be successful in experienced hands in even up 
to 71% of CD patients.65 The majority of the MAF-reports are, however, limited to patients 
with cryptoglandular disease, obscuring its clinical value in CD patients. Incontinence may 
occur in 13% and 9%, respectively.66 
Fibrin glue 
The success rates of sealing the fistula tract with a mix of both fibrin and thrombin are 
varying. Fibrin can be retrieved from autologous blood but commercial fibrin adhesives are 
available as well. Optimistic reports on patients with cryptoglandular disease disclose 
success rates from 68% to 85% at one year.67, 68 Results in CD are less favourable: a 
randomised trial including 77 patients with moderate disease were randomised between 
observation after seton removal and fibrin glue administration.69 After 8 weeks, 38% of the 
glue patients experienced disease remission whereas only 16% did in the observation group. 
Fistula plug 
Fistula plugs consist of inert porcine intestinal submucosa that is known to avoid 
inflammatory reaction after implantation due to its inert nature. After 3 months the plug is 
populated with patient’s endogenous cells.70, 71 In patients with CD healing rates were 54%72 




anorectal fistulas of differing etiologies. Only 8 CD patients were included of which 4 
patients (50%) were successfully managed by plug insertion.67 Fistula plugs were compared 
with MAF in two randomized studies, however no CD patients were included. One trial 
reported poor healing rates in patients with plug insertion (29%) being not statistically 
different from patients who received an advancement flap (48%).74 The other trial was 
stopped early due dramatic performance of the plug (only 20% success), being much worse 
than the advancement flap group (88%).75 Plug protrusion shortly after surgery is the 
predominant cause of treatment failure. 
Ligation of the intersphincteric fistula tract (LIFT) 
This rather new technique was launched by Rojanasakul in 200976 and consists of dissection 
between the internal and external sphincter up to the level of the fistula tract. There, the 
fistula is ligated and the rest of the external tract is curetted77 The (theoretical) advantage 
of LIFT over MAF is the complete preservation of sphincter function. LIFT is an emerging 
technique that has proved to be effective in 57 to 83% of patients with cryptoglandular 
disease who had previous unsuccessful treatment78-80 There is no randomized comparison 
with other techniques yet. A small series of 15 CD patients was recently published showing 
a LIFT healing rate of 67% at 12 months of follow-up without any development of fecal 
incontinence.81 
Fecal diversion 
Only if other options have proved to be ineffective, the construction of a stoma can 
ameliorate symptoms related to perianal fistulas.82 Patients should know that many of these 
stomas, although often considered as a temporary measure, turn out to be definite.83-85  
Proctectomy 
If all treatments fail, proctectomy may be considered. These patients suffer from 
debilitating abscess formation, colonic disease, complex high fistulas and/or anal stenosis. 
Unfortunately, also proctectomy has the risk of bad wound healing and perianal sinus 
development in almost 50% of the cases.86 
Outcomes of treatment 
Although a range of medical and surgical options is available nowadays, the treatment of 
perianal fistulas is still challenging. Achieving complete closure of the fistula tract is a long 
process with in many cases multiple relapses. Spontaneous closure of complex fistula in CD 
is rare, though it has been reported that a simple transsphincteric fistula has a spontaneous 
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closure rate up to 50%.87 Nevertheless the chance of recurrence after the combination of the 
different available treatments is up to 60% after 2 years.88 Therefore, effective therapies for 
patients with perianal fistulizing CD, refractory or dependent on the conventional strategies, 
are needed. 
MESENCHYMAL STROMAL CELLS 
A new experimental approach to the treatment of perianal fistulas in CD is cellular therapy 
with mesenchymal stromal cells (MSCs). MSCs are non-hematopoietic precursors of 
connective tissue cells with immunomodulatory and tissue regenerative properties, making 
them a potential therapeutic option for inflammatory disorders, including fistulizing CD. 
Apart from the bone marrow, MSCs have been isolated from several other tissues, such as 
adipose tissue89, peripheral blood90, umbilical cord blood91 and placenta92. According to the 
minimal criteria proposed by the International Society for Cellular Therapy93 MSCs should be 
identified based on their ability to adhere to plastic in standard culture conditions and on 
their ability to differentiate in vitro into bone, fat and cartilage. Human MSCs must express 
CD73, CD90 and CD105 and may not express CD11b or CD14, CD19, CD45, CD79α and HLA-DR 
surface molecules.  
MSCs are thought to be immunologically relatively inert since they are poor antigen 
presenting cells (APCs) and do not express MHC class II or co-stimulatory molecules. In 
accordance, expanded MSCs do not stimulate T cell proliferation in mixed lymphocyte 
reactions (MLRs) and are also able to downregulate alloreactive T cell responses when 
added to mixed lymphocyte cultures.94-98 These findings suggest that allogeneic MSCs could 
be used in the clinic and their expansion potential provides the possibility to generate a 
stock with ‘off the shelf’-treatment potential.  
Immunomodulatory capacities of MSCs 
MSCs have been shown to alter cytokine secretion profiles of dendritic cells (DC), naïve and 
effector T cells, and natural killer (NK) cells, which is accompanied by the induction of a more 
anti-inflammatory or tolerant phenotype.99 
Allogeneic human MSCs (hMSCs) have a reversible inhibitory effect on the differentiation of 
monocytes into dendritic cells (DCs) and are able to down-regulate the expression of the 
costimulatory molecules CD80 and CD86 in the case of mature DCs.100-102 DCs that are 
cocultured with MSCs before adding them to T cells, show a reduced ability to activate these 
T cells to proliferate.100 Furthermore, Aggarwal et al.99 showed a significant decrease of 50% 
in TNF-α secretion in response to lipopolysaccharides (LPS) when type 1 DCs are cocultured 
with hMSCs. Interestingly, when type 2 DCs are cocultured with hMSCs, the percentage of 
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the anti-inflammatory cytokine interleukin (IL)-10 increases with 140% upon LPS stimulation 
compared to type 2 DCs cultured without hMSCs. These results suggest that hMSCs 
cocultured with matured DCs provide a more anti-inflammatory milieu in vitro.  
In the same paper, the interaction between MSCs and T cells is described.99 Naïve T cells 
were activated to differentiate into T helper cell type 1 (Th1) or T helper cell type 2 (Th2) in 
the presence or absence of hMSCs. A significant decrease of 60% in levels of interferon-ɣ 
(IFNɣ) was observed when hMSCs were present during the differentiation into Th1 cells 
compared to differentiation without hMSCs. The average increase in the amount of IL-4 in 
the presence of hMSCs during this differentiation process into Th2 cells was 500%, 
suggesting that hMSCs provide significant help for naïve T cells to differentiate into Th2 cells. 
Besides Th1 and Th2 cells, a subset of Th cells that produces high levels of IL-17 exists. These 
so-called Th17 cells protect against extracellular pathogens at mucosal surfaces and are 
thought to play an important role in inflammation and tissue damage in autoimmune 
diseases such as CD. During the differentiation of naïve T cells into Th17 cells, the presence 
of MSCs inhibits the production of inflammatory cytokines and slightly induces the 
production of IL-10 and concomitantly strongly enhances the expression of FoxP3 mRNA 
levels. The induction of FoxP3 mRNA expression gives rise to a functional regulatory T cell 
(Treg).103  
NK cells are cytotoxic effector cells of the innate immune system that play a key role in the 
elimination of virally infected or transformed cells. Upon stimulation with IL-2, purified NK 
cells produce IFN-γ and when these stimulated NK cells are subsequently cocultured with 
hMSCs, the levels of secreted IFN-γ decreases with 80%.99  
Although MSCs are able to alter cytokine secretion profiles of different immune cells in order 
to induce a more anti-inflammatory or tolerant phenotype, the question remains, what are 
the mechanisms by which MSCs exert this biological activity? Several studies suggest that 
MSC-derived soluble factors may contribute to this induced immunosuppression.95, 98  
Prostaglandin E2 (PGE2) is one of the immunosuppressive molecules produced by MSCs 
when activated by inflammatory cytokines such as IFN-γ and TNF-α.99 Intestinal lamina 
propria cells constitutively produce COX-2-dependent PGE2, which suggests that the 
expression of inflammatory mediator COX-2 by lamina propria stromal cells contributes to 
the low immune response against antigens in the mucosa of the small intestine.104 The ability 
of MSCs to inhibit Th17 differentiation and to induce a regulatory phenotype is strongly 
believed to be mediated by the COX-2-dependent soluble factor PGE2.105 In an experimental 
arthritis model secreted PGE2 was the main factor in reducing the inflammation locally 
whereas systemical immune suppression by MSCs was mediated by the switch of the 
inflammatory Th1/Th17 profile towards a more Th2 response.106 In addition, in a TNBS-
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induced colitis model PGE2 produced by MSCs played an important role in suppressing the 
inflammation by inhibiting Th1 cell proliferation and inducing Tregs.107  
Nitric oxide (NO) is an important signaling molecule and is involved in tissue homeostasis 
and (immuno)regulatory functions. Inducible nitric oxide synthase (iNOS) is expressed by 
murine MSCs as a result of stimulation with IFN-ɣ combined with TNF-α, IL-1α or IL-1β.108 
Immunosuppression is achieved when MSCs release high levels of NO, but not when MSCs 
derived from iNOS-/- or IFNɣR1-/- mice are used. In addition, only wild-type MSCs but not iNOS-
/-- or IFNɣR1-/--MSCs prevented graft-versus-host disease and delayed-type hypersensitivity in 
mice. Interestingly, iNOS-/--MSCs even worsened this delayed-type hypersensitivity.108 
Substantiating this theory, a recently published paper on the therapeutic effect of aspirin in 
TNBS-induced colitis demonstrated that NO-releasing aspirin accelerated colonic healing 
characterized by a downregulation of COX-2, iNOS, IL-1β and TNF-α mRNAs.109 
The mechanism of MSC-mediated immunosuppression is different in mice and humans. 
While murine MSCs use iNOS to control immune responses, human MSCs utilize indoleamine 
2,3-dioxygenase (IDO), an immunoregulatory enzyme regulating tryptophan levels, and 
express only very low levels of iNOS.110 However, both mouse MSCs and human MSCs need 
IFN-ɣ, combined with TNF-α, IL-1α or IL-1β, in the induction of the suppression of immune 
cells such as T cells and NK cells through these enzymes.111, 112 
Whether or not MSCs need to be in contact with immune cells to release soluble factors and 
influence those cells is still under debate. Inhibition of T cell proliferation by MSCs was 
abolished when these cells were separated by transwells.110 On the other hand, 
intraperitoneally injected MSCs alleviated dextran sulphate sodium (DSS)-induced colitis by 
forming spheroids in the peritoneal cavity that produced the anti-inflammatory protein TNF-
stimulated gene 6 (TSG-6). Fewer than 1% of the injected MSCs reached the inflamed colon 
in this study, thereby contradicting the need of MSCs to migrate to the site of inflammation 
to attenuate inflammation.113  
CLINICAL TRIALS IN PATIENTS WITH PERIANAL FISTULIZING CD 
In the past years several reports on clinical trials using MSCs derived from bone marrow or 
adipose tissue as a treatment for perianal fistulizing CD have been published.114-117 A phase I 
trial in which 9 fistulas were injected with autologous MSCs derived from adipose tissue, 
demonstrated 75% healed fistulas after 8 weeks without the occurrence of serious adverse 
events.114 This trial was followed by a phase II study of the same group115 in which they 
included 49 adult patients with complex cryptoglandular (n = 35) and CD (n = 14) perianal 
fistulas. Treatment consisted of either local application of fibrin glue or fibrin glue plus 20 
million autologous MSCs derived from adipose tissue. Evaluation took place 8 weeks after 
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the treatment and in case of no healing, a second dose of fibrin glue or fibrin glue plus 40 
million MSCs was injected. Although the majority of the patients had perianal fistulas based 
on cryptoglandular disease, overall healing of the fistulas was observed in 16% of the patients 
who received only fibrin glue versus 71% of the patients who received fibrin glue with 
additional MSC treatment. An Italian group treated 10 patients with refractory fistulizing CD 
every four weeks with a local injection of 20 million autologous MSCs derived from bone 
marrow as long as the autologous MSCs were available.116 In 70% of the patients, fistulas 
closed completely without any serious adverse events. Furthermore, rectal mucosal healing 
was observed and PDAI was improved. The first paper on the treatment of perianal 
fistulizing CD with allogeneic MSCs was published last year.117 Patients were treated locally 
with 20 million MSCs derived from adipose tissue per fistula. If the fistula was not healed 
after 12 weeks, another 40 million cells were injected. Although the investigators and 
patients were not blinded, 69.2% of the patients showed a reduction in the number of 
draining fistulas after 24 weeks. In more than half of the patients complete closure of the 
treated fistula was achieved and in 30% of the patients complete healing of all fistulas was 
observed after 24 weeks. However, all these studies were not powered for efficacy analysis, 
so double blind randomized controlled trials with a sufficient number of patients are needed 
in order to prove the actual efficacy of MSCs in the treatment of fistulizing CD. 
 
SAFETY CONCERNS 
Until now, only a few MSC-related adverse events have been described in the performed 
clinical trials. However, not much is known about the long-term effects of MSC 
administration. One of the safety concerns is the possibility of malignant transformation. No 
neoplasia were observed after at least 3 years of follow-up in one study.118 In addition, a 
recently published meta-analysis reported no de novo tumor formations after MSC 
administration.119 However, malignancies did occur in patients with previous malignancies, 
underlining the importance of screening of patients before MSC administration. 
In contrast to the general idea that MSCs are not immunogenic, multiple injections of 
allogeneic MSCs after bone marrow transplantation in sublethally irradiated mice decreased 
engraftment whereas syngeneic MSCs promoted engraftment.120 In addition, allogeneic 
MSCs are capable of inducing a memory T cell response in immunocompetent hosts. 
Although further studies are needed to elucidate the situations wherein MSCs can be 
immunogenic, these findings should be taken into account when allogeneic MSCs are used 
in a clinical setting by, for instance, using MSCs from different donors when multiple 
infusions are required to avoid a possible memory T cell response and to reduce the 
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the treatment and in case of no healing, a second dose of fibrin glue or fibrin glue plus 40
million MSCs was injected. Although the majority of the patients had perianal fistulas based
on cryptoglandular disease, overall healing of the fistulas was observed in 16% of the patients
who received only fibrin glue versus 71% of the patients who received fibrin glue with
additional MSC treatment. An Italian group treated 10 patients with refractory fistulizing CD
every four weeks with a local injection of 20 million autologous MSCs derived from bone
marrow as long as the autologous MSCs were available.116 In 70% of the patients, fistulas
closed completely without any serious adverse events. Furthermore, rectal mucosal healing
was observed and PDAI was improved. The first paper on the treatment of perianal
fistulizing CD with allogeneic MSCs was published last year.117 Patients were treated locally
with 20 million MSCs derived from adipose tissue per fistula. If the fistula was not healed
after 12 weeks, another 40 million cells were injected. Although the investigators and
patients were not blinded, 69.2% of the patients showed a reduction in the number of
draining fistulas after 24 weeks. In more than half of the patients complete closure of the
treated fistula was achieved and in 30% of the patients complete healing of all fistulas was
observed after 24 weeks. However, all these studies were not powered for efficacy analysis,
so double blind randomized controlled trials with a sufficient number of patients are needed
in order to prove the actual efficacy of MSCs in the treatment of fistulizing CD.
SAFETY CONCERNS
Until now, only a few MSC-related adverse events have been described in the performed
clinical trials. However, not much is known about the long-term effects of MSC 
administration. One of the safety concerns is the possibility of malignant transformation. No 
neoplasia were observed after at least 3 years of follow-up in one study.118 In addition, a 
recently published meta-analysis reported no de novo tumor formations after MSC 
administration.119 However, malignancies did occur in patients with previous malignancies,
underlining the importance of screening of patients before MSC administration.
In contrast to the general idea that MSCs are not immunogenic, multiple injections of
allogeneic MSCs after bone marrow transplantation in sublethally irradiated mice decreased
engraftment whereas syngeneic MSCs promoted engraftment.120 In addition, allogeneic
MSCs are capable of inducing a memory T cell response in immunocompetent hosts.
Although further studies are needed to elucidate the situations wherein MSCs can be
immunogenic, these findings should be taken into account when allogeneic MSCs are used
in a clinical setting by, for instance, using MSCs from different donors when multiple
infusions are required to avoid a possible memory T cell response and to reduce the
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Despite the wide range of available medical and surgical therapies for perianal fistulizing CD 
nowadays, treatment of perianal fistulas is far from satisfactory. Achieving complete closure 
of the fistula tract is a long process with in many cases multiple relapses. Chapter 3 
elaborates on the effect of different treatment strategies for perianal fistulas on response, 
remission and relapse rates. A disappointing remission rate of only 37.0% at the end of a 
median follow-up of 10 years was observed. Therefore, we concluded that there is an unmet 
need for effective medical options for patients who do not respond to the conventional 
strategies. Local cellular therapy with both adipose and bone marrow-derived MSC has been 
reported to be a safe, feasible and effective treatment for refractory perianal fistulizing CD. 
However, none of these trials was really placebo-controlled. Chapter 4 describes our early 
phase II, double-blind, placebo-controlled, randomized clinical trial performed to address 
the use of allogeneic bone marrow-derived MSCs in the treatment of refractory perianal 
fistulizing CD. The aim of this trial was to evaluate the safety and preliminary efficacy of 
allogeneic MSCs in the treatment of perianal fistulas. The possibility to create a stock with 
‘off-the-shelf’ treatment potential from MSCs harvested from young healthy donors is a 
major advantage of an allogeneic cell source. In total, 21 patients with refractory perianal 
fistulizing CD were included in this trail who received locally either 1x107 (n=5), 3x107 (n=5), 
or 9x107 (n=5) MSCs, or placebo (n=6). To be able to reliably assess efficacy of local MSC 
therapy, all procedures were standardized.  MSCs were injected after removal of setons in 
situ, curettage of the fistulous tract(s), trimming the mucosa and skin of the internal and 
external opening and closing the internal opening, respectively. In all patients, MSCs 
suspension or placebo was equally divided and injected in the wall around the closed internal 
opening. In chapter 5 we elaborate on the protocol that was executed in this clinical trial as 
a standard for such procedures in this setting. 
Although the results of the clinical trial of local MSC therapy for perianal fistulizing CD are 
very encouraging, the exact mechanism of action of these cells remain to a large extent 
unknown. One of the questions to be answered is the optimal time of administration to 
achieve maximal efficacy of MSC treatment. In chapter 6 we evaluated whether the timing 
of MSC administration and the presence of an ongoing inflammatory response are 
important to reach treatment efficacy in experimental colitis. Dextran sulphate sodium 
(DSS) was given to C57BL/6 mice resulting in either mild or severe colitis depending on the 
percentage of DSS added to the drinking water. MSCs were injected intraperitoneally before 
or after the introduction of DSS to examine if the moment of injection is important to 
alleviate colitis. In addition, the effect of MSCs on colitis when multiple MSC injections were 
given during the disease course was compared to a single injection at the start of the 
experiment. To investigate the mode of action of the MSC-mediated immunosuppression 
OUTLINE AND AIMS 
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we evaluated if MSCs need to migrate to the place of inflammation to alleviate experimental 
colitis (chapter 7). To this end, we used bioluminescence imaging (BLI) to be able to trace 
intraperitoneally injected MSCs transduced with a luciferase gene, in mice with established 
2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis. In addition, MSCs were 
prestimulated in vitro with interferon-gamma (IFNɣ) and tumor necrosis factor-alpha (TNFα) 
to evaluate the effect of these proinflammatory cytokines on the migration abilities of 
MSCs, next to their therapeutic efficacy. In our search to identify molecules important for 
the migration of MSCs on one side and immunosuppression mediated by MSCs on the other 
side, we generated MSCs with short hairpin RNAs to silence vascular cell adhesion molecule 
(VCAM), or inducible nitric oxide synthase (iNOS) and TNF-stimulated gene 6 (TSG-6). 
Recently, MSCs were observed to form spherical shaped cell-aggregates (spheroids) in 
colitis mice. To evaluate if the formation of spheroids is one of the mechanisms by which 
MSCs induce immunosuppression, MSC spheroids were generated in vitro and infused 
locally via an enema in mice with established DSS-induced colitis (chapter 8). In this way the 
MSC spheroids are in direct contact with the damaged colonic mucosa and do not need to 
migrate to the place of inflammation. Finally, the different studies in this thesis are 
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ABSTRACT 
Background: Despite potent drugs and surgical techniques, the treatment of perianal 
fistulizing Crohn’s disease (CD) remains challenging. We assessed treatment strategies for 
perianal fistulizing CD and their effect on remission, response, and relapse. 
Methods: Patients with perianal fistulizing CD visiting the Erasmus MC between January 1, 
1980 and January 1, 2000 were identified. Demographics, fistula characteristics, and received 
treatments aimed at the outcome of these strategies were noted. 
Results: In total, 232 patients were identified (98 male; 42.2%). Median follow-up was 10.0 
years (range, 0.5–37.5 years). Complex fistulas were present in 78.0%. Medical treatment 
(antibiotics, steroids, immunosuppressants, and anti-tumor necrosis factor) commenced in 
79.7% of the patients and in 53.2%, surgery (colectomy, fistulectomy, stoma, and rectum 
amputation) was performed. Simple fistulas healed more often than complex fistulas (88.2% 
versus 64.6%; P < 0.001). Rectum involvement was not associated with a lower remission 
rate, and anti-tumor necrosis factor therapy did not increase complete fistula healing rates 
in simple and complex fistula. Initially, healed fistulas recurred in 26.7% in case of simple 
fistulas and in 41.9% in case of complex fistulas (P = 0.051). Only 37.0% of the complex fistulas 
were in remission at the end of follow-up compared with 66.7% of the simple fistulas (P < 
0.001). 
Conclusions: Only the minority of CD complex perianal fistulas were in remission after 
conventional treatment strategies after a median follow-up of 10 years. Simple fistulas were 
more likely to heal than complex fistulas, and less of these healed fistulas relapsed. 
However, more than 3 quarters of the patients had complex perianal fistulas. 
Keywords: complex perianal fistulas, Crohn’s disease, healing 
DISAPPOINTING DURABLE REMISSION RATES PERIANAL FISTULAS 
39 
INTRODUCTION 
The development of perianal fistulas along with rectal pain and continuous drainage is a 
common complication of Crohn’s disease (CD).1–5 The cumulative incidence of perianal 
fistulas was estimated at 23% to 26% after 20 years of CD.6,7 In almost half of the patients, 
perianal fistulas were diagnosed before or at the time of the diagnosis of CD.6,7 Patients with 
active rectal disease have more frequently perianal fistulas compared with patients with 
isolated ileal disease.6–12 Furthermore, male gender, age at diagnosis of CD, and smoking are 
associated with the development of perianal fistulas, although data are conflicting.6–8,10,12–15 
Although a range of medical and surgical options is available nowadays, the treatment of 
perianal fistulas remains challenging. Current medical strategies include antibiotics 
(ciprofloxacin and metronidazole),16–18 immunosuppressants, such as azathioprine and 6-
mercaptopurine,19,20 and the antitumor necrosis factors (TNFs), such as infliximab, 
adalimumab, and certolizumab pegol.21–25 Symptomatic simple fistulas can be treated with 
a noncutting seton or fistulotomy. Active luminal disease should be treated before surgical 
treatment.26 In case of complex fistulas, drainage is achieved by placement of a noncutting 
seton to reduce the risk of perianal abscess formation preferably in combination with anti-
TNF and antibiotics. In the ADAFI trial,27 patients with perianal fistulas treated with the anti-
TNF agent, adalimumab along with ciprofloxacin for 12 weeks, had a significant higher 
response and remission rate than patients treated with adalimumab alone. 
With this study, we aimed to assess in a single center retrospective cohort different 
treatment strategies for perianal fistulizing CD and the effect of these treatments on the 
response, remission, and relapse rate. 
MATERIALS AND METHODS 
Patients 
Patients treated for perianal fistulizing CD who visited the Erasmus MC University Hospital 
between January 1, 1980 and the January 1, 2000 were identified through a search in the 
hospital diagnosis system. This search was performed as follows: First, all letters from 
patients were identified by the term fistulizing disease. Second, letters containing the words 
CD were obtained, and finally, these letters were combined with the obtained letters from 
the first search. The patient charts obtained from the latter search were reviewed 
independently by 2 investigators. Patients with the first diagnosis of perianal fistulizing 
disease at or after the diagnosis of CD and with a follow-up for at least 6 months were 
included. Follow-up time was from the onset of fistulizing CD until the date of last follow-up 
or January 1, 2010.  
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Demographic information, date of diagnosis CD, disease localization, time between the 
diagnosis of CD and the development of perianal fistulas, fistula character, medical and 
surgical treatment received for perianal fistulas, and subsequently response, remission, and 
relapse were extracted from all charts. The diagnosis of CD and the extent of the disease 
were confirmed, according to the Lennard-Jones28 criteria. The localization of the disease 
was classified into 7 groups: upper gastrointestinal tract, small bowel, large bowel, ileocecal, 
large and small bowel, perianal, and entire gastrointestinal tract. In addition, involvement of 
the rectum was determined. The diagnosis of perianal fistulizing disease was based on 
endoscopic, radiographic, or clinical evidence. Fistula character was classified as “simple” or 
“complex” following the criteria of Sandborn et al.29 The medical therapies received as 
treatment for perianal fistulas were divided in antibiotics, corticosteroids, 
immunosuppressants, and anti-TNFs. Furthermore, the patient’s history of colon resection, 
fistulectomy, placement of a stoma, and rectum amputation was noted. The response to 
medical and/or surgical treatment was defined as a decrease of discharge, pain, and 
bleeding from the fistula tract, and remission was defined as the absence of an external 
opening without discharge on history and physical examination. Relapse was defined as 
recurred discharge on history and physical examination with reopening of the previous 
external opening and/or formation of new perianal fistulas after initial remission. Worsening 
of the disease after the start of medical and/or surgical treatment with or without an initial 
response was defined as an increase of discharge, pain, and bleeding from the fistula tract.  
Outcome assessment 
The primary objective was to assess the remission rate of CD perianal fistulas after medical 
and/or surgical treatment. Secondary parameters included response and relapse. 
Statistical analysis 
The data were presented in percentages, medians, and ranges. The Mann–Whitney U test 
was used to compare nonparametric data sets, and the Fisher’s exact test was used to 
determine whether a significant association existed between 2 data sets. All statistical 
analyses were performed using the SPSS statistical package (version 20.0.0; SPSS Inc., 
Chicago, IL). P < 0.05 was considered statistically significant. 




In the final search, 436 patients who visited the Erasmus MC University Hospital between 
January 1, 1980 and January 1, 2000 from whom letters contained the terms “fistulizing 
disease” and “CD” were identified (table 1 and figure 2). Of these patients, 204 were 
excluded because of the following reasons: CD was not confirmed endoscopically, 
histologically, or radiologically (13.1%); the diagnosis of fistulizing disease was before the 
diagnosis of CD (10.1%); fistulizing disease was not diagnosed (1.4%); only enterocutaneous 
or enteroenteric fistulas (6.0%), rectovaginal fistulas (2.8%), or pouch–vaginal fistulas (0.7%) 
were confirmed; the fistulas were related to a complicated surgery (0.9%); the follow-up 
period after the diagnosis of perianal fistulas was ,6 months (10.1%); and no information on 
complexity of perianal fistulas was documented (1.8%). A total of 232 patients (98 men 
[42.2%]) were included for further evaluation. The median age at diagnosis of CD was 22.8 
years (range, 4.0–68.7 years). CD localization is shown in table 1. The median age at diagnosis 
of fistulizing disease was 29.4 years (range, 9.1–77.3 years). In total, 66 patients (28.4%) 
FIGURE 1 Cumulative perianal fistula-free survival after diagnosis of CD. 
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FIGURE 1 Cumulative perianal fistula-free survival after diagnosis of CD. 




























Perianal fistulizing CD (n = 232) 
Male (n,%) 98 (42.2) 
CD characteristics 
Age at diagnosis (median, range (years)) 22.8 (4.0 – 68.7) 
Localization (n,%) 
- Upper GI 
- Small bowel 
- Ileocecal 
- Large bowel 
- Small + large bowel 
- Whole GI tract 
- Isolated perianal disease 
  11 (4.7) 




  2 (0.9) 
  13 (5.6) 
Rectal involvement (n,%) 96 (41.4) 
Perianal fistula characteristics 
Diagnosis after 1999 (n,%) 129 (55.6) 
Age at diagnosis (median, range (years)) 29.4 (9.1 – 77.3) 
Diagnosis within 6 months after diagnosis  
   CD (n,%) 66 (28.4) 
Time to diagnosis if > 6 months after  
  diagnosis CD (median, 
   range (years)) 7.0 (0.7 – 38.0) 
Follow-up time (median, range (years)) 10.0 (0.5 – 37.5) 
Complex (n,%) 181 (78.0) 
TABLE 1 Demographic characteristics of the perianal fistulizing CD cohort. 
developed fistulas within 6 months after the onset of CD and in 78.9%, perianal fistulas 
developed within 10 years after the diagnosis of CD with a median duration of 7.0 years 
(range, 0.7–38.0 years) (figure 1). Median followup time from fistula diagnosis was 10.0 
years (range, 0.5–37.5 years). Patients with a complex fistula (78.0%) did not significantly 
differ from patients with a simple fistula (22.0%) about sex, age at diagnosis of (fistulizing) 
CD, time of diagnosis (before or after 1999), and rectal involvement. 





In this cohort, 185 patients (79.7%) received any drugs (antibiotics, steroids, 
immunosuppresants, and anti-TNFs) (tables 2 and 3). Of the patients with simple fistulas 
(51), 41.2% underwent no treatment (6) or solely surgery (15). In 15 patients (29.4%), the 
treatment included drugs solely (table 2), and in the remaining 15 patients, (29.4%) the 
treatment involved both drugs and surgery. Of the 30 patients (58.8%) with a simple fistula 
who received drugs, only 1 type of drug was prescribed in 12 patients (40.0%) (table 3). 
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Steroids 27 (27.8)   8 (53.3) 19 (23.2) 0.027 
Immunosuppressants 82 (84.5) 13 (86.7) 69 (84.1) 1.000 
Induction with anti-TNFs 
Maintenance therapy anti-TNFs 
55 (56.7) 
36 (37.1) 
  9 (60.0) 






TABLE 2 Drugs prescribed in patients who received solely drugs, divided as simple and complex fistulas. 
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In patients with simple fistulas, significantly more often no drugs were prescribed (41.2%) 
compared with patients with complex fistulas (14.4%) (P < 0.001). When drugs were the 
only treatment administered, significantly more antibiotics were prescribed in case of 
complex fistulas (P = 0.047) and significantly more steroids in case of simple fistulas (P = 
0.027) (Table 2). Off all patients who received drugs with or without additional surgery 
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TABLE 3 Drugs prescribed for simple and complex fistulas. 
 
 
The number of patients receiving antibiotic therapy combined with one or more of the 
other drugs was significantly higher when a complex fistula was diagnosed compared with 




   Total (n,%)      Simple (n,%)           Complex (n,%)    
 
1 type of drug 
   
  n = 54 
   
    n = 12 
 
  n = 42 





  8 (14.8) 
 
    2 (16.7) 
 
  6 (14.3) 
 
1.000 
Steroids   9 (16.7)     3 (25.0)   6 (14.3) 0.399 
Immunosuppressants 34 (63.0)     7 (58.3) 27 (64.3) 0.744 
Induction with anti-TNFs     3 (5.5)       0 (0.0)     3 (7.1) 1.000 
Maintenance therapy anti-TNFs      0 (0.0)       0 (0.0) 
 
    0 (0.0) n/a 
 
≥ 2 types of drugs 
   
  n = 131 
       
   n = 18 
   






  79 (60.3) 
 
    5 (27.8) 
 
  74 (65.5) 
 
0.004 
Steroids   54 (41.2)   15 (83.3)   39 (34.5) <0.001 
Immunosuppressants 118 (90.1)   16 (88.9) 102 (90.3) 1.000 
Induction with anti-TNFs   90 (68.7)   14 (77.8)   76 (67.3) 0.427 
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Induction with anti-TNFs 
Maintenance therapy anti-TNFs 
 
  87 (47.0) 
  63 (34.1) 
152 (82.2) 
  93 (50.3) 
  64 (34.6) 
 
    7 (23.3) 
  18 (60.0) 
  23 (76.7) 
  14 (46.7) 
  13 (43.3) 
 
  80 (51.6) 
  45 (29.0) 
129 (83.2) 
  79 (51.0) 
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with one or more drugs and maintenance anti-TNFs in combination with one or more drugs 
were used more often by patients with the diagnosis of simple fistula compared with 
patients with a complex fistula (P < 0.001 and P = 0.042, respectively) (table 3). 
Overall, the most often prescribed drugs in both simple and complex fistula were 
immunosuppressants (82.2%). If immunosuppress-sants were prescribed, steroids were 
part of the treatment in simple fistulas in 13 patients (56.5%). In complex fistulas, induction 
with anti-TNF was most often given concomitant with immunosuppressants (52.7%). In 13 
(43.3%) of patients with simple fistulas and in 51 of patients with complex fistulas (32.9%), 
anti-TNF mainte-nance therapy was prescribed. Almost all of these patients received 
concomitant immuno-suppressant drugs (92.3% versus 88.2%). 
 Total (n,%)   Simple (n,%)    Complex (n,%)  
n = 124 n = 30 n = 94  p value 
Colectomy 63 (50.8) 11 (36.7) 52 (55.3) 0.094 
Fistulectomy 62 (50.0) 22 (73.3) 40 (42.6) 0.006 
Fecal diversion (stoma) 68 (54.8)   8 (26.7) 60 (63.6) 0.001 
Rectum amputation 26 (21.0)   2 (6.7) 24 (25.5) 0.037 
TABLE 4 Surgery for simple and complex fistulas divided per type of surgery. 
Surgery 
In total, 124 patients (53.4%) underwent surgery for their fistulizing disease (table 4). In 
patients with a simple fistula, significantly more fistulectomies were performed than in 
patients with a complex fistula (73.3% versus 42.6%; P = 0.006). Of patients with a complex 
fistula, 60 (63.8%) underwent a fecal diversion compared with 8 (26.7%) in patients with 
simple fistulas (P = 0.001). In addition, significantly more patients with a complex fistula 
underwent rectum amputation (25.5% versus 6.7%; P = 0.037). Surgery was combined with 
medical treatment in 15 patients (29.4%) with a simple fistula and in 73 patients (40.3%) 
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Overall effect of treatment strategies 
The overall response to treatment rate was 83.7% (figure 2). There was no significant 
difference between simple fistulas (93.3%) and complex fistulas (81.3%) (P = 0.068) regarding 
the response rate. The overall remission rate was significantly higher in patients with simple 
fistulas (88.2%) compared with complex fistulas (64.6%) (P < 0.001), with a total overall 
remission rate of 69.8%. Fistula remission was achieved after a median duration of 27.0 
months (range, 0–303.0 months): in case of simple fistulas, the median duration was 34.0 
months (range, 0–187.0 months) and after 27.0 months (range, 0–303.0 months) in complex 
fistulas (P = 0.785). Initially healed fistulas recurred in 37.7%. Simple fistulas relapsed 
less often compared with complex fistulas (26.7% versus 41.9%; P = 0.051). Only 37.0% of the 
complex fistulas were in remission at the end of follow-up compared with 66.7% of the 
simple fistulas (P < 0.001). 
Response, remission and relapse rates per treatment strategy 
No Treatment 
In 6 patients (11.8%) with a simple fistula and 5 (2.8%) patients with a complex fistula, no 
treatment was given (figure 2). In 4 of these patients with simple fistulas (66.7%) and 2 
patients with complex fistulas (40.0%), durable remission was achieved. The time to 
remission was comparable between patients with a simple fistula (40.0 months [range, 12.0–
187.0 months] versus 37.5 months [range, 3.0–72.0 months]; P = 1.000). 
Drugs only 
The overall response in this group was 72.2%, with no difference between simple and 
complex fistulas (P = 0.222) (figure 2). The remission rate after an initial response to the 
medication was 64.3% without a significant difference between simple and complex fistulas 
(P = 0.121). Immunosuppressants, anti-TNF therapy, or the combination of both somewhere 
in the disease course of patients with simple fistula did not improve remission rates 
compared with patients who did not receive one of these drugs or the combination of the 
both (P = 1.000, P = 0.525, and P = 0.569, respectively). Similar results were seen for patients 
with complex perianal fistulas treated with immunosuppressants (P = 0.379), anti-TNF (P = 
0.119), and the combination of the both (P = 0.121). Overall, fistula remission was achieved 
after a median duration of 43.0 months (range, 5.0–101.0 months) in simple fistulas and after 
23.5 months (range, 3.0–203.0 months) in complex fistulas (P = 0.254). The recurrence rate 
after an initial response and remission in simple fistulas was 27.3% and 11.8% in complex 
fistulas (P = 0.337) with an overall relapse rate of 15.6%. 
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Fistulas that were treated with surgery only had an overall response rate of 91.7% (Fig. 2). 
Overall remission after an initial response was 97.0%. Median time to remission was 13.0 
months (range, 0.0–137.0 months) in case of simple fistulas and 24.5 months (range, 1.0–
264.0 months) in case of complex fistulas (P = 0.589). No significant difference was found in 
relapse rate between simple (14.3%) and complex (27.8%) fistulas (P = 0.426) with an overall 
recurrence of 21.9%. 
Drugs and surgery combined 
In 29.4% of the simple fistulas and 40.3% of the complex fistulas, a multimodal treatment 
with medication and surgery was necessary (figure 2). The overall response rate was 93.2% 
with no difference between simple and complex fistulas (P = 0.584). The overall remission 
rate after an initial response was 86.6%. Fistulas went more often in remission in case of a 
simple fistula (100.0%) compared with complex fistulas (83.6%) (P = 0.202) after a median 
duration of 48.0 months (range, 0.0–136.0 months) versus 34.0 months (range, 0.0–303.0 
months) (P = 0.854). When remission was achieved after initial response, the overall 
recurrence rate was 64.8%. 
Remission rates per CD localization 
All patients with CD localized only perianal or in the whole gastrointestinal tract had a 
complex fistula. These complex fistulas healed in 69.2% when isolated perianal disease was 
present and in all patients with involvement of the entire gastrointestinal tract. Simple 
fistulas healed significantly more often when luminal CD was present in both small intestine 
and colon compared with complex fistulas (95.2% versus 62.2%; P = 0.006). When luminal CD 
was localized in the large bowel or ileocecal, no significant difference in fistula closure was 
found between simple and complex fistulas (P = 0.130 and P = 0.121). Involvement of the 
rectum was not associated with a lower remission rate in both simple and complex fistulas 
(P = 0.321 and P = 0.255). 
DISCUSSION 
In this large retrospective cohort of patients with CD suffering from perianal fistula, we 
assessed the effect of different treatment strategies including surgery on the healing of 
these fistulas. Because of the long-term median follow-up of 10 years, we were able not only 
to investigate the time to first remission, but also the rate of relapse after a first remission. 
Remission rate of the first episode of perianal fistulas of the 232 patients was 69.8%. Overall 
simple fistulas were more likely to heal than complex fistulas (88.2% versus 64.6%; P < 0.001) 
DISAPPOINTING DURABLE REMISSION RATES PERIANAL FISTULAS 
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without a significant difference in median duration to first fistula healing. These rates are 
comparable with previous studies reporting remission rates of 66% to 68% with also a higher 
healing rate of simple fistulas compared with complex fistulas. In addition, no significant 
difference in time to fistula remission between simple and complex fistulas was observed.7,9 
The overall recurrence after initial healing, including the whole range of applied strategies, 
was a disappointing 37.7%. Only 37.0% of the complex fistulas were in remission at the end 
of follow-up compared with 66.7% of the simple fistulas (P < 0.001). In several population-
based cohorts,6,7,9 the overall recurrence rate of fistulas was about one-third. A prospective 
study in patients with solely perianal fistulas observed a recurrence rate of 44.4%,30 which 
was higher than the 37.7% in our cohort. 
Active rectal disease is indicated as a risk factor for perianal fistula; in our cohort, only the 
minority of the patients had active rectal disease. Involvement of the rectum was not 
associated with a lower remission rate in both simple and complex fistulas (P = 0.321 versus 
P = 0.255). However, our cohort included more patients than previous studies.6,7,12 
Furthermore, in patients with active rectal disease, the risk for developing perianal fistulas 
compared with patients with sole involvement of the small intestine was reported to be 
higher. Only a small proportion of our cohort had luminal disease present in solely the small 
intestine (6.9%) or only ileocecal involvement (15.1%). Most patients had involvement of the 
colon (37.9%) or colon and small intestine (28.9%), which is in agreement with the literature 
that 5.6% of our patients presented with isolated perianal disease and most of our patients 
had colonic involvement or small intestine plus colonic disease.6,10,11 
We showed that 2.6% of the perianal fistulas healed without any form of treatment that is 
even less than the already very low spontaneous healing rates of 6% to 13% known from 3 
placebo-controlled studies.21,31,32 Healing rates after treatment with drugs only vary between 
9% and 78%7,9; however, the lowest reported healing rates did not include anti-TNF therapy, 
and the number of patients in these studies treated solely with drugs was low. In a recent 
published meta-analysis including 453 patients with active perianal fistulizing CD, complete 
closure of the fistula was observed in only 32.8% of the patients after anti-TNF therapy 
alone.25 Combining different medical treatments resulted in our cohort in twice as higher 
closure rates (64.3%), suggesting that solely anti-TNF therapy is not the optimal treatment 
for perianal fistulizing CD. Surgery only did lead to a remission rate of 3 quarters; however, 
the number of patients treated with surgery only was small (15.5%). 
Infliximab was available in our hospital from 1999, and 57.7% of the patients treated solely 
with drugs received at least 1 gift of anti-TNF, however, not leading to higher remission rates 
of perianal fistulas compared with patients who did not receive infliximab (P = 1.000). Our 
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healing rate of simple fistulas compared with complex fistulas. In addition, no significant 
difference in time to fistula remission between simple and complex fistulas was observed.7,9 
The overall recurrence after initial healing, including the whole range of applied strategies, 
was a disappointing 37.7%. Only 37.0% of the complex fistulas were in remission at the end 
of follow-up compared with 66.7% of the simple fistulas (P < 0.001). In several population-
based cohorts,6,7,9 the overall recurrence rate of fistulas was about one-third. A prospective 
study in patients with solely perianal fistulas observed a recurrence rate of 44.4%,30 which 
was higher than the 37.7% in our cohort. 
Active rectal disease is indicated as a risk factor for perianal fistula; in our cohort, only the 
minority of the patients had active rectal disease. Involvement of the rectum was not 
associated with a lower remission rate in both simple and complex fistulas (P = 0.321 versus 
P = 0.255). However, our cohort included more patients than previous studies.6,7,12 
Furthermore, in patients with active rectal disease, the risk for developing perianal fistulas 
compared with patients with sole involvement of the small intestine was reported to be 
higher. Only a small proportion of our cohort had luminal disease present in solely the small 
intestine (6.9%) or only ileocecal involvement (15.1%). Most patients had involvement of the 
colon (37.9%) or colon and small intestine (28.9%), which is in agreement with the literature 
that 5.6% of our patients presented with isolated perianal disease and most of our patients 
had colonic involvement or small intestine plus colonic disease.6,10,11 
We showed that 2.6% of the perianal fistulas healed without any form of treatment that is 
even less than the already very low spontaneous healing rates of 6% to 13% known from 3 
placebo-controlled studies.21,31,32 Healing rates after treatment with drugs only vary between 
9% and 78%7,9; however, the lowest reported healing rates did not include anti-TNF therapy, 
and the number of patients in these studies treated solely with drugs was low. In a recent 
published meta-analysis including 453 patients with active perianal fistulizing CD, complete 
closure of the fistula was observed in only 32.8% of the patients after anti-TNF therapy 
alone.25 Combining different medical treatments resulted in our cohort in twice as higher 
closure rates (64.3%), suggesting that solely anti-TNF therapy is not the optimal treatment 
for perianal fistulizing CD. Surgery only did lead to a remission rate of 3 quarters; however, 
the number of patients treated with surgery only was small (15.5%). 
Infliximab was available in our hospital from 1999, and 57.7% of the patients treated solely 
with drugs received at least 1 gift of anti-TNF, however, not leading to higher remission rates 
of perianal fistulas compared with patients who did not receive infliximab (P = 1.000). Our 





addition of ciprofloxacin to anti-TNF significantly increased the rate of healed fistulas in the 
ADAFI trial.27 If this strategy fails to heal the fistula, options are scarce. Therefore, it is 
desirable to start treatment as soon as possible after ruling out the presence of abscesses 
and preferably placement of noncutting setons to reduce the risk of new perianal abscess 
formation. 
Recently, Sandborn et al33 reported the results of the first induction and maintenance trials 
of vedolizumab, an a4b7-integrin antibody. Although the number of patients with fistulas in 
this trial was quite low, vedolizumab every 8 weeks resulted in a significant higher closure 
rate compared with placebo (P = 0.03).33 A new promising approach in perianal fistula in CD 
is cellular therapy with mesenchymal stromal cells. In the past years, several reports on 
clinical trials using mesenchymal stromal cells as a treatment for perianal fistulizing CD have 
demonstrated that the local administration of mesenchymal stromal cells is safe and 
feasible, and some of these studies have suggested a potential therapeutic effect.34–37 
In conclusion, we demonstrated in this large cohort of 232 patients with fistulising CD that 
only one third of the patients with complex perianal fistulas achieved a durable remission 
after conventional treatment strategies. Simple fistulas were more likely to heal than 
complex fistulas, and less of these healed fistulas relapsed. However, more than 3 quarters 
of the patients had complex perianal fistulas. Rectum involvement and anti-TNF therapy was 
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Background & Aims: Patients with perianal fistulizing Crohn’s disease have a poor prognosis 
because these lesions do not heal well. We evaluated the effects of local administration of 
bone marrow-derived mesenchymal stromal cells (MSCs) to these patients from healthy 
donors in a double-blind, placebo-controlled study.  
Methods: Twenty-one patients with refractory perianal fistulizing Crohn’s disease were 
randomly assigned to groups given injections of 1x107 (n=5, group 1), 3x107 (n=5, group 2), or 
9x107 (n=5, group 3) MSCs, or placebo (solution with no cells, n=6), into the wall of 
curettaged fistula, around the trimmed and closed internal opening. The primary outcome, 
fistula healing, was determined by physical examination 6, 12 and 24 weeks later; healing 
was defined as absence of discharge and less than 2 cm of fluid collection—the latter 
determined by magnetic resonance imaging at week 12. All procedures were performed at 
Leiden University Medical Center, The Netherlands, from June 2012 through July 2014. 
Results: No adverse events were associated with local injection of any dose of MSCs. Healing 
at week 6 was observed in 3 patients in group 1 (60.0%), 4 patients in group 2 (80.0%), and 1 
patient in group 3 (20.0%), vs 1 patient in the placebo group (16.7%) (P=.08 for group 2 vs 
placebo). At week 12, healing was observed in 2 patients in group 1 (40.0%), 4 patients in 
group 2 (80.0%), and 1 patient in group 3 (20.0%), vs 2 patients in the placebo group (33.3%); 
these effects were maintained until week 24 and even increased to 4 (80.0%) in group 1. At 
week 6, 4/9 individual fistulas had healed in group 1 (44.4%), 6/7 had healed in group 2 
(85.7%), and 2/7 had healed in group 3 (28.6%) vs 2/9 (22.2%) in the placebo group (P=.04 for 
group 2 vs placebo). At week 12, 3/9 individual fistulas had healed in group 1 (33.3%), 6/7 had 
healed in group 2 (85.7%), 2/7 had healed in group 3 (28.6%), and 3/9 had healed in the placebo 
group (33.3%). These effects were stable through week 24 and even increased to 6/9 (66.7%) 
in group 1 (P=.06 group 2 vs placebo, weeks 12 and 24).  
Conclusion: Local administration of allogeneic MSCs was not associated with severe adverse 
events in patients with perianal fistulizing Crohn’s disease. Injection of 3x107 MSCs appeared 
to promote healing of perianal fistulas. ClinicalTrials.gov no: NCT01144962 
Keywords: cell therapy; perianal fistulas; treatment; IBD 
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INTRODUCTION 
Perianal fistulizing Crohn’s disease (CD) remains a significant clinical challenge greatly 
affecting patients’ quality of life due to pain, discharge, and abscess formation.1 At least 23-
26% of CD patients develop perianal fistulas within 20 years after diagnosis.2,3 Achieving 
complete fistula healing is often a long process accompanied by multiple relapses. Patients 
frequently fail to respond to current medical options including antibiotics, 
immunosuppressive agents and anti-tumor necrosis factor (TNF) biologicals.4-6 To prevent 
abscess formation, surgical placement of non-cutting setons is often required. In more 
severe cases, fecal diversion is needed to attenuate perianal disease.7 The ultimate 
treatment goal is complete fistula healing without sphincter damage. Unfortunately, 
despite the best available therapies, durable remission rates of complex perianal fistulas 
remains low at 37.0%.8  
An emerging therapeutic approach is the use of mesenchymal stromal cells (MSCs). These 
are non-hematopoietic multipotent cells able to downregulate immune responses and 
promote tissue healing. It has been reported that human MSCs are able to inhibit generation 
of dendritic cells (DCs) from monocytes, are capable of downregulating expression of 
presentation- and costimulatory molecules on mature DCs preventing T cell activation, and 
promote the generation of T regulatory cells (Tregs).9-14 Furthermore, MSCs participate in 
tissue repair processes providing a strong rationale for the use of these cells as a treatment 
for perianal fistulizing CD. Recently, phase I and II clinical trials have shown promising results 
on the healing rates of perianal fistulas.15-20 Locally injected MSCs demonstrated 69-82% 
fistula healing.16-18,20 MSCs used in these trials were predominantly harvested from 
autologous adipose tissue and were reported to be a safe and feasible option. However, 
autologous MSCs are not immediately available upon request since isolation and expansion 
of MSCs to sufficient numbers of cells requires weeks which results in treatment delay. In 
addition, the possibility of disease-related effects on autologous MSCs must be taken into 
account. Therefore, we used allogeneic MSCs derived from bone marrow aspirates of 
healthy donors. Until now, no similar placebo-controlled trials have been performed. We 
report the results of a randomized, double-blind, placebo-controlled, dose-escalating clinical 
trial evaluating the safety and efficacy of allogeneic bone marrow-derived MSCs additional 
to surgical treatment of refractory perianal fistulizing CD.  
PATIENTS AND METHODS 
Patient selection and study design 
56 
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abscess formation, surgical placement of non-cutting setons is often required. In more 
severe cases, fecal diversion is needed to attenuate perianal disease.7 The ultimate 
treatment goal is complete fistula healing without sphincter damage. Unfortunately, 
despite the best available therapies, durable remission rates of complex perianal fistulas 
remains low at 37.0%.8  
An emerging therapeutic approach is the use of mesenchymal stromal cells (MSCs). These 
are non-hematopoietic multipotent cells able to downregulate immune responses and 
promote tissue healing. It has been reported that human MSCs are able to inhibit generation 
of dendritic cells (DCs) from monocytes, are capable of downregulating expression of 
presentation- and costimulatory molecules on mature DCs preventing T cell activation, and 
promote the generation of T regulatory cells (Tregs).9-14 Furthermore, MSCs participate in 
tissue repair processes providing a strong rationale for the use of these cells as a treatment 
for perianal fistulizing CD. Recently, phase I and II clinical trials have shown promising results 
on the healing rates of perianal fistulas.15-20 Locally injected MSCs demonstrated 69-82% 
fistula healing.16-18,20 MSCs used in these trials were predominantly harvested from 
autologous adipose tissue and were reported to be a safe and feasible option. However, 
autologous MSCs are not immediately available upon request since isolation and expansion 
of MSCs to sufficient numbers of cells requires weeks which results in treatment delay. In 
addition, the possibility of disease-related effects on autologous MSCs must be taken into 
account. Therefore, we used allogeneic MSCs derived from bone marrow aspirates of 
healthy donors. Until now, no similar placebo-controlled trials have been performed. We 
report the results of a randomized, double-blind, placebo-controlled, dose-escalating clinical 
trial evaluating the safety and efficacy of allogeneic bone marrow-derived MSCs additional 
to surgical treatment of refractory perianal fistulizing CD.  
PATIENTS AND METHODS 




Eligible patients were men and women of at least 18 years of age with actively draining 
perianal fistulizing CD refractory to conventional therapies meaning that at some time 
during the perianal fistula disease course, patient must have received anti-TNF agents and, 
in addition, antibiotics, steroids, thiopurines, methotrexate, surgery or combinations 
thereof which did not result in an adequate treatment response. Eligible patients had to 
have 1-2 internal openings and 1-3 fistula tracts. Further criteria for inclusion were: diagnosis 
of CD at least 3 months before enrolment, CD Activity Index (CDAI) score of <250 at 
screening and baseline, stable dose of current drugs (5-ASA and steroids ≥ 4 weeks; 
immunosuppressive drugs ≥ 8 weeks; anti-TNF agents ≥ 8 weeks) which were continued 
during the entire study period. Patients were not allowed to use antibiotics after inclusion 
in the trial. Furthermore, patients were not eligible if there was need for immediate surgery 
(obstruction, strictures or abscesses); pregnancy; breastfeeding; or when they did not use 
adequate contraception. Further exclusion criteria were: evidence of any infection needing 
antibiotic treatment; rectovaginal fistulas; complex perianal fistulas with more than 2 
internal openings; evidence of acute perianal infection; and presence of an anal or rectal 
stricture hindering the surgeon to adequately perform the intervention; active luminal 
disease; renal- or hepatic failure; use of any investigational drug within 1 month prior to 
screening or within 5 half-lives of the investigational agent (whichever is longer); not able 
or willing to undergo magnetic resonance imaging (MRI); change in concomitant 
medication; documented HIV infection; active hepatitis B, C or tuberculosis; an opportunistic 
infection within 6 months prior to screening or a serious infection in the previous 3 months; 
malignancy within the past 5 years; or a history of lymphoproliferative disease.  
Screening assessment included physical examination, laboratory measurements (incl. 
hepatitis B, C, HIV serology, PCR-CMV and PCR-EBV, IFNɣ release assay (IGRA) and β-hCG), 
stool cultures (incl. Clostridium difficile toxin A and B) and a chest X-ray to rule out the 
presence of tuberculosis. MRI was performed at screening to evaluate the exact anatomy 
and internal opening(s) of the fistula(s), their relation to the sphincters and the presence of 
abscesses. When MRI results were non-conclusive, an examination under anesthesia (EUA) 
was performed to determine the exact location of the fistula(s). Abscesses > 2 cm were 
surgically drained at EUA. Subsequently the patient was re-screened before proceeding to 
inclusion or exclusion. At baseline, sigmoidoscopy was performed to rule out luminal 
inflammation. Perianal fistulas were classified using the ‘simple or complex’ classification.21  
All patients who did not have setons in situ after inclusion in the study received temporarily 
setons to ensure that the internal opening was still open at time of surgical intervention. 
These setons were removed during the surgical intervention.  
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The study overview is shown in figure 1. Patients were enrolled in a double-blind, 
randomized 5:2 fashion to receive locally either 1x107 (group 1), 3x107 (group 2) or 9x107 
(group 3) MSCs or 0.9% NaCl/5% human albumin solution with no cells (placebo group). 
Randomization was performed at the Immunohematology and Blood Transfusion 
department by a researcher who did not have any contact with and any knowledge about 
the included patients. The study was posted on ClinicalTrials.gov. under number 
NCT01144962. Dose escalation took place after all subjects in the previous group were 
treated and the Data Safety Monitoring Board (DSMB) reviewed the safety outcomes and 
approved study continuation. The study was approved by the Medical Ethical Committee of 
the Leiden University Medical Center (LUMC) and the Central Committee on Research 
involving Human Subjects (CCMO, The Hague, Netherlands) and all patients gave written 
informed consent. All data was collected in the LUMC. 
FIGURE 1 Study overview. 
Preparation of MSCs 
MSCs were prepared from 5 different donors from 50-100 mL bone marrow aspirates of 
healthy donors without a history of cancer or hereditary diseases and after written informed 
consent. Cells from different donors were processed separately and MSC yield from 1 donor 
was sufficient to create batches of 1x107, 3x107 and 9x107 MSCs. Therefore, MSCs from one 
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a medical screening including routine serology testing for hepatitis B, C, HIV, syphilis and 
HTLV. Upon medical indication, tuberculosis, Chagas disease and West Nile virus infection 
were ruled out. Bone marrow was collected by aspiration from the iliac crest under local 
anaesthesia and mononuclear cells were subsequently isolated by Ficoll separation 
techniques. Cells were then washed and resuspended in MSC culture medium [Dulbecco’s 
modified Eagle’s medium (DMEM)-low glucose/penicillin/streptomycin/10% fetal calf serum 
(FCS)], plated in tissue culture flasks and incubated at 37°C and 5% CO2. MSCs were expanded 
according to the standardized LUMC protocol for expansion of MSCs. Twice a week, cultures 
were microscopically examined and medium was refreshed. Cells were trypsinized when 
>70% confluence was reached and MSC half products (passage 1) of various sizes were 
cryopreserved with 10% dimethyl sulfoxide. The half products were subsequently thawed for 
further expansion enabling the use of MSC products with similar passage numbers from all 
5 donors in each study group.  
Two weeks before the intervention was planned, the patient was randomized to receive 
either MSCs or placebo (figure 1). When the patient was randomized to receive MSCs, 
cryopreserved MSC half product was thawed, washed and replated in MSC culture medium 
for expansion to sufficient number of cells (maximally 2 passages). MSCs were then 
harvested and suspended at study group-dependent final concentrations in 5 mL of 0.9% 
NaCl/5% human albumin solution divided over 2 syringes with 2.5 mL cell suspension each. 
This end product was released when it met the following criteria: >90% of the cells 
CD73+/CD90+/CD105+, ≤ 1% of the cells CD45+, ≤0.01% of the cells CD3+, no microbial 
contamination (visual screening and BacTec culture) at 3-4 days before harvest and a final 
cell product with spindle shaped cell morphology and a colourless cell suspension 
appearance devoid of cell aggregates. Viability was determined by Trypan blue exclusion 
staining in a Bürker chamber. Study group-dependent final concentration of the final 
product was based on the number of viable cells. Placebo consisted of 2x 2.5 mL of 0.9% 
NaCl/5% human albumin solution. 
 
Surgical intervention 
Surgery was performed under general anaesthesia by surgeons with expertise in IBD 
surgery. In total 2 surgeons performed the procedures. MSC or placebo implantation was 
preceded by surgical localization of the internal opening, removal of seton(s), curettage of 
the fistulous tract(s), trimming of the mucosa and skin of respectively the internal and 
external opening and closure of the internal opening with a PDS II 4/0 suture to diminish 
fecal contamination of the fistula tract. Subsequently, the 5 mL of MSC- or placebo 
suspension was divided in the following two steps: the first syringe with 2.5 mL MSCs or 
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placebo was injected via the anus in the wall at 4 quadrants and equal volume around the 
closed internal opening. In case of two internal openings, the MSCs or placebo were divided 
over both closed internal openings in equal volumes. The second volume was injected in the 
wall as close as possible to the internal opening by introducing the syringe as far as possible 
into the fistula tract via the external opening. In case of more external openings, the MSCs 




Follow-up visits after surgical intervention took place at week 6, 12 and 24 (figure 1). Safety 
was assessed blindly by a physician by monitoring for (serious) adverse events and changes 
in vital signs at time of surgical intervention with MSC or placebo injection, at the day of 
treatment and at all follow-up visits. Routine laboratory measurements were performed and 
complications after surgery (bleeding, wound infection, perianal abscesses) were assessed 
blindly at week 6, 12 and 24 by a different surgeon than the surgeon who performed the 
surgical intervention with MSC or placebo injection. The perianal area was examined every 
study visit to assess possible detrimental effects of local injections such as abnormal tissue 
formation. The rectum was also evaluated at week 12 during sigmoidoscopy. The primary 
safety endpoint was the incidence of (serious) adverse events at week 12. Toxicity grade of 
adverse events was determined using the Common Terminology Criteria for Adverse Events 
(CTCAE version 3.0). Secondary endpoints included the incidence of surgical intervention 
and infections at week 12 and 24. 
 
Efficacy 
To evaluate fistula healing, a physician assessed blindly fistula discharge by gentile finger 
pressure at the external opening. In addition, patients underwent a MRI at week 12. Fistula 
tracts were classified blindly by a radiologist and then compared to the MRI at screening. At 
baseline, week 12 and 24 digital photographs were taken of the perianal area. The primary 
efficacy endpoint at week 12 was defined as a reduction in the number of draining fistulas 
determined by absence of discharge at physical examination and absence of collections of 
≥2 cm directly related to the treated fistula tracts as measured by MRI. Secondary endpoints 
included changes in Perianal Disease Activity Index (PDAI), adapted Vaizey fecal 
incontinence score, CDAI, endoscopic scores [CD Endoscopic Index of Severity (CDEIS) and 
simplified endoscopic activity score for CD (SES-CD)], quality of life using the short IBD 
Questionnaire (sIBDQ) and Short Form (SF)-36 score, and C-reactive protein (CRP) from 
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Laboratory methods for supportive research 
Homogenates were prepared from rectal biopsies taken at endoscopy at baseline and week 
12 (n = 21), and curettage material obtained at surgical intervention (n = 20) with a Potter-
Elvehjem glass homogenizer at 4°C in Greenberger lysis buffer (150 mM NaCl, 15 mM Tris, pH 
7.4, 1 mM MgCl2, and 1% Triton X-100). Samples were centrifuged for 15 minutes (11,000g at 
4°C) and stored at -80°C. The BCA Protein Assay Kit (Thermo Scientific Pierce, Etten-Leur, The 
Netherlands) was used to determine the total concentration of protein in the samples and 
cytokine levels of IL-8, IL-1β, IL-6, IL-10, TNF and IL-12p70 were measured using the 
Cytometric Bead Array System (BD Biosciences, San Diego, CA, USA) following the 
manufacturer’s instructions. Data was analysed with FlowJo software (version 8.7.1., Tree 
Star Inc. Ashland, OR, USA). Cytokine levels measured were corrected for the amount of 
total protein in the homogenate.  
 
Statistical analysis 
In this early phase II study, a sample size calculation was not performed. To compare two 
groups with numerical values, parametric or nonparametric analyses were performed using 
an unpaired Student t test or Mann-Whitney U-test, respectively. Paired data were 
compared using the unpaired t test. Categorical data was analyzed with the Fisher’s Exact 
test. Data were analyzed using SPSS statistical package (version 20.0.0; SPSS Inc., Chicago, 
IL) or GraphPad Prism software (version 5.01, San Diego, CA) and expressed as means ± 
standard error of the mean (SEM). P ≤ 0.05 was considered statistically significant. All 




A total of 80 patients from all over the Netherlands were referred to the Leiden University 
Medical Hospital (LUMC) to evaluate their eligibility for this clinical trial. Of these 80 
patients, 47 patients (58.8%) did not meet the inclusion criteria and 33 patients underwent 
screening of which 12 patients did not meet the inclusion criteria on MRI or EUA 
(supplementary information). Finally, 21 eligible patients were randomized, 12 were male 
(57.1%) and the mean age was 38.0 years (range, 21-54). The first patient received 
intervention in June 2012, the last patient in July 2014. Additional baseline characteristics of 
the patients are summarized in table 1.  
The mean fistula duration was 5.5 years (range, 1-19), most were complex fistulas with a 
transsphincteric route (both 65.2%) and the internal opening was predominantly observed  
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5-ASA = mesalazine; 6-MP = 6-mercaptopurine; AB = antibiotics; ADA = adalimumab; AZA = azathioprine; CER = certolizumab; CS = 
corticosteroids; IFX = infliximab; MTX = methotrexate; TGN = thioguanine. * CDAI was not calculated in patients with a stoma. 
 
 









(n = 6) 
 
 
Age at inclusion, mean (SEM), yr 
     (min-max) 
Male, n (%) 
Smoker, n (%) 
     Yes 
     No 
     Past 
 
Duration CD, mean (SEM),  yr 
     (min-max) 
Montreal classification CD, n (%) 
     L1  
     L2 
     L3 
     L3+L4 
Stoma* 
CDAI at baseline, mean (SEM)* 
     (min-max) 
Medication, n (%) 
Current 
     5-ASA 
     6-MP 
     ADA 
     AZA 
     CS 
     IFX 
     MTX 
Previous 
     5-ASA 
     6-MP 
     AB 
     ADA 
     AZA 
     CER 
     CS 
     IFX 
     MTX 
     TGN 
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   1 (20.0) 
   2 (40.0) 
   2 (40.0) 
 
7.6 (1.1)  
   (5-11) 
 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
   0 
0 
80.2 (12.1)  
   (44-115) 
 
 
   1 (20.0) 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
   1 (20.0) 
   2 (40.0) 
   1 (20.0) 
 
   2 (40.0) 
   1 (20.0) 
   3 (60.0) 
   0 
   4 (80.0) 
   0 
   5 (100) 
   3 (60.0) 
   1 (20.0) 
   0 
 
40.8 (1.7) 
   (37-47) 
4 (80.0) 
 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
 
16.8 (4.0) 
   (5-28) 
 
   1 (20.0) 
   2 (40.0) 
   2 (40.0) 
   0 
1 (20.0) 
203.3 (51.2)  
   (59-283) 
 
 
   2 (40.0) 
   1 (20.0) 
   2 (40.0) 
   2 (40.0) 
   0 
   1 (20.0) 
   1 (20.0) 
 
   2 (40.0) 
   1 (20.0) 
   3 (60.0) 
   3 (60.0) 
   2 (40.0) 
   1 (20.0) 
   4 (80.0) 
   3 (60.0) 
   1 (20.0) 
   1 (20.0) 
 
33.4 (5.2)  
   (21-48) 
1 (20.0) 
 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
 
13.2 (4.1)  
   (2-23) 
 
   2 (40.0) 
   1 (20.0) 
   2 (40.0) 
   0 
1 (20.0) 
57.3 (14.1)  
   (38-99) 
 
 
   0 
   2 (40.0) 
   4 (80.0) 
   1 (20.0) 
   0 
   1 (20.0) 
   0 
 
   2 (40.0) 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
   3 (60.0) 
   0 
   5 (100) 
   2 (40.0) 
   0 
   1 (20.0) 
 
37.3 (3.6)  
   (27-49) 
3 (50.0) 
 
   2 (33.3) 
   1 (16.7) 
   3 (50.0) 
 
6.8 (2.9) 
   (1-20) 
 
   1 (16.7) 
   2 (33.3) 
   2 (33.3) 
   1 (16.7) 
2 (33.3) 
75.8 (28.2)  
   (20-148) 
 
 
   0 
   0 
   4 (66.7) 
   2 (33.3) 
   0 
   2 (33.3) 
   1 (16.7) 
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   0 
   4 (66.7) 
   2 (33.3) 
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The mean fistula duration was 5.5 years (range, 1-19), most were complex fistulas with a 
transsphincteric route (both 65.2%) and the internal opening was predominantly observed  
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5-ASA = mesalazine; 6-MP = 6-mercaptopurine; AB = antibiotics; ADA = adalimumab; AZA = azathioprine; CER = certolizumab; CS = 
corticosteroids; IFX = infliximab; MTX = methotrexate; TGN = thioguanine. * CDAI was not calculated in patients with a stoma. 
 
 









(n = 6) 
 
 
Age at inclusion, mean (SEM), yr 
     (min-max) 
Male, n (%) 
Smoker, n (%) 
     Yes 
     No 
     Past 
 
Duration CD, mean (SEM),  yr 
     (min-max) 
Montreal classification CD, n (%) 
     L1  
     L2 
     L3 
     L3+L4 
Stoma* 
CDAI at baseline, mean (SEM)* 
     (min-max) 
Medication, n (%) 
Current 
     5-ASA 
     6-MP 
     ADA 
     AZA 
     CS 
     IFX 
     MTX 
Previous 
     5-ASA 
     6-MP 
     AB 
     ADA 
     AZA 
     CER 
     CS 
     IFX 
     MTX 
     TGN 
  
40.4 (4.6) 
   (27-54) 
4 (80.0) 
 
   1 (20.0) 
   2 (40.0) 
   2 (40.0) 
 
7.6 (1.1)  
   (5-11) 
 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
   0 
0 
80.2 (12.1)  
   (44-115) 
 
 
   1 (20.0) 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
   1 (20.0) 
   2 (40.0) 
   1 (20.0) 
 
   2 (40.0) 
   1 (20.0) 
   3 (60.0) 
   0 
   4 (80.0) 
   0 
   5 (100) 
   3 (60.0) 
   1 (20.0) 
   0 
 
40.8 (1.7) 
   (37-47) 
4 (80.0) 
 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
 
16.8 (4.0) 
   (5-28) 
 
   1 (20.0) 
   2 (40.0) 
   2 (40.0) 
   0 
1 (20.0) 
203.3 (51.2)  
   (59-283) 
 
 
   2 (40.0) 
   1 (20.0) 
   2 (40.0) 
   2 (40.0) 
   0 
   1 (20.0) 
   1 (20.0) 
 
   2 (40.0) 
   1 (20.0) 
   3 (60.0) 
   3 (60.0) 
   2 (40.0) 
   1 (20.0) 
   4 (80.0) 
   3 (60.0) 
   1 (20.0) 
   1 (20.0) 
 
33.4 (5.2)  
   (21-48) 
1 (20.0) 
 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
 
13.2 (4.1)  
   (2-23) 
 
   2 (40.0) 
   1 (20.0) 
   2 (40.0) 
   0 
1 (20.0) 
57.3 (14.1)  
   (38-99) 
 
 
   0 
   2 (40.0) 
   4 (80.0) 
   1 (20.0) 
   0 
   1 (20.0) 
   0 
 
   2 (40.0) 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
   3 (60.0) 
   0 
   5 (100) 
   2 (40.0) 
   0 
   1 (20.0) 
 
37.3 (3.6)  
   (27-49) 
3 (50.0) 
 
   2 (33.3) 
   1 (16.7) 
   3 (50.0) 
 
6.8 (2.9) 
   (1-20) 
 
   1 (16.7) 
   2 (33.3) 
   2 (33.3) 
   1 (16.7) 
2 (33.3) 
75.8 (28.2)  
   (20-148) 
 
 
   0 
   0 
   4 (66.7) 
   2 (33.3) 
   0 
   2 (33.3) 
   1 (16.7) 
 
   2 (33.3) 
   1 (16.7) 
   5 (83.3) 
   0 
   2 (33.3) 
   0 
   4 (66.7) 
   2 (33.3) 
   0 






at 6 o’clock (52.2%). The external openings were mostly located at 5, 6 and 7 o’clock (all 
18.8%). A detailed overview of perianal fistula characteristics at baseline is shown in table 2. 
The primary endpoints were met in all patients. For the secondary endpoints, one patient 
in group 2 was not able to undergo week 12-endoscopy and one patient in group 2 did not 
complete the week 24 questionnaires.  
 
 









(n = 6) 
 
Duration fistulas, mean (SEM), yr 
     (min-max) 
PDAI at baseline, mean (SEM) 
     (min-max) 
Horseshoeing, n (%) 
     Intralevator 
     Intersphincteric 
Abscess, n (%) 
     Superficial 
     Supralevator 
 
Internal openings 
Internal openings, n (%) 
     1 
     2 
Internal opening with respect to rectum, n (%) 
     Below 
     At 
Route of fistula, n (%) 
     Intersphincteric  
     Transsphincteric  
     Suprasphincteric 
     Extrasphincteric  
     Superficial 
 
External openings 
External openings, n (%) 
     1 
     2 
     3 
 
Classification fistula, n (%)21 
     Simple 
     Complex 
  
3.6 (0.7)  
   (2-5) 
4.4 (0.5)  
   (3-6) 
1 (20.0) 
   1 (100) 
   0 
3 (60.0) 
   3 (100) 
   0 
 
   
5 (100) 
   5 (100)    
   0  
 
   4 (80.0) 
   1 (20.0) 
 
   1 (20.0) 
   3 (60.0) 
   1 (20.0) 
   0 




   2 (40.0) 
   2 (40.0) 
   1 (20.0) 
 
 
   2 (40.0) 
   3 (60.0) 
 
5.4 (2.5)  
   (1-13) 
3.8 (0.8)  
   (2-6) 
2 (40.0) 
   1 (50.0) 
   1 (50.0) 
1 (20.0) 
   0 
   1 (100) 
 
    
5 (100) 
   5 (100)    
   0 
 
   2 (40.0) 
   3 (60.0) 
 
   1 (20.0) 
   2 (40.0) 
   0 
   2 (40.0) 




   3 (60.0) 
   2 (40.0) 
   0 
 
 
   1 (20.0) 
   4 (80.0) 
 
9 (3.2)  
   (2-19) 
5 (1.1)  
   (3-9) 
1 (20.0) 
   0 
   1 (100) 
2 (40.0) 
   2 (100) 
   0 
 
    
5 (100) 
   5 (100) 
   0 
 
   2 (40.0) 
   3 (60.0) 
 
   0 
   5 (100) 
   0 
   0 




   3 (60.0) 
   2 (40.0) 
   0 
 
 
   1 (20.0) 
   4 (80.0) 
 
4.2 (1.1)  
   (1-8) 
5.2 (0.9)  
   (3-8) 
4 (66.7) 
   2 (50.0) 
   2 (50.0) 
2 (33.3) 
   2 (100) 




   4 (66.7) 
   2 (33.3) 
 
   5 (62.5) 
   3 (37.5) 
 
   1 (12.5) 
   5 (62.5)  
   0 
   1 (12.5) 




   4 (66.7) 
   1 (16.7) 
   1 (16.7) 
 
 
    2 (33.3) 
    4 (66.7) 
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FIGURE 2 Efficacy outcomes. (A): Percentage of patients per group without draining perianal fistulas at week 
6, 12 and 24. (B): Percentage of reduction in the number of draining perianal fistulas per group at week 6, 12 
and 24. At week 6, the percentage of reduction in the number of draining perianal fistulas was significantly 
higher in patients treated with 3x107 MSCs (group 2) compared to patients in the placebo group (P = 0.04).
FIGURE 3 Fistula healing in relation to MSC donor. (A): Percentage of reduction in the number of draining 
perianal fistulas per MSC donor at week 6, 12 and 24.  
*
A.
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at 6 o’clock (52.2%). The external openings were mostly located at 5, 6 and 7 o’clock (all 
18.8%). A detailed overview of perianal fistula characteristics at baseline is shown in table 2.
The primary endpoints were met in all patients. For the secondary endpoints, one patient
in group 2 was not able to undergo week 12-endoscopy and one patient in group 2 did not 
complete the week 24 questionnaires.
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FIGURE 3 Fistula healing in relation to MSC donor. (B): Overview of efficacy after treatment with MSCs or 
placebo. 
Efficacy 
Six weeks after treatment, all draining fistulas had healed in 3/5 (60.0%), 4/5 (80.0%) and 1/5 
(20.0%) of the patients in group 1, 2 and 3, respectively, and in 1/6 (16.7%) of the patients who 
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received placebo as determined by absence of discharge at physical examination and 
absence of ≥2 cm collections on MRI (P = 0.08 group 2 vs placebo).  
At week 12, all draining perianal fistulas were healed in 2/5 (40.0%), 4/5 (80.0%) and 1/5 (20.0%) 
patients in group 1, 2 and 3 versus 2/6 (33.3%) of placebo treated patients (figure 2A; group 
1, 2 and 3 vs placebo, all NS). Fistula healing rates persisted throughout week 24 in all 3 MSC 
groups. In group 1, fistula healing increased to 4/5 (80.0%) at week 24.  
Analysis of all individual fistulas at week 6 demonstrated complete healing in 4/9 (44.4%), 6/7 
(85.7%) and 2/7 (28.6) in group 1, 2 and 3, respectively, vs 2/9 (22.2%) after treatment with 
placebo (P = 0.04 group 2 vs placebo). At week 12 after treatment, complete fistula healing 
was observed in 3/9 (33.3%), 6/7 (85.7%) and 2/7 (28.6%) in group 1, 2 and 3 versus 3/9 (33.3%) 
in placebo (P = 0.06 group 2 vs placebo) (figure 2B and illustrated in figure 4A). At week 24, 
healing was observed in 6/9 (66.7%), 6/7 (85.7%); 2/7 (28.6%) in group 1, 2 and 3 versus 3/9 
(33.3%) in placebo (P = 0.06 group 2 vs placebo). The characteristics of fistula healing in 
relation to MSC donor is indicated in figure 3. 
 
MRI evaluation at week 12 revealed the presence of ≥2 cm collections directly related to the 
treated fistulas tracts in 2 patients (1 in group 1 and 1 in the placebo group). In 2 other 
patients (1 in group 2 and 1 in group 3) an abscess was formed after week 12.  
No de novo fistulas were observed. At week 12-MRI 3 patients showed no active fistulas 
anymore (1 in group 1 and 2 in group 2; see figure 4B).  
Decreased amounts of fistula fluid was observed in 2/5 (40.0%), 2/5 (40.0%), 1/5 (20.0%) in 
groups 1, 2 and 3 versus 1/6 (16.7%) in the placebo group. All patients with no or less fluid in 
the fistulas at the week 12-MRI also had a clinically reduction in the number of draining 
fistulas. 
 
PDAI scores at week 0, 12 and 24 correlated well with therapy efficacy observed with 
physical examination and MRI. In group 1 PDAI scores decreased from 4.4 to 1.8 over 24 
weeks. In group 2 this PDAI decrease was most prominent and significantly lower at week 
12 compared to baseline as well as to placebo treatment at week 12 (P = 0.03 group 2 from 
baseline to week 12; P = 0.04 week 12 group 2 vs placebo group; figure 5). In group 3 PDAI 
did not change over time and was comparable to placebo treatment. Effects of MSC 
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weeks. In group 2 this PDAI decrease was most prominent and significantly lower at week 
12 compared to baseline as well as to placebo treatment at week 12 (P = 0.03 group 2 from 
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FIGURE 5 Perianal Disease Activity Index (PDAI) scores per study visit in all groups. Mean PDAI score at week 12 
was significantly decreased compared to baseline-PDAI score after treatment with 3x107 MSCs (group 2, P = 
0.03). In addition, treatment with 3x107 MSCs (group 2) resulted in a significantly lower PDAI score at week 12 
compared to mean PDAI score in the placebo group (P = 0.04). Bars represent mean and SEM. 
Safety 
All patients tolerated the local injections of MSCs well, no infusion reactions during or 
directly after the surgical intervention occurred. One group 2 patient developed a fever 
(39.7°C) 6 hours after surgery, probably related to a stenosis dilatation of the anal canal prior 
to surgery. Hospitalization was prolonged and one dose of cefuroxime/metronidazole was 
prescribed. The day after surgery this patient developed abdominal pain with diarrhoea and 
elevated CRP levels, but feces, urine and blood cultures were negative. No abnormalities 
were observed on chest X-ray. No microbial contamination in the supernatant of the last 
washing step before packaging the MSCs for injection was found, and two days later the 
patient was discharged in good condition.  
During follow-up visits all adverse events were recorded (table 5). All patients reported for 
approximately one week complaints of postoperative anal pain and pus and/or blood 
discharge from the fistula or anus (not shown in table 5). No changes in vital signs and no 
wound infections or bleedings as a result of surgical intervention were observed during the 
study period. In addition, no abnormal tissue formation at the perianal area by physical 
examination or in the rectum at endoscopy at week 12 was found. One patient in each group 
developed a perianal abscess that required surgical drainage at week 12, 16, 21 and 18 in 
group 1, 2, 3 and placebo, respectively. The patients with an abscess in group 1, 3 and placebo 
needed seton drainage. The fistula of the patient in group 2 was healed at week 24. The 
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three patients in the placebo group with a painful perianal swelling were treated with 
antibiotics. None of the adverse events were judged to be related to MSC injection. One of the 
patients treated with 1x107 MSCs developed an adenocarcinoma of the cecum with peritoneal 
carcinomatosis more than 15 months after the surgical intervention. Baseline and week 12-
endoscopy of the rectum revealed no abnormalities. Moreover, in retrospect, the last 
endoscopy of the entire colon and the biopsies taken at that time (June 2011) were completely 
normal. Further evaluation revealed that the uncle of this patient died from colon cancer at the 
age of 42.  
 







(n = 6) 
Mean (SEM) (min-max) 
CDAI*  
     Week 0 
     Week 12 
     Week 24** 
CDEIS 
     Week 0 
     Week 12 
SES-CD 
     Week 0 
     Week 12 
Adapted Vaizey 
incontinence 
     Week 0 
     Week 12 
     Week 24** 
CRP 
     Week 0 
     Week 12 
     Week 24** 
sIBDQ 
     Week 0 
     Week 12 





























































































* CDAI was not calculated in patients with a stoma. 
** At week 24, one patient in cohort 2 did not fill in the questionnaires and blood was not withdrawn in this patient.  
*** One patient in cohort 2 was not able to undergo endoscopy at week 12, therefore CDEIS and SES-CD were not calculated. 
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* CDAI was not calculated in patients with a stoma. 
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(n = 6) 
Mean (SEM) 
Physical functioning 
  Week 0 
  Week 12 
  Week 24 
Physical role functioning 
  Week 0 
  Week 12 
  Week 24 
Bodily pain 
  Week 0 
  Week 12 
  Week 24 
General health perceptions 
  Week 0 
  Week 12 
  Week 24 
Vitality 
  Week 0 
  Week 12 
  Week 24 
Social functioning 
  Week 0 
  Week 12 
  Week 24 
Emotional role functioning 
     Week 0 
     Week 12 
     Week 24 
Mental health 
  Week 0 
  Week 12 

































































































At week 24, one patient in cohort 2 did not fill in the SF-36. 
TABLE 4 SF-36 scores per group at baseline, week 12 and week 24. 
Cytokine levels in rectal biopsies and fistula curettage material 
In order to study MSC healing mechanisms and avoiding invasive fistula biopsies which  
would compromise fistula healing, we compared rectum cytokine levels (baseline and week 
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TABLE 5 Adverse events. 
 
12) with fistula curettage obtained at surgery. Mean levels of IL-8, IL-1β and IL-6 in the rectal 
biopsies were similar at baseline and after surgical intervention at week 12 (figure 6), 
irrespective of treatment. No differences in the levels of these cytokines were observed at 
week 12 after treatment with 1x107, 3x107 or 9x107, or placebo (data not shown), which 










(n = 6) 
Mean (SEM) 
Physical functioning 
  Week 0 
  Week 12 
  Week 24 
Physical role functioning 
  Week 0 
  Week 12 
  Week 24 
Bodily pain 
  Week 0 
  Week 12 
  Week 24 
General health perceptions 
  Week 0 
  Week 12 
  Week 24 
Vitality 
  Week 0 
  Week 12 
  Week 24 
Social functioning 
  Week 0 
  Week 12 
  Week 24 
Emotional role functioning 
     Week 0 
     Week 12 
     Week 24 
Mental health 
  Week 0 
  Week 12 

































































































At week 24, one patient in cohort 2 did not fill in the SF-36. 
TABLE 4 SF-36 scores per group at baseline, week 12 and week 24. 
Cytokine levels in rectal biopsies and fistula curettage material 
In order to study MSC healing mechanisms and avoiding invasive fistula biopsies which  
would compromise fistula healing, we compared rectum cytokine levels (baseline and week 
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TABLE 5 Adverse events. 
 
12) with fistula curettage obtained at surgery. Mean levels of IL-8, IL-1β and IL-6 in the rectal 
biopsies were similar at baseline and after surgical intervention at week 12 (figure 6), 
irrespective of treatment. No differences in the levels of these cytokines were observed at 
week 12 after treatment with 1x107, 3x107 or 9x107, or placebo (data not shown), which 




of IL-8, IL-1β and IL-6 were overall significantly higher in the fistula curettage material 
compared to the mean levels in the rectal biopsies at either week 0 or 12 (all P < 0.0001). 
Cytokine levels of TNF, IL-10 and IL-12p70 were below the detection rate in all samples. 
FIGURE 6 Cytokine levels in rectal biopsies and fistula curettage material. Cytokine levels were measured in 
homogenates of rectal biopsies and fistula curettage material. Levels of IL-8 (A), IL-1β (B) and IL-6 (C) in the 
rectal biopsies obtained at endoscopy were comparable at baseline and week 12. Significantly higher levels of 
these cytokines were observed in the curettage material from the fistulas obtained at surgical intervention (all 
p < 0.0001). Bars represent mean and SEM. 
DISCUSSION 
Recently, several papers have reported efficacy of local treatment of refractory perianal 
fistulizing CD with MSCs.15-20 However, none of these trials was really placebo-controlled. 
Therefore we performed an early phase II, double-blind, placebo-controlled, randomized 
study addressing the use of allogeneic bone marrow-derived MSCs in the treatment of 
refractory perianal fistulizing CD. We showed that local administration of allogeneic bone 
marrow-derived MSCs was safe and feasible in patients with refractory perianal fistulizing 
CD.  
Local treatment with lower dosages of MSCs resulted in higher fistula healing rates 
compared to placebo which seems to be a dose-dependent response as administration of 
3x107 MSCs resulted in high fistula healing rates and 9x107 in rates similar to placebo 
treatment. Previously, the importance of MSC cell dose was described in both a sheep model 
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dose escalation was performed with autologous and/or allogeneic cells that were locally 
injected in the diseased myocardium. Only low-dose administration resulted in a beneficial 
effect of MSCs. The authors argued that higher cell concentrations could result in a lower 
survival rate and/or cell function and, secondly, that larger number of cells could behave 
immunogenic resulting in increased clearance or deactivation of the cells.  
Fistula healing appeared to be accelerated after treatment with 3x107 MSCs compared to 
placebo treatment as all healed fistulas in this group were already non-draining 6 weeks 
after the surgical intervention as compared to at 12 weeks in patients with healed fistulas in 
the placebo group. Although our fistula healing rates after treatment with 3x107 MSCs are 
very encouraging, it has to be taken into account that we only included patients where the 
luminal Crohn’s disease was in remission. Local MSC-treatment in patients with active 
luminal disease or more internal or external openings might be less successful and therefore 
merit further study. Larger phase III trials are warranted to confirm our observations. 
Although MSC-treatment was effective in group 1 and 2, quality of life measured by sIBDQ 
and SF-36, did not increase during the study. At baseline PDAI scores were lower than 
expected for patients with perianal fistulizing CD. Both quality of life and PDAI scores consist 
partially of questions on restrictions in daily activities. All these questions were answered 
negative, indicating that our patients did not experience restrictions in their daily life due to 
the fistulas, probably because after a mean 5.5 years they were ‘used to’ having fistulas with 
continuously discharge and pain, and managed to continue with their activities despite the 
daily discomfort. In addition, abscesses larger than 2 cm were drained before inclusion in the 
trial resulting in less anal pain and thus in lower PDAI scores and possibly a better quality of 
life.  
In our study we used allogeneic MSCs harvested from bone marrow of healthy donors. One 
of the advantages of allogeneic MSCs is the possibility to generate a stock with ‘off-the-
shelf’ treatment potential without the requirement to expand autologous MSCs for weeks 
before a patient can be treated. Immediate availability of MSCs for the treatment of fistulas 
is warranted as the development of abscesses requires surgery and results in a reduced 
quality of life. In addition, MSCs can be harvested from healthy young donors with a higher 
yield compared to older donors and possessing a higher regenerative and 
immunomodulatory potential, thereby also avoiding possible disease-related effects on the 
autologous MSCs.24-26 Similar to autologous MSCs, in this study allogeneic MSCs were 
observed to be safe. During the study period, none of the included patients reported 
adverse events related to MSC injection.  
One of the concerns of cell-based therapy is the safety regarding malignant transformation 
of the administered cells. While no neoplasia were observed during the long-term follow-up 
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of IL-8, IL-1β and IL-6 were overall significantly higher in the fistula curettage material 
compared to the mean levels in the rectal biopsies at either week 0 or 12 (all P < 0.0001). 
Cytokine levels of TNF, IL-10 and IL-12p70 were below the detection rate in all samples. 
FIGURE 6 Cytokine levels in rectal biopsies and fistula curettage material. Cytokine levels were measured in 
homogenates of rectal biopsies and fistula curettage material. Levels of IL-8 (A), IL-1β (B) and IL-6 (C) in the 
rectal biopsies obtained at endoscopy were comparable at baseline and week 12. Significantly higher levels of 
these cytokines were observed in the curettage material from the fistulas obtained at surgical intervention (all 
p < 0.0001). Bars represent mean and SEM. 
DISCUSSION 
Recently, several papers have reported efficacy of local treatment of refractory perianal 
fistulizing CD with MSCs.15-20 However, none of these trials was really placebo-controlled. 
Therefore we performed an early phase II, double-blind, placebo-controlled, randomized 
study addressing the use of allogeneic bone marrow-derived MSCs in the treatment of 
refractory perianal fistulizing CD. We showed that local administration of allogeneic bone 
marrow-derived MSCs was safe and feasible in patients with refractory perianal fistulizing 
CD.  
Local treatment with lower dosages of MSCs resulted in higher fistula healing rates 
compared to placebo which seems to be a dose-dependent response as administration of 
3x107 MSCs resulted in high fistula healing rates and 9x107 in rates similar to placebo 
treatment. Previously, the importance of MSC cell dose was described in both a sheep model 
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dose escalation was performed with autologous and/or allogeneic cells that were locally 
injected in the diseased myocardium. Only low-dose administration resulted in a beneficial 
effect of MSCs. The authors argued that higher cell concentrations could result in a lower 
survival rate and/or cell function and, secondly, that larger number of cells could behave 
immunogenic resulting in increased clearance or deactivation of the cells.  
Fistula healing appeared to be accelerated after treatment with 3x107 MSCs compared to 
placebo treatment as all healed fistulas in this group were already non-draining 6 weeks 
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luminal disease or more internal or external openings might be less successful and therefore 
merit further study. Larger phase III trials are warranted to confirm our observations. 
Although MSC-treatment was effective in group 1 and 2, quality of life measured by sIBDQ 
and SF-36, did not increase during the study. At baseline PDAI scores were lower than 
expected for patients with perianal fistulizing CD. Both quality of life and PDAI scores consist 
partially of questions on restrictions in daily activities. All these questions were answered 
negative, indicating that our patients did not experience restrictions in their daily life due to 
the fistulas, probably because after a mean 5.5 years they were ‘used to’ having fistulas with 
continuously discharge and pain, and managed to continue with their activities despite the 
daily discomfort. In addition, abscesses larger than 2 cm were drained before inclusion in the 
trial resulting in less anal pain and thus in lower PDAI scores and possibly a better quality of 
life.  
In our study we used allogeneic MSCs harvested from bone marrow of healthy donors. One 
of the advantages of allogeneic MSCs is the possibility to generate a stock with ‘off-the-
shelf’ treatment potential without the requirement to expand autologous MSCs for weeks 
before a patient can be treated. Immediate availability of MSCs for the treatment of fistulas 
is warranted as the development of abscesses requires surgery and results in a reduced 
quality of life. In addition, MSCs can be harvested from healthy young donors with a higher 
yield compared to older donors and possessing a higher regenerative and 
immunomodulatory potential, thereby also avoiding possible disease-related effects on the 
autologous MSCs.24-26 Similar to autologous MSCs, in this study allogeneic MSCs were 
observed to be safe. During the study period, none of the included patients reported 
adverse events related to MSC injection.  
One of the concerns of cell-based therapy is the safety regarding malignant transformation 





study27, a recently published meta-analysis 14 papers28 did show occurrence of malignancies 
but only in patients with previous or current malignancies, no formation of de novo tumours 
were reported. In our study, only one patient (in group 1) developed an adenocarcinoma but 
it was localized in the cecum. In our patient, the rectum was and remained completely 
normal at baseline and follow-up endoscopy of the local administration site. The local 
injection of MSC in this regard argues against causing cancer at a different site. Also, the 
patient developed this cancer more than 15 months after MSC-therapy. Adult MSCs are 
reported to have a very limited lifespan in vivo; such a late cancer development seems not 
compatible with a direct relation to MSC administration. Lastly, the patients’ uncle died from 
colon cancer at age 42 suggesting a hereditary component.  
Although the recently published results on MSC treatment for perianal fistulizing CD are 
promising, there are substantial differences in the origin and preparation of MSCs, and 
techniques of administration among these studies, making it difficult to compare.15-20 We 
believe that an important step to achieve MSC efficacy is the removal of the epithelial layer 
present in long-standing perianal fistulas hindering fistula healing. In addition, attention 
must be paid to the closure of the internal opening since that is the place where the fistula 
has emerged and prohibits fecal contamination of the treated fistula tract. For this reason, 
this was also the location of MSCs injection.  
The mechanism(s) by which the administered MSCs exert their action was not studied in our 
trial. MSCs possess a broad range of immunomodulatory properties interfering in both the 
innate and adaptive immune system.29,30 Pre- and post-MSC administration, biopsies with 
subsequent analysis of infiltrates could shed light whether the immunosuppressive effects 
of MSCs in vitro can be confirmed. It has been reported that the percentage of Tregs was 
increased in both rectal biopsies and peripheral blood 12 months after intrafistular MSC 
treatment, compared to baseline, suggesting a systemic effect of injected MSCs.18 In our 
patients, active CD was only localized in the fistula with luminal disease in remission as 
reflected by the stable CDAI, CDEIS and SES-CD during the entire study period. This was also 
reflected by the stable and low levels of inflammatory cytokines in the biopsies. 
Interestingly, examining the mean levels of proinflammatory cytokines IL-8, IL-1β and IL-6 in 
the fistula curettage material obtained at surgical intervention revealed baseline fistula 
cytokine levels were at least significantly higher as found in rectal biopsies either in week 0 
or 12. Unfortunately, no follow-up material of the fistulas could be studied.  
In conclusion, local administration of allogeneic bone marrow-derived MSCs was found to 
be safe and feasible in patients with refractory perianal fistulizing CD. Local treatment with 
3x107 MSC showed superior fistula healing compared to placebo, and lower MSC dosage 
seemed superior to the use of a higher dose. 
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Background: Durable remission rates of perianal fistulas in Crohn’s disease (CD) are still low 
despite novel drugs and advanced surgical techniques. Local administration of 
mesenchymal stromal cells (MSCs) and anti-TNF in the fistula tract seem to improve 
patient’s outcome.  
Objective: To propose a standardized and validated protocol for the administration of local 
treatment of CD perianal fistulas. 
Methods: A working group consisting of gastroenterologists and surgeons with expertise 
on perianal Crohn’s from the Leiden University Medical Center (LUMC) in The Netherlands 
developed a perianal fistula map (PFM) for local MSC treatment of perianal fistulizing CD. 
The PFM was validated during our recently performed trial on allogeneic bone marrow-
derived mesenchymal stromal cells for the treatment of refractory perianal Crohn fistulas 
(NCT01144962).  
Results: Localization and classification of perianal fistulas with magnetic resonance imaging 
(MRI) and rectoscopy is of crucial importance prior to surgical intervention with local 
therapy administration. Examination under anesthesia (EUA) is necessary to incise and drain 
abscesses when present. Optimization of medical treatment when active luminal CD is 
present, is the first step before embarking on surgery and local therapy administration. In 
addition, strictures hindering the surgeon to adequately perform standard operating 
procedures (SOPs) have to be endoscopically dilated. Curettage of the fistula tract has an 
important role as long-standing CD perianal fistulas will not close without removal of 
epithelium. To diminish bacterial contamination of the fistula, the internal opening has to be 
closed. The origin of the fistula is the internal opening, therefore, efficacy of MSCs is 
presumably the highest when they are infused into the wall around the internal opening. 
Conclusion: In this paper we proposed a standardized and validated protocol for the 
administration of local treatment of CD perianal fistulas to be able to reliably assess efficacy 
of local therapy.  
 
 




Despite all the available drugs and advanced surgical techniques durable remission rates of 
perianal fistulas in Crohn’s disease (CD) still remain low.1 The treatment outcome of perianal 
fistulas is dependent of multiple factors. Not only the activity of the underlying 
inflammatory disease, but also genetic and microbiological factors determine the clinical 
course of CD fistulas and the success rates of medical and surgical treatment. Anti-tumor 
necrosis factor (TNF) agents such as infliximab, especially combined with antibiotics, are 
effective in treating perianal fistulas.2,3 However, after infliximab treatment more than one 
third of the patients with an initially healed perianal fistula had a recurrence of their fistula 
after 5 years.4 Surgically, fistulotomy is an effective treatment for simple superficial fistulas 
with success rates of 80-100%.5 Unfortunately, most patients with perianal fistulizing Crohn’s 
disease have complex fistulas often with multiple branches and involvement of the anal 
sphincters. A temporary non-cutting seton to promote drainage and diminish inflammation 
before embarking on surgery is crucial in the treatment of these patients. However, fistula 
healing rates after fibrin glue treatment (38%) or the insertion of an anal fistula plug (55%) 
are disappointing.6,7 A mucosal advancement flap is successful in 64% but incontinence 
occurred in almost 10% of the treated patients.8  
Recently, the administration of local therapies for perianal fistulas is emerging. Various 
studies have demonstrated encouraging results of local injection of anti-TNF9-13 in the fistula 
tract and local cellular therapy with mesenchymal stromal cells (MSCs).14-17 MSCs are 
multipotent cells capable of modulating immune responses by for instance interfering in the 
differentiation of T cells18 and maturation of antigen presenting cells.19 In addition, MSCs are 
able to ‘sense’ inflammation as they appear to be capable of migrating to the damaged 
tissue to contribute in the repair processes.20-23 However, the number of MSCs that 
specifically migrate to the site of inflammation is low after systemic injection and therefore, 
local injection might enhance their therapeutic efficacy.24-26 Indeed, local injection of fibrin 
glue in combination with MSCs resulted in higher fistula healing rates compared to 
treatment with fibrin glue alone (71% vs 16%).14 Even a slightly higher complete closure rate 
of 82% was observed in a recently published phase II trial including 43 patients with perianal 
Crohn’s who received MSCs locally proportioned to fistula length.17 Also without fibrin glue, 
local injection of MSCs originating from both adipose tissue and bone marrow induced 
reduction of draining CD perianal fistulas.15,16 Although this mode of therapy administration 
seems effective, preoperative workup and practice among surgeons regarding injection 
techniques is likely to differ substantially. In order to standardize local therapy for perianal 
Crohn’s, we developed a new standardized approach and validated this during a recent 
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(NCT01144962).  
Results: Localization and classification of perianal fistulas with magnetic resonance imaging 
(MRI) and rectoscopy is of crucial importance prior to surgical intervention with local 
therapy administration. Examination under anesthesia (EUA) is necessary to incise and drain 
abscesses when present. Optimization of medical treatment when active luminal CD is 
present, is the first step before embarking on surgery and local therapy administration. In 
addition, strictures hindering the surgeon to adequately perform standard operating 
procedures (SOPs) have to be endoscopically dilated. Curettage of the fistula tract has an 
important role as long-standing CD perianal fistulas will not close without removal of 
epithelium. To diminish bacterial contamination of the fistula, the internal opening has to be 
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presumably the highest when they are infused into the wall around the internal opening. 
Conclusion: In this paper we proposed a standardized and validated protocol for the 
administration of local treatment of CD perianal fistulas to be able to reliably assess efficacy 
of local therapy.  
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Process to consensus of the perianal fistula map (PFM) 
An working group consisting of IBD-specialized gastroenterologists and -surgeons with 
expertise on perianal Crohn’s from the Leiden University Medical Center (LUMC) in The 
Netherlands was formed to develop a perianal fistula map (PFM) for local MSC treatment of 
perianal fistulizing CD. The working group achieved decisions by consensus on the following 
four topics: (1) localization and classification of perianal fistulas, (2) surgical intervention 
prior to therapy administration, (3) local therapy administration, and (4) follow-up.  
 
Validation of the PFM 
Validation of the PFM was performed during our recently performed study on allogeneic 
bone marrow-derived mesenchymal stromal cells for the treatment of refractory perianal 
Crohn fistulas (NCT01144962). Eligible patients had refractory actively draining perianal 
fistulas with 1-2 internal openings and 1-3 fistula tracts. Patients with rectovaginal fistulas or 
complex perianal fistulas with more than 2 internal openings were not included in this trial.  
 
RESULTS 
Consensus of the PFM (figure 1) 
(1) Localization and classification of perianal fistulas  
Magnetic resonance imaging (MRI) 
Classification of perianal fistulas by determining the location of the internal opening and the 
exact route of the fistula with respect to both sphincters is of crucial importance before 
embarking on surgery. Examination under anesthesia (EUA) is essential when an abscess is 
present to be able to incise and drain the abscess.  
 
Rectoscopy 
As proctitis complicates surgical procedures, rule out the presence of proctitis with a 
rectoscopy. If proctitis is present, it is important to optimize medical treatment before 
administrating local therapy for perianal Crohn’s. Strictures hindering the surgeon to 
adequately perform the standard operating procedures (SOPs) are important to dilate 
endoscopically. 
 
(2) Surgical intervention prior to therapy administration 
It was agreed to be of utmost importance to prevent adverse effects by minimalizing the 
surgical trauma. Excessive and long-lasting stretch of the anal sphincter by introducing 
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rectal retractors must be omitted in order to reduce the risk of decreased continence. No 
fistulotomy should be performed for transsphincteric fistulas involving more than one third 
of the sphincter muscle. As long-standing CD perianal fistulas are often epithelialized, these 
fistulas will not close without curettage of the fistula tract. Closure of the internal opening 
is paramount to prevent continuous contamination of the fistula tract with feces. 
 
(3) Local therapy administration 
The goal of local treatment with MSCs is the reduction in the number of actively draining 
fistulas caused by CD. Therefore, it was decided that MSCs needed to be placed at the origin 
of the fistula where the inflammation resides: in the walls of the fistula around the closed 
internal opening. Moreover, leaving the suspension in the lumen leads to a waste of 
therapeutic agents as the majority of the suspension will just seep out of the lumen.  The 
number of injection sites was kept to the minimum to ensure administration of enough 
MSCs per injection site. 
 
(4) Follow-up 
First 6 hours after local therapy administration 
Observation of the patient with monitoring of the vital signs after local therapy 
administration is important to be able to quickly interfere when infusion reactions occur or 
when the patient develops fever during the first 6 hours after surgery. If no adverse events 
are observed, the patient can be discharged the same day. 
 
6, 12 and 24 weeks after local therapy administration 
Follow-up visits at the outpatients clinic are performed by an IBD-specialized 
gastroenterologist and/or -surgeon. The patient is checked for persistent or recurrent active 
fistulas, abscesses, wound infections and/or rebleedings. Efficacy defined as absence of 
discharge from the fistula(s) by gentle finger compression is determined at physical 
examination. MRI is not helpful in the evaluation of fistula healing within the first year after 
local therapy administration as radiological healing can lag behind clinical healing by a 
median of one year.27 Most perianal abscesses are easily diagnosed during physical 
examination. However, when physical examination is not evident and an abscess cannot be 
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Feasibility and outcomes of surgical intervention with local therapy administration 
We validated the PFM in our recently performed study (NCT01144962). In our hands, 5 ml of 
3x107 MSCs was enough to achieve a fistula healing rate of 85.7% compared to 33.3% in the 
placebo group at 12 and 24 weeks after local MSC administration. At these time points, 80% 
FIGURE 1 Consensus of the perianal fistula map (PFM). 
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of the patients had no draining perianal fistulas anymore after local treatment with 3x107 
MSCs compared to 33.3% in the placebo group. Surgery with local injection of MSCs was 
feasible as we were able to perform all surgical SOPs in all included patients. In addition, the 
surgical procedures took only 20-40 minutes per patient depending on the number and 
complexity of the perianal fistulas. Surgical intervention was well tolerated by all patients: 
no wound infection or -bleedings were reported. Moreover, local MSC administration was 
without treatment related adverse events. 
 
Standard operating procedures (SOPs) (figure 2) 
(1) Localization and classification of perianal fistulas 
Perform a MRI and a rectoscopy to describe the localization and classification of the perianal 
fistula(s) following the Parks and ‘simple/complex’ criteria.5,28,29 In figure 3 possible routes 
of perianal fistulas are schematically shown. 
1. Locate the internal opening(s): 
- Use the ‘anal clock’ when patient is in lithotomy position to describe the location;  
- Use the anorectal junction to indicate the level of the internal opening: below, at or 
above 
2. Determine the exact route of the fistula(s) with respect to both sphincters: 
intersphincteric, transsphincteric, suprasphincteric or extrasphincteric. 
3. Locate the external opening(s): use the ‘anal clock’ when patient is in lithotomy position 
to describe the location. 
4. Assess the presence of horseshoeing: intersphincteric, infra- or supralevator. 
5. Assess the presence of a rectovaginal fistula. 
6. Assess the presence of perianal abscesses: superficial or supralevator. 
If present, perform an examination under anesthesia with incision and drainage of the 
abscess. 
7. Perform a rectoscopy to assess luminal activity of CD.  
- If proctitis is present, optimize medical treatment before local therapy 
administration. 
- If a stricture that might hinder the surgeon to perform the SOPs is present, 
endoscopic dilatation of the stricture before local therapy administration is 
recommended.  






Feasibility and outcomes of surgical intervention with local therapy administration 
We validated the PFM in our recently performed study (NCT01144962). In our hands, 5 ml of 
3x107 MSCs was enough to achieve a fistula healing rate of 85.7% compared to 33.3% in the 
placebo group at 12 and 24 weeks after local MSC administration. At these time points, 80% 
FIGURE 1 Consensus of the perianal fistula map (PFM). 
Perianal fistula(s) MRI Abscess








EUA examination under anesthesia 
MRI magnetic resonance imaging 
De-epithelialization of the fistula 
tract, trimming of the mucosa and 
skin around respectively the inter-
nal and external opening and 






STANDARDIZATION OF MSC ADMINISTRATION 
87 
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- If proctitis is present, optimize medical treatment before local therapy 
administration. 
- If a stricture that might hinder the surgeon to perform the SOPs is present, 
endoscopic dilatation of the stricture before local therapy administration is 
recommended.  







(2) Surgical intervention prior to therapy administration 
Perform the surgery and local therapy administration under general anesthesia with the 
patient in lithotomy position. 
1. Inspect perianal area for external openings. Use a Hill-Ferguson retractor for optimal
exposure. Self-retaining devices such as the Parks’ anal retractor are likely to increase the
risk of postoperative incontinence.
FIGURE 2 Standard operating procedures (SOPs). Timeline of SOPs. (1) Localization and classification of perianal 
fistulas. (2) Surgical intervention prior to therapy administration. (3) Local therapy administration. 
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FIGURE 3 Schematic routes of perianal fistulas. (A) Single internal opening and single external opening. (B) 
Single internal opening and two external openings. (C) Single internal opening and three external openings. 
(D) Single internal opening with one blind ending tract and one external opening. (E) Single internal opening 
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(2) Surgical intervention prior to therapy administration 
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exposure. Self-retaining devices such as the Parks’ anal retractor are likely to increase the
risk of postoperative incontinence.
FIGURE 2 Standard operating procedures (SOPs). Timeline of SOPs. (1) Localization and classification of perianal 
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FIGURE 3 Schematic routes of perianal fistulas. (A) Single internal opening and single external opening. (B) 
Single internal opening and two external openings. (C) Single internal opening and three external openings. 
(D) Single internal opening with one blind ending tract and one external opening. (E) Single internal opening 
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2. Explore the fistula tract(s) and identify the connection between the external and internal 
opening(s) by introducing a malleable probe via the external opening(s). 
3. Remove seton(s) if in situ. 
4. Trim the mucosa around the internal opening(s). 
5. Remove the tissue surrounding the external opening(s).  
6. Thoroughly scrape the entire fistula tract(s) using a curette.  
7. Close the internal opening(s) with an absorbable polydioxanone (PDS) II 4/0 interrupted 
suture.  
8. Check with a malleable probe by inserting it via the external opening(s) if the internal 
opening(s) is/are completely closed to prevent fecal contamination of the tract.  
If not, repeat step 7.  
 
(3) Local therapy administration 
Inject equal volumes of MSCs at 4 quadrants per injection site. Inject the MSCs in the fistula 
wall around the closed opening. 
1. Resuspend MSCs before injection. 
2. Use a long fine needle for the administration of MSCs. 
3. Half of the MSC suspension must be injected into the fistula wall around the closed 
internal opening(s) by introducing the syringe via the anus. 
4. The second half must be divided equally into the fistula wall as close as possible to the 
closed internal opening(s) by introducing the syringe via the external opening(s) into the 
fistula tract(s) as far as possible. 
 
(4) Follow-up 
The patient needs to be monitored for adverse events related to the surgery and/or local 
therapy administration. 
1. Observe the patient with monitoring of the vital signs during the first 6 hours after local 
therapy administration for infusion reactions and the development of fever. The patient 
can be discharged if no adverse events are observed after 6 hours. 
2. Evaluate at the outpatients clinic the occurrence of wound infections and -bleedings, and 
changes in vital signs and laboratory measurements 6, 12 and 24 weeks after local therapy 
administration. 
3. Evaluate efficacy of the local treatment by gentle finger compression at the external 
opening(s) to assess discharge from the fistula. 
4. Use ultrasound when there is suspicion of a perianal abscess (fever and a fluctuating 
painful perianal swelling). 
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If present, EUA with incision and drainage of the abscess with subsequently placement 
of a non-cutting seton to promote drainage and reduce inflammation of the fistula is the 
first step before embarking on surgery. Antibiotics as ciprofloxacin and/or metronidazole 
are recommended. 
DISCUSSION 
In this paper we proposed a standardized protocol for the local treatment of perianal 
fistulizing CD which was validated in our recently performed clinical trial on allogeneic bone 
marrow-derived mesenchymal stromal cells for the treatment of refractory perianal Crohn 
fistulas (NCT01144962). Differences in surgical practice are likely to impact on treatment 
outcome. Therefore, standardization is crucial to assess the efficacy of current and future 
local treatment strategies. 
The ultimate treatment goal is to achieve complete closure of the perianal fistulas. 
Unfortunately, treatment of perianal fistulizing CD remains challenging despite a range of 
both medical as surgical options, and is often accompanied by multiple relapses.1 
Therapeutic efficacy might be enhanced when drugs are locally administrated. Promising 
results after local administration of MSCs have been published with fistula healing rates of 
69-82% in uncontrolled trials14-17 and 80% in our recently performed randomized double-blind 
placebo-controlled trial. In addition, local therapy with anti-TNF agents might also resulted 
in fistula closure, however, until now only open-label studies with small sample size and no 
randomized controlled trials have been reported.9-13 Fistula remission rates varied largely 
after local administration of anti-TNF drugs (36-88%) possibly as a result of additional 
fistulectomy in the trial with the highest efficacy rate.11  
Although fistula healing rates after local therapy with either MSCs or anti-TNF are 
encouraging, there are substantial differences in the techniques of administration, making 
it difficult to reliable assess the effect of local therapy. Therefore, we developed a 
standardized PFM. Although this protocol was validated with MSCs, we are convinced that 
these SOPs can also be implemented for local therapy with anti-TNF agents. Our rationale 
behind the location of injection is similar for all CD perianal fistulas and is not dependent on 
the type of local treatment. In all CD perianal fistulas, the origin of the fistula is the internal 
opening. Therefore we believe that local treatment should be injected around the closed 
internal opening. Closure of the opening prevents bacterial contamination of the fistula. 
Moreover, the treatment has presumable the most efficacy when it can reside at the site of 
injection. Therefore, administration of the drugs should be inside the walls of the fistula 
since suspension that is left in the lumen of the fistula will automatically be discharged from 
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fistulectomy in the trial with the highest efficacy rate.11  
Although fistula healing rates after local therapy with either MSCs or anti-TNF are 
encouraging, there are substantial differences in the techniques of administration, making 
it difficult to reliable assess the effect of local therapy. Therefore, we developed a 
standardized PFM. Although this protocol was validated with MSCs, we are convinced that 
these SOPs can also be implemented for local therapy with anti-TNF agents. Our rationale 
behind the location of injection is similar for all CD perianal fistulas and is not dependent on 
the type of local treatment. In all CD perianal fistulas, the origin of the fistula is the internal 
opening. Therefore we believe that local treatment should be injected around the closed 
internal opening. Closure of the opening prevents bacterial contamination of the fistula. 
Moreover, the treatment has presumable the most efficacy when it can reside at the site of 
injection. Therefore, administration of the drugs should be inside the walls of the fistula 
since suspension that is left in the lumen of the fistula will automatically be discharged from 





epithelialization of the fistula tract is present.30 Therefore, curettage of the entire fistula 
tract is required as the presence of epithelium inside the tract hinders the closure of the 
fistula. The possibility to locally treat different CD related fistulas such as rectovaginal and 
enterocutaneous fistulas, has not been examined. However, it is plausible that this 
standardized protocol can also be used in the treatment of different types of fistulas as the 
origin of the fistula remains the internal opening in the intestine.  
Our proposed SOPs were validated in 21 patients and resulted in 100% feasibility since we 
were able to perform all SOPs in all included patients without treatment related side effects. 
However, when the syringe with MSC suspension was introduced via the external opening, 
we cannot ensure that all MSCs were indeed injected around the internal opening. It is likely 
that in patients with a longer or tortuous fistula tract, we were not able to reach the internal 
opening via this route. However, only half of the MSC suspension was injected by 
introducing the syringe via the external opening, the other half was always administered 
into the wall around the closed internal opening by introducing the syringe via the anus. 
In this article, a proposal to standardize the method of local treatment administration for 
perianal fistulizing CD was made. We suggest to use our standardized and validated protocol 
for the administration of local treatment of CD perianal fistulas to be able to reliably assess 
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Despite the wide range of available medical therapies for inflammatory bowel disease (IBD) 
nowadays, treatment of IBD is far from satisfactory and there is an unmet need for effective 
medical therapeutics in patients with IBD not responding to the conventional strategies. 
Currently, mesenchymal stromal cells (MSCs) are under investigation as a potential 
therapeutic option because they possess both immunomodulatory and tissue regenerative 
properties. However, an optimal treatment strategy of MSC-administration to reach 
maximal efficacy is not yet known. Therefore, the aim of our current study was to investigate 
whether timing of human bone marrow-derived MSC (hBM-MSCs) administration and 
presence of an ongoing inflammatory response are important for treatment efficacy. We 
induced both mild and severe DSS colitis in mice and treated ‘pre-emptively’ or 
‘therapeutically’ with hBM-MSCs. One intraperitoneal therapeutic injection of hBM-MSCs 
was found to significantly attenuate severe but not mild colitis, accompanied by reduced 
mucosal IL-6, TNFα and IL-17a levels, resulting in less mucosal damage in the distal colon. 
Neither in vitro prestimulation of hBM-MSCs with IFNγ nor multiple MSC injections during 
the colitis, subsequent to a pre-emptive injection, resulted in improvement of efficacy. 
Furthermore, engraftment of hBM-MSCs at the site of inflammation did not seem to be 
important to elicit their anti-inflammatory effect suggesting that excreted soluble factors 
are the key players in MSC-mediated immunosuppression. Taken together, our results 
indicate that the timing of MSC-administration and the presence of an ongoing severe 
inflammatory response is crucial to achieve efficacy in DSS-induced colitis.  
 
 




Crohn’s disease (CD) and ulcerative colitis (UC), collectively called inflammatory bowel 
disease (IBD), are chronic diseases characterized by recurrent inflammation of the 
gastrointestinal tract. An inappropriate immune response to extracellular pathogens in the 
gut in a genetically predisposed host is thought to be the cause of IBD.1,2 Although a wide 
range of medical therapies for IBD is available3,4, treatment of IBD is far from satisfactory. In 
UC a colectomy can be the only effective treatment, however, in CD recurrent disease after 
surgery is very common. Therefore, there is an unmet need for effective medical 
therapeutics in patients with IBD not responding to the conventional strategies.  
Mesenchymal stromal cells (MSCs) are non-haematopoietic precursors of connective tissues 
and can be found as fibroblast-like cells in the stroma of solid organs and in the bone 
marrow. MSCs are capable of differentiating in vitro into multiple lineages of the 
mesenchyme, including osteoblasts, adipocytes and chondroblasts.5-7 Due to their 
immunomodulatory properties and their ability to actively participate in tissue repair8, MSCs 
obtained from different sources have emerged as a potential new treatment for IBD. In 
experimental colitis models, MSCs were reported to ameliorate the inflammatory tissue 
destruction by downregulating Th1 and Th17 responses in colonic tissue and increasing the 
regulatory cytokine IL-10.9-12 Several studies, however, indicate that MSCs are not 
intrinsically immunosuppressive but that activation by proinflammatory cytokines in vivo, 
e.g. by an ongoing immune response, is necessary to induce their full immunomodulatory 
capacity. Furthermore, when not primed sufficiently, MSCs might even enhance immune 
responses.13-15 In addition, in vitro prestimulation of MSCs with proinflammatory cytokines 
such as IFNγ have been reported to increase efficacy in vivo.9 Therefore, the aim of our 
current study was to investigate whether the timing of the administration of human bone 
marrow-derived MSCs (hBM-MSCs) is important for their efficacy in mice with DSS-induced 
colitis and whether this efficacy is enhanced with multiple injections during the colitis or 
when hBM-MSCs were prestimulated in vitro with IFNγ. In addition, both mild and severe 
colitis models were applied to evaluate the importance of an ongoing inflammation in 
reaching this efficacy. 
 
MATERIALS AND METHODS 
MSC isolation 
Bone marrow-derived MSC (BM-MSC) were obtained by aspiration from three patients 
undergoing orthopedic surgery. The bone marrow mononuclear cells (MNC) were isolated 





Despite the wide range of available medical therapies for inflammatory bowel disease (IBD) 
nowadays, treatment of IBD is far from satisfactory and there is an unmet need for effective 
medical therapeutics in patients with IBD not responding to the conventional strategies. 
Currently, mesenchymal stromal cells (MSCs) are under investigation as a potential 
therapeutic option because they possess both immunomodulatory and tissue regenerative 
properties. However, an optimal treatment strategy of MSC-administration to reach 
maximal efficacy is not yet known. Therefore, the aim of our current study was to investigate 
whether timing of human bone marrow-derived MSC (hBM-MSCs) administration and 
presence of an ongoing inflammatory response are important for treatment efficacy. We 
induced both mild and severe DSS colitis in mice and treated ‘pre-emptively’ or 
‘therapeutically’ with hBM-MSCs. One intraperitoneal therapeutic injection of hBM-MSCs 
was found to significantly attenuate severe but not mild colitis, accompanied by reduced 
mucosal IL-6, TNFα and IL-17a levels, resulting in less mucosal damage in the distal colon. 
Neither in vitro prestimulation of hBM-MSCs with IFNγ nor multiple MSC injections during 
the colitis, subsequent to a pre-emptive injection, resulted in improvement of efficacy. 
Furthermore, engraftment of hBM-MSCs at the site of inflammation did not seem to be 
important to elicit their anti-inflammatory effect suggesting that excreted soluble factors 
are the key players in MSC-mediated immunosuppression. Taken together, our results 
indicate that the timing of MSC-administration and the presence of an ongoing severe 
inflammatory response is crucial to achieve efficacy in DSS-induced colitis.  
 
 




Crohn’s disease (CD) and ulcerative colitis (UC), collectively called inflammatory bowel 
disease (IBD), are chronic diseases characterized by recurrent inflammation of the 
gastrointestinal tract. An inappropriate immune response to extracellular pathogens in the 
gut in a genetically predisposed host is thought to be the cause of IBD.1,2 Although a wide 
range of medical therapies for IBD is available3,4, treatment of IBD is far from satisfactory. In 
UC a colectomy can be the only effective treatment, however, in CD recurrent disease after 
surgery is very common. Therefore, there is an unmet need for effective medical 
therapeutics in patients with IBD not responding to the conventional strategies.  
Mesenchymal stromal cells (MSCs) are non-haematopoietic precursors of connective tissues 
and can be found as fibroblast-like cells in the stroma of solid organs and in the bone 
marrow. MSCs are capable of differentiating in vitro into multiple lineages of the 
mesenchyme, including osteoblasts, adipocytes and chondroblasts.5-7 Due to their 
immunomodulatory properties and their ability to actively participate in tissue repair8, MSCs 
obtained from different sources have emerged as a potential new treatment for IBD. In 
experimental colitis models, MSCs were reported to ameliorate the inflammatory tissue 
destruction by downregulating Th1 and Th17 responses in colonic tissue and increasing the 
regulatory cytokine IL-10.9-12 Several studies, however, indicate that MSCs are not 
intrinsically immunosuppressive but that activation by proinflammatory cytokines in vivo, 
e.g. by an ongoing immune response, is necessary to induce their full immunomodulatory 
capacity. Furthermore, when not primed sufficiently, MSCs might even enhance immune 
responses.13-15 In addition, in vitro prestimulation of MSCs with proinflammatory cytokines 
such as IFNγ have been reported to increase efficacy in vivo.9 Therefore, the aim of our 
current study was to investigate whether the timing of the administration of human bone 
marrow-derived MSCs (hBM-MSCs) is important for their efficacy in mice with DSS-induced 
colitis and whether this efficacy is enhanced with multiple injections during the colitis or 
when hBM-MSCs were prestimulated in vitro with IFNγ. In addition, both mild and severe 
colitis models were applied to evaluate the importance of an ongoing inflammation in 
reaching this efficacy. 
 
MATERIALS AND METHODS 
MSC isolation 
Bone marrow-derived MSC (BM-MSC) were obtained by aspiration from three patients 
undergoing orthopedic surgery. The bone marrow mononuclear cells (MNC) were isolated 





105/cm2 in DMEM-low glucose (DMEM-LG; Invitrogen Corp., Paisley, UK) supplemented with 
10% fetal calf serum (FCS; Greiner Bio-one) and Penicillin/Streptomycin (P/S; Invitrogen Corp., 
Paisley, UK). All sampling procedures were performed in accordance with the Helsinki 
Declaration and use for research purposes was approved by the ethics committee of Leiden 
University Medical Center (LUMC). All patients provided informed consent. 
 
MSC expansion and preparation 
Cells were grown in 175 cm2 flasks (Corning Life Sciences B.V., Schiphol-Rijk, The 
Netherlands) in a 37°C humidified incubator containing 5% CO2, and the medium was 
refreshed every 3-4 days. When the spindle shaped MSC monolayer reached >80% 
confluence, cells were detached using trypsin/EDTA (Invitrogen Corp., Paisley, UK) and 
replated at a density of 4,000 cells per cm2. In the indicated experiments, MSCs were 
cultured in the presence of 10 ng/ml recombinant human interferon-gamma (IFNɣ) (Sigma-
Aldrich, St. Louis, MO) for 7 days to generate IFNɣ-stimulated MSCs (IFNɣ-hBM-MSCs). MSCs 
from passages 4 to 5 were used for transplantation experiments. In some studies MSCs were 
used after lentiviral transduction with a human vector expressing the enhanced green 
fluorescent protein (eGFP) gene (a kind gift of Jim Swildens, LUMC, The Netherlands).  
Immunophenotyping of cultured human MSC was performed using the following primary 
antibodies: CD90, CD73, human leukocyte antigen (HLA)-ABC, CD31, CD34, CD45, CD80, HLA-
DR (BD Biosciences, San Diego, CA, USA), and CD105 (Ancell Corp., Bayport, MN, USA). 
Samples were analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Diego, CA, 
USA) and the data were evaluated with FlowJo software (version 7.6.3., Tree Star Inc. 
Ashland, OR, USA). 
 
In vitro differentiation  
For osteogenic differentiation MSCs were grown to 80% confluency in 24-well culture plates 
and stimulated for 21 days in osteogenic differentiation medium consisting of  complete 
medium supplemented with  0,1 μM dexamethason, 50 μg/ml Vitamin C (both from Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands), and 5 mM β-glycerophosphate (Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands) and stained for alkaline phosphatase 
activity with Fast Blue (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). For 
adipogenic differentiation, MSC were stimulated for 21 days in adipogenic differentiation 
medium consisting of complete medium supplemented with  0,1 μM dexamethason, insulin 
(10 μg/ml), indomethacin (5μM) and 3-isobutyl-1-methylxanthine (5μM) (all from Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands). Formation of lipid droplets was 
visualized with Oilred O staining (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). 
MSCS IN DSS COLITIS 
101 
FIGURE 1 Administration of DSS in the drinking water for 7 days results in a colitis characterized by body 
weight loss with shortening and thickening of the colon dependent on the dose of DSS supplied. (A): Body 
weight changes expressed as a percentage of body weight at day 0. (B): Mean weight/length ratio of the 
colons per DSS dose at sacrifice (day 9). Colons become shorter and thicker when more inflammation is 
present. *, p = 0.05 1.0% vs 2.0% DSS and **, p = 0.003 control (0.0%) vs 2.0% DSS. (C): Macroscopic image of a 
colon after 7 days of 2.0% DSS in the drinking water compared to control (0.0% DSS). 
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from passages 4 to 5 were used for transplantation experiments. In some studies MSCs were
used after lentiviral transduction with a human vector expressing the enhanced green
fluorescent protein (eGFP) gene (a kind gift of Jim Swildens, LUMC, The Netherlands).
Immunophenotyping of cultured human MSC was performed using the following primary
antibodies: CD90, CD73, human leukocyte antigen (HLA)-ABC, CD31, CD34, CD45, CD80, HLA-
DR (BD Biosciences, San Diego, CA, USA), and CD105 (Ancell Corp., Bayport, MN, USA). 
Samples were analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Diego, CA,
USA) and the data were evaluated with FlowJo software (version 7.6.3., Tree Star Inc.
Ashland, OR, USA). 
In vitro differentiation
For osteogenic differentiation MSCs were grown to 80% confluency in 24-well culture plates
and stimulated for 21 days in osteogenic differentiation medium consisting of  complete
medium supplemented with 0,1 μM dexamethason, 50 μg/ml Vitamin C (both from Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands), and 5 mM β-glycerophosphate (Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands) and stained for alkaline phosphatase
activity with Fast Blue (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). For
adipogenic differentiation, MSC were stimulated for 21 days in adipogenic differentiation
medium consisting of complete medium supplemented with 0,1 μM dexamethason, insulin
(10 μg/ml), indomethacin (5μM) and 3-isobutyl-1-methylxanthine (5μM) (all from Sigma-
Aldrich Chemie BV, Zwijndrecht, The Netherlands). Formation of lipid droplets was
visualized with Oilred O staining (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands).
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FIGURE 1 Administration of DSS in the drinking water for 7 days results in a colitis characterized by body 
weight loss with shortening and thickening of the colon dependent on the dose of DSS supplied. (A): Body 
weight changes expressed as a percentage of body weight at day 0. (B): Mean weight/length ratio of the 
colons per DSS dose at sacrifice (day 9). Colons become shorter and thicker when more inflammation is 
present. *, p = 0.05 1.0% vs 2.0% DSS and **, p = 0.003 control (0.0%) vs 2.0% DSS. (C): Macroscopic image of a 
colon after 7 days of 2.0% DSS in the drinking water compared to control (0.0% DSS). 
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Suppression of PBMC proliferation by MSC 
Cultured MSC were plated in graded doses in 96-well flat-bottom plates (Corning, Life 
Sciences) and allowed to adhere overnight. Human peripheral blood mononuclear cells 
(PBMCs) isolated from buffy coats (1 x 105/well) were added to the MSC and stimulated with 
human T-activator CD3/CD28 dynabeads (Invitrogen Corp., Paisley, UK) in a bead:cell ratio 
1:5. After 5 days of co-culture, cells were pulsed with [3H]-thymidine (0.5 µCi/well) and 
incubated for 16 h at 37°C. The cultures were harvested on a glass fiber filter and thymidine 
incorporation was measured with a liquid scintillation counter (Wallac, Turku, Finland). Data 
are expressed as mean corrected counts per minute (CCPM) of triplicate co-cultures 
stimulated with anti-CD28/anti- CD3-coated Dynabeads (one bead/5 cells, Invitrogen) and 
seeded in Iscove’s modified Dulbecco’s media (Invitrogen) supplemented with 5% human 
serum (Sanquin, Leiden, The Netherlands), and 5% FCS.   
Induction of colitis and cell transplantation 
All experiments were approved by the Committee on Animal Welfare (CAW) of the Leiden 
University Medical Center. Animals were housed in individually ventilated cages and were 
given drinking water and food ad libitum. Colitis was induced in 8-week-old female 
C57BL/6Jico mice (Charles River Laboratories, The Netherlands) with dextran sulphate 
sodium (DSS; MW 36,000-50,000 kDA; MP Biomedicals, Illkirch, France) supplied in the 
drinking water for 7 days. Severity of the colitis is defined by their weight loss, with a 
maximal tolerated weight loss by the CAW of 20%. In order to be able to evaluate 
improvement and worsening of the induced colitis and based on DSS dose finding 
experiments, with characteristic shortening and thickening of the colon (figure 1), we 
induced ‘mild’ colitis with 1.25% DSS, characterized by a mean weight loss of approximately 
5%, and ‘severe’ colitis with 1.75% DSS, attained at a weight loss of approximately 15%. In this 
setting both intentionally ‘pre-emptive’ treatment with MSCs was assessed, by 
administration prior to onset of colitis, as well as intentionally ‘therapeutic’ treatment of 
colitis. In the pre-emptive model, six hours before DSS introduction, all mice were injected 
intraperitoneally with 0.5x106 hBM-MSCs in 100 µl PBS or with PBS alone as a control (figure 
2A). Some groups of mice received, after this pre-emptive injection, three additional 
injections of hBM-MSCs at day 2, 4 and 6. Mice were sacrificed 10 days after the start of the 
experiment, except for 2 animals per treatment group with severe colitis. These mice were 
sacrificed at day 63 to evaluate the long term effect of hBM-MSC therapy (figure 2B). In the 
‘therapeutic’ treatment model, mice received 6 hours after DSS introduction one injection 
with 0.5x106 hBM-MSCs or IFNγ-hBM-MSCs in 100 µl PBS or with PBS alone as a control (fig-
ure 2C). Mice were sacrificed at day 9. Body weight of all mice was measured daily and 
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disease progression and recovery were calculated as a percentage of weight loss from initial 
body weight.  
Histological evaluation of disease activity 
Segments of colon were stored in 4% neutral buffered formalin and were serially 
dehydrated, cleared in xylene and embedded in paraffin. Serial sections of 4 µm were cut, 
stained with hematoxylin and eosin (H&E) and blindedly scored by an independent 
researcher. The histological disease activity score (maximum score: 28) was calculated using 
the following criteria: (a) percentage of involved area (0, normal; 1, 1-10%; 2, 10-50%; 3, >50%), 
(b) number of follicle aggregates (0, normal (0-1); 1, little (2-3); 2 moderate (4-5); 3, extensive 
(>5)), (c) presence of edema and (d) presence of fibrosis (0, absent; 1, little; 2, moderate; 3, 
extensive), (e) localisation of erosion/ulceration (0, absent; 1, lamina propria; 2, submucosa; 
3, transmural), (f) percentage of crypt loss (0, normal; 1, 1-10%; 2, 10-50%; 3, >50%), (g) 
infiltration of granulocytes and (h) mononuclear cells (0, normal; 1, few; 2, moderate; 3, 
extensive) and (i) histologic changes (0, no evidence of inflammation; 1, low level of 
inflammation with scattered infiltrating mononuclear cells (1-2 foci); 2, moderate 
inflammation with multiple foci; 3, high level of inflammation with increased vascular density 
and marked wall thickening; 4, maximal severity of inflammation with transmural leukocyte 
infiltration and loss of goblet cells).9 
Immunohistochemistry 
GFP transduced MSCs were detected with an anti-GFP antibody (1:600, Invitrogen, Bleiswijk, 
The Netherlands). In brief, slides were incubated in 0.3% H2O2/methanol for 20 minutes at 
room temperature to block endogenous peroxidase activity. After antigen retrieval, slides 
were blocked with Teng-T (10 mM Tris, 5 mM EDTA, 0.15 M NaCl, 0.25% gelatin, 0.05% (v/v) 
Tween-20, pH 8.0) for 30 minutes, incubated overnight at 4°C with primary antibody in PBS 
containing 0.1% Triton X-100 and 1% bovine serum albumin (BSA) and followed by a 
peroxidase labelled polymer (EnVision+, Dako Netherlands BV, Heverlee, Belgium). 
Peroxidase activity was detected with 3,3’-diaminobenzidine tablets (DAB Fast Tablet, 
Sigma-Aldrich, St. Louis, MO). Sections were counterstained with hematoxylin, dehydrated, 
and mounted in Entellan (Merck KGaA, Darmstadt, Germany). 
Cytokine measurements 
Homogenates were prepared from distal colon (n = 5 per treatment group) with a Potter-
Elvehjem glass homogenizer at 4°C in Greenberger lysis buffer (150 mM NaCl, 15 mM Tris, pH 
7.4, 1 mM MgCl2, and 1% Triton X-100). Total protein content was determined using the BCA 
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Suppression of PBMC proliferation by MSC 
Cultured MSC were plated in graded doses in 96-well flat-bottom plates (Corning, Life 
Sciences) and allowed to adhere overnight. Human peripheral blood mononuclear cells 
(PBMCs) isolated from buffy coats (1 x 105/well) were added to the MSC and stimulated with 
human T-activator CD3/CD28 dynabeads (Invitrogen Corp., Paisley, UK) in a bead:cell ratio 
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incubated for 16 h at 37°C. The cultures were harvested on a glass fiber filter and thymidine 
incorporation was measured with a liquid scintillation counter (Wallac, Turku, Finland). Data 
are expressed as mean corrected counts per minute (CCPM) of triplicate co-cultures 
stimulated with anti-CD28/anti- CD3-coated Dynabeads (one bead/5 cells, Invitrogen) and 
seeded in Iscove’s modified Dulbecco’s media (Invitrogen) supplemented with 5% human 
serum (Sanquin, Leiden, The Netherlands), and 5% FCS.   
Induction of colitis and cell transplantation 
All experiments were approved by the Committee on Animal Welfare (CAW) of the Leiden 
University Medical Center. Animals were housed in individually ventilated cages and were 
given drinking water and food ad libitum. Colitis was induced in 8-week-old female 
C57BL/6Jico mice (Charles River Laboratories, The Netherlands) with dextran sulphate 
sodium (DSS; MW 36,000-50,000 kDA; MP Biomedicals, Illkirch, France) supplied in the 
drinking water for 7 days. Severity of the colitis is defined by their weight loss, with a 
maximal tolerated weight loss by the CAW of 20%. In order to be able to evaluate 
improvement and worsening of the induced colitis and based on DSS dose finding 
experiments, with characteristic shortening and thickening of the colon (figure 1), we 
induced ‘mild’ colitis with 1.25% DSS, characterized by a mean weight loss of approximately 
5%, and ‘severe’ colitis with 1.75% DSS, attained at a weight loss of approximately 15%. In this 
setting both intentionally ‘pre-emptive’ treatment with MSCs was assessed, by 
administration prior to onset of colitis, as well as intentionally ‘therapeutic’ treatment of 
colitis. In the pre-emptive model, six hours before DSS introduction, all mice were injected 
intraperitoneally with 0.5x106 hBM-MSCs in 100 µl PBS or with PBS alone as a control (figure 
2A). Some groups of mice received, after this pre-emptive injection, three additional 
injections of hBM-MSCs at day 2, 4 and 6. Mice were sacrificed 10 days after the start of the 
experiment, except for 2 animals per treatment group with severe colitis. These mice were 
sacrificed at day 63 to evaluate the long term effect of hBM-MSC therapy (figure 2B). In the 
‘therapeutic’ treatment model, mice received 6 hours after DSS introduction one injection 
with 0.5x106 hBM-MSCs or IFNγ-hBM-MSCs in 100 µl PBS or with PBS alone as a control (fig-
ure 2C). Mice were sacrificed at day 9. Body weight of all mice was measured daily and 
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disease progression and recovery were calculated as a percentage of weight loss from initial 
body weight.  
Histological evaluation of disease activity 
Segments of colon were stored in 4% neutral buffered formalin and were serially 
dehydrated, cleared in xylene and embedded in paraffin. Serial sections of 4 µm were cut, 
stained with hematoxylin and eosin (H&E) and blindedly scored by an independent 
researcher. The histological disease activity score (maximum score: 28) was calculated using 
the following criteria: (a) percentage of involved area (0, normal; 1, 1-10%; 2, 10-50%; 3, >50%), 
(b) number of follicle aggregates (0, normal (0-1); 1, little (2-3); 2 moderate (4-5); 3, extensive 
(>5)), (c) presence of edema and (d) presence of fibrosis (0, absent; 1, little; 2, moderate; 3, 
extensive), (e) localisation of erosion/ulceration (0, absent; 1, lamina propria; 2, submucosa; 
3, transmural), (f) percentage of crypt loss (0, normal; 1, 1-10%; 2, 10-50%; 3, >50%), (g) 
infiltration of granulocytes and (h) mononuclear cells (0, normal; 1, few; 2, moderate; 3, 
extensive) and (i) histologic changes (0, no evidence of inflammation; 1, low level of 
inflammation with scattered infiltrating mononuclear cells (1-2 foci); 2, moderate 
inflammation with multiple foci; 3, high level of inflammation with increased vascular density 
and marked wall thickening; 4, maximal severity of inflammation with transmural leukocyte 
infiltration and loss of goblet cells).9 
Immunohistochemistry 
GFP transduced MSCs were detected with an anti-GFP antibody (1:600, Invitrogen, Bleiswijk, 
The Netherlands). In brief, slides were incubated in 0.3% H2O2/methanol for 20 minutes at 
room temperature to block endogenous peroxidase activity. After antigen retrieval, slides 
were blocked with Teng-T (10 mM Tris, 5 mM EDTA, 0.15 M NaCl, 0.25% gelatin, 0.05% (v/v) 
Tween-20, pH 8.0) for 30 minutes, incubated overnight at 4°C with primary antibody in PBS 
containing 0.1% Triton X-100 and 1% bovine serum albumin (BSA) and followed by a 
peroxidase labelled polymer (EnVision+, Dako Netherlands BV, Heverlee, Belgium). 
Peroxidase activity was detected with 3,3’-diaminobenzidine tablets (DAB Fast Tablet, 
Sigma-Aldrich, St. Louis, MO). Sections were counterstained with hematoxylin, dehydrated, 
and mounted in Entellan (Merck KGaA, Darmstadt, Germany). 
Cytokine measurements 
Homogenates were prepared from distal colon (n = 5 per treatment group) with a Potter-
Elvehjem glass homogenizer at 4°C in Greenberger lysis buffer (150 mM NaCl, 15 mM Tris, pH 




   
   








   
   
   



































































































   
   































































































































































   
   








   
   
   





















































   






































































































































































































































































































































































































































































   
   








   
   
   




























































































   
   




































































































   
   








   
   
   



































































































   
   































































































































































   
   








   
   
   





















































   






































































































































































































































































































































































































































































   
   








   
   
   




























































































   
   





































































































Protein Assay (Thermo Scientific Pierce, Etten-Leur, The Netherlands) and cytokine levels 
were measured using the Cytometric Bead Array (BD Biosciences, San Diego, CA, USA) 
following the manufacturer’s instructions. Cytokine levels measured were corrected for the 
amount of total protein per mg colon. 
Flow cytometry 
Mice were sacrificed on day 9 after colitis induction with DSS (n = 5 mice per treatment 
group). Colonic tissue was harvested, minced with fine scissors and placed in a solution of 5 
mM EDTA and 1 mM dithiothreitol in Hanks balanced salt solution for 20 min at 37°C under 
slow rotation to detach epithelial cells. To collect lamina propria cells pieces of colonic tissue 
were placed into a solution of 2% collagenase IA (Sigma-Aldrich) in PBS and shaken at 37°C 
for 1 h. The cell suspension was then triturated through a nylon mesh and centrifuged in PBS 
at 300 g for 10 min at 4°C. Red blood cells in the cell pellet were lysed with lysis buffer (AZL, 
Leiden, The Netherlands), and the cells were washed in PBS and subsequently resuspended 
in medium containing IMDM (Lonza, Verviers, Belgium) supplemented with 2.5% FCS and P/S. 
Total cell numbers were determined with a Sysmex cell counter (SysmexAmerica, Inc. 
Mundelein, Illinois, US). In addition, peripheral blood was drawn via cardiac puncture and 
mononuclear cells were isolated with density centrifugation. Total cell numbers were 
determined with a Sysmex cell counter (Sysmex America, Inc. Mundelein, Illinois, US). The 
resulting single-cell suspensions were stained for flow cytometry with primary antibodies 
for 30 minutes at 4°C in the dark and the cells were washed with PBS/1% human Albumin 
(Sanquin, Leiden, The Netherlands) before analysis using a FACSCanto II (BD Biosciences, 
San Diego, CA, US). The following antibodies were used: F4/80 (AbD Serotec, Düsseldorf, 
Germany), CD90, B220, Ly6G, NK1.1, CD49b, CD11c, I-A(b), CD11b and CDLy6C (BD Biosciences, 
San Diego, CA, USA). The analysis of the acquired data was done with FlowJo software 
version 7.6.1 (Tree Star Inc. Ashland, OR, USA). Monocytes were defined as Ly6Chi or Ly6Clo 
in a CD11b positive population that was negative for CD90, B220, CD49b, NK1.1, Ly-6G, F4/80, 
CD11c and I-A(b). Macrophages/dendritic cells were identified in a CD11b positive population 
expressing F4/80, CD11c and I-A(b) but no CD90, B220, CD49b, NK1.1, Ly-6G. 
Statistical analysis 
Numerical values were expressed as means ± standard error of the mean (SEM). To compare 
two groups, parametric analyses were performed using an unpaired Student t-test. All 
analyses were performed using GraphPad Prism software (version 5.01). P ≤ 0.05 was 
considered statistically significant. 
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RESULTS 
Characterisation of isolated hBM-MSCs 
Culture-expanded MSC expressed CD90, CD73, CD105 and HLA-ABC, but did not express the 
haematopoietic surface markers CD31, CD34, CD45 and CD80 (figure 3A). Furthermore, hBM-
MSCs of all donors were able to differentiate into osteoblasts and adipocytes (figure 3B) 
and inhibited PBMC proliferation in a dose-dependent fashion (figure 3C). Stimulation with 
IFNγ did not alter the morphology or differentiation capacity of hBM-MSCs. However, upon 
IFNγ-stimulation, HLA-DR expression on the surface of hBM-MSCs was upregulated (figure 
3A). 
Administration of hBM-MSCs prior to induction of colitis does not attenuate subsequent 
colitis  
Efficacy of MSCs in an intentionally ‘pre-emptive’ setting was assessed in mice were injected 
intraperitoneally with 0.5x106 hBM-MSCs or PBS six hours prior to colitis induction, i.e., the 
start of DSS introduction (figure 2A).One injection with hBM-MSCs resulted in an average 
decrease in body weight of 5.4±1.5% at sacrifice compared to 6.8±1.8% in PBS-treated mice 
with mild colitis (p = 0.56) (figure 4A). Mice with severe colitis lost on average 13.0±1.1% in 
body weight when treated with hBM-MSCs, again not significantly different from mice 
treated with PBS (14.4±1.3%; p = 0.41) (figure 4B). To examine whether multiple injections 
during the establishment of colitis could increase the efficacy of hBM-MSCs, ten mice 
received after the pre-colitis induction injection at day 0 three more injections of 0.5x106 
hBM-MSCs at day 2, 4 and 6 (figure 2A). Although in the mild colitis group mice treated with 
four successive injections of hBM-MSCs had a reduced weight loss compared to a single 
injection and PBS-treated mice (2.5±1.4% vs 5.4±1.5% and 6.8±1.8%, respectively), this 
difference was not statistically significant (figure 4A). The body weight of mice with severe 
colitis decreased 13.9±1.2% in case of treatment with multiple injections which was similar to 
a single MSC injection and PBS-treated mice (13.0±1.1% and 14.4±1.3%; respectively) (figure 
4B). 
In the H&E-stained sections of the colon, morphological changes were predominantly 
observed in the distal colon of the DSS-colitis mice compared to healthy controls. No 
significant differences in histological disease activity scores between hBM-MSC and PBS 
treatment were observed in either mild or severe colitis (figure 4C and D). 
Approximately 14 days after DSS introduction, mice with severe colitis had a body weight 
comparable to day 0 (data not shown). After seven weeks all mice increased on average 
20.0% in body weight and at sacrifice all colons were comparable in length to controls 
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Protein Assay (Thermo Scientific Pierce, Etten-Leur, The Netherlands) and cytokine levels 
were measured using the Cytometric Bead Array (BD Biosciences, San Diego, CA, USA) 
following the manufacturer’s instructions. Cytokine levels measured were corrected for the 
amount of total protein per mg colon. 
Flow cytometry 
Mice were sacrificed on day 9 after colitis induction with DSS (n = 5 mice per treatment 
group). Colonic tissue was harvested, minced with fine scissors and placed in a solution of 5 
mM EDTA and 1 mM dithiothreitol in Hanks balanced salt solution for 20 min at 37°C under 
slow rotation to detach epithelial cells. To collect lamina propria cells pieces of colonic tissue 
were placed into a solution of 2% collagenase IA (Sigma-Aldrich) in PBS and shaken at 37°C 
for 1 h. The cell suspension was then triturated through a nylon mesh and centrifuged in PBS 
at 300 g for 10 min at 4°C. Red blood cells in the cell pellet were lysed with lysis buffer (AZL, 
Leiden, The Netherlands), and the cells were washed in PBS and subsequently resuspended 
in medium containing IMDM (Lonza, Verviers, Belgium) supplemented with 2.5% FCS and P/S. 
Total cell numbers were determined with a Sysmex cell counter (SysmexAmerica, Inc. 
Mundelein, Illinois, US). In addition, peripheral blood was drawn via cardiac puncture and 
mononuclear cells were isolated with density centrifugation. Total cell numbers were 
determined with a Sysmex cell counter (Sysmex America, Inc. Mundelein, Illinois, US). The 
resulting single-cell suspensions were stained for flow cytometry with primary antibodies 
for 30 minutes at 4°C in the dark and the cells were washed with PBS/1% human Albumin 
(Sanquin, Leiden, The Netherlands) before analysis using a FACSCanto II (BD Biosciences, 
San Diego, CA, US). The following antibodies were used: F4/80 (AbD Serotec, Düsseldorf, 
Germany), CD90, B220, Ly6G, NK1.1, CD49b, CD11c, I-A(b), CD11b and CDLy6C (BD Biosciences, 
San Diego, CA, USA). The analysis of the acquired data was done with FlowJo software 
version 7.6.1 (Tree Star Inc. Ashland, OR, USA). Monocytes were defined as Ly6Chi or Ly6Clo 
in a CD11b positive population that was negative for CD90, B220, CD49b, NK1.1, Ly-6G, F4/80, 
CD11c and I-A(b). Macrophages/dendritic cells were identified in a CD11b positive population 
expressing F4/80, CD11c and I-A(b) but no CD90, B220, CD49b, NK1.1, Ly-6G. 
Statistical analysis 
Numerical values were expressed as means ± standard error of the mean (SEM). To compare 
two groups, parametric analyses were performed using an unpaired Student t-test. All 
analyses were performed using GraphPad Prism software (version 5.01). P ≤ 0.05 was 
considered statistically significant. 
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haematopoietic surface markers CD31, CD34, CD45 and CD80 (figure 3A). Furthermore, hBM-
MSCs of all donors were able to differentiate into osteoblasts and adipocytes (figure 3B) 
and inhibited PBMC proliferation in a dose-dependent fashion (figure 3C). Stimulation with 
IFNγ did not alter the morphology or differentiation capacity of hBM-MSCs. However, upon 
IFNγ-stimulation, HLA-DR expression on the surface of hBM-MSCs was upregulated (figure 
3A). 
Administration of hBM-MSCs prior to induction of colitis does not attenuate subsequent 
colitis  
Efficacy of MSCs in an intentionally ‘pre-emptive’ setting was assessed in mice were injected 
intraperitoneally with 0.5x106 hBM-MSCs or PBS six hours prior to colitis induction, i.e., the 
start of DSS introduction (figure 2A).One injection with hBM-MSCs resulted in an average 
decrease in body weight of 5.4±1.5% at sacrifice compared to 6.8±1.8% in PBS-treated mice 
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body weight when treated with hBM-MSCs, again not significantly different from mice 
treated with PBS (14.4±1.3%; p = 0.41) (figure 4B). To examine whether multiple injections 
during the establishment of colitis could increase the efficacy of hBM-MSCs, ten mice 
received after the pre-colitis induction injection at day 0 three more injections of 0.5x106 
hBM-MSCs at day 2, 4 and 6 (figure 2A). Although in the mild colitis group mice treated with 
four successive injections of hBM-MSCs had a reduced weight loss compared to a single 
injection and PBS-treated mice (2.5±1.4% vs 5.4±1.5% and 6.8±1.8%, respectively), this 
difference was not statistically significant (figure 4A). The body weight of mice with severe 
colitis decreased 13.9±1.2% in case of treatment with multiple injections which was similar to 
a single MSC injection and PBS-treated mice (13.0±1.1% and 14.4±1.3%; respectively) (figure 
4B). 
In the H&E-stained sections of the colon, morphological changes were predominantly 
observed in the distal colon of the DSS-colitis mice compared to healthy controls. No 
significant differences in histological disease activity scores between hBM-MSC and PBS 
treatment were observed in either mild or severe colitis (figure 4C and D). 
Approximately 14 days after DSS introduction, mice with severe colitis had a body weight 
comparable to day 0 (data not shown). After seven weeks all mice increased on average 




without colitis (figure 5A and B). Histological evaluation showed no crypt lesions or signs of 
inflammation (figure 5C). No evidence for malignancy was found in the colons of any of 
these animals. 
FIGURE 3 Immunophenotypical characterization of the hBM-MSCs. (A): Surface markers for CD90, CD73, CD105, 
HLA-ABC (positive) and CD31, CD34, CD45, CD80 and HLA-DR (negative) on hBM-MSCs as analysed by flow 
cytometry. Surface markers did not differ between the three donors. When stimulated with IFNγ, hBM-MSCs 
expressed HLA-DR. (B): Differentiation capacity of hBM-MSCs into osteoblasts (alkaline phosphatase) and 
adipocytes (lipid droplets). Magnification x10. (C): hBM-MSCs and IFNγ-hBM-MSCs inhibit the proliferation of 
activated PBMCs in a dose-dependent fashion. Data are expressed as mean ± SEM. 
Colitis is alleviated by administration of hBM-MSCs after colitis induction 
Next, we examined whether administration of hBM-MSCs after colitis induction would 
increase the therapeutic efficacy MSCs. Mice were injected intraperitoneally with one 
injection of 0.5x106 hBM-MSCs or PBS six hours after the induction of DSS in the drinking 
water (figure 2C). Previous studies already showed that stimulation of human MSCs with 
proinflammatory cytokines such as IFNγ increases the immunosuppressive capacities of 
MSCs.16,17 Therefore, we also treated mice with IFNγ-hBM-MSCs.  
In the mild colitis model, no major differences in body weight at sacrifice were observed 
between one of the treatment groups and PBS (figure 6A), although mice treated with 
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(IFNγ-)hBM-MSCs showed a clear trend towards higher body weights compared to mice that 
received PBS. Particularly mice with severe colitis showed consistently less weight loss when 
treated with hBM-MSCs compared to PBS, from day 7 until the end of experiment (p < 0.05; 
figure 6C).  
DSS-induced colitis resulted in changes in the crypt architecture (goblet cell depletion and 
ulcerations of the epithelium) and infiltration of mononuclear cells in the lamina propria was 
observed (figure 6C). These lesions were significantly less present after treatment with 
hBM-MSCs in mice with severe colitis compared to PBS treated mice, as reflected by the 
histological disease activity score. 
Treatment with hBM-MSCs affect local cytokine levels and monocyte composition in 
severe colitis.  
To investigate the immunomodulatory effects of hBM-MSCs on experimental colitis, 
cytokine concentrations were determined in homogenates of the distal colons of mice with 
severe colitis. Colitis induction by DSS resulted in (dose-dependent) mucosal upregulation 
of the proinflammatory cytokines IL-6, TNFα and IL-17a in the distal colon (figure 7). 
Administration of hBM-MSCs in these mice resulted in a clear trend towards lower levels of 
these cytokines, particularly IL-6 and IL-17a, whereas treatment with IFNγ-hBM-MSCs had 
hardly any effect (figure 8). After hBM-MSCs injection the IL-17a levels were even decreased 
to levels observed in healthy control mice (figure 7 and 8A). The reduction in the cytokine 
profile in the intestinal mucosa suggests that hBM-MSCs may affect (pro)inflammatory 
subtypes of monocytes. Interestingly, the ratio of the anti-inflammatory Ly6Clo- over the 
Ly6Chi-monocytes in the colonic mucosa was remarkably higher in the hBM-MSC-treated 
mice as opposed to the IFNγ-hBM-MSCs and PBS treated mice, whereas in the peripheral 
blood the Ly6Clo/ Ly6Chi ratios were highly comparable (figure 8B). 
hBM-MSCs cluster at the serosal side of the colon 
To assess whether MSCs migrate to the inflamed colon, hBM-MSCs were transduced with 
GFP and intraperitoneally injected at day 0 of DSS introduction. Ten days later, mice were 
sacrificed. We were able to trace the injected MSCs at that time point as 
immunohistochemistry of the colons revealed GFP-positive cells at the serosal side of the 
colon. There they clustered to form spheroid-like structures as illustrated in figure 9. MSCs 
were never observed within the colonic (sub)mucosa, indicating that they did not 
transmigrate into the damaged luminal mucosal wall.  
MSCS IN DSS COLITIS 
111 
DISCUSSION 
Although encouraging results on MSC-treatment in human IBD have been published18,19, the 
exact moment and frequency of administration to reach an optimal efficacy is not clear yet. 
The present study indicates that the time of administration is crucial to achieve efficacy of 
hBM-MSCs, at least in DSS-induced colitis. One injection of hBM-MSCs prior to colitis 
induction did not alleviate mild or severe colitis. However, ‘therapeutic’ administration of 
hBM-MSCs, i.e., injection after colitis induction, ameliorated severe colitis indicating that an 
initiated/ongoing severe inflammation is needed before MSCs exert their 
immunosuppressive capacity. Supporting this hypothesis were the observations that hBM-
MSCs injected after the start of DSS did not result in a significantly reduced weight loss and 
lower histological disease activity score in mice with mild colitis model. In contrast, in mice 
of the ‘pre-emptive’ study, i.e., MSC injection prior to DSS-colitis induction, treated with 
three extra injections at day 2, 4 and 6, the efficacy of hBM-MSCs did not increase although 
these latter injections were given during the establishment of the colitis with ongoing 
inflammation. Although MSCs do not seem to elicit alloreactive lymphocyte responses and 
have a low expression of MHC-I without the presence of co-stimulatory molecules20-22, they 
do express MHC-II intracellularly.7 Nauta et al.23 showed in a murine transplantation model, 
with sublethally irradiated recipients, that allogeneic bone marrow engraftment was 
hampered when co-transplanted with allogeneic or third-party MSCs, whereas syngeneic 
MSCs promoted engraftment. Interestingly, memory T cells were generated suggesting that 
MSCs are not intrinsically immunoprivileged and that they can trigger an immune response 
in vivo after multiple injections of the same MSC-donor. This notion is supported by 
Eliopoulos et al.24 who showed that splenocytes from mice that received implants with 
human MSCs for 15 days, had a strong IFNɣ response after coculture in vitro with the same 
human MSCs for 24 hours. This elevation of IFNɣ was not observed after coculture with 
syngeneic mouse MSCs or when human MSCs were cocultured with splenocytes of mice that 
did not receive an implant with human MSCs prior to the in vitro coculture. Taken together, 
these results suggest that allogeneic and xenogeneic MSCs may provoke a specific anti-
donor T cell response in immunocompetent mice with generation of memory T cells leading 
to a possible enhanced rejection of these cells after multiple injections. Although these 
results argue against the potential of an ‘off-the-shelf’ repeated treatment of allogeneic 
MSCs, the possibility of an unwanted immune response after administration of allogeneic or 
xenogeneic MSCs in mice does not per definition resemble the situation in humans. Multiple 
clinical trials have proven allogeneic MSC treatment to be safe and feasible.25-28 Recently, 
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FIGURE 6 DSS-induced colitis is alleviated by administration of hBM-MSCs after colitis induction. DSS was 
introduced in the drinking water for 7 days. Six hours after this introduction mice received 0.5x106 hBM-MSCs 
or PBS. Mice were sacrificed at day 9. Data are expressed as mean ± SEM; n = 5 in all groups. See figure 2 for 
study design. Body weight changes of mice with (A): mild and (B): severe colitis. The values of body weight 
change are expressed as a percentage of body weight at day 0. In mild colitis: *, p = 0.05 IFNγ-hBM-MSCs vs 
PBS and p = 0.051 hBM-MSCs vs PBS. In severe colitis: day 7 *, p = 0.05, day 8 *, p = 0.02 and day 9 *, p = 0.02 
hBM-MSCs vs PBS. (C): Microscopic images of H&E-stained paraffin slides of representative colons of mice with 
severe colitis. Magnification x20. (D): Histology scores of colons with mild and severe inflammation harvested 
on day 9. Scores were determined after microscopic analysis of the colon slides from each mouse. * p = 0.05 
hBM-MSCs vs PBS.  
geneic MSCs in moderate to severe refractory CD.18 Fifteen patients received four infusions 
of 2x106 cells/kg at weekly intervals. Three weeks after the last infusion of MSCs clinical 
response was observed in 80% of the patients and clinical remission in even 53% of the pati- 
  A.   B.Mild colitis
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FIGURE 7 Adding DSS to the drinking water results in elevated levels of IL-6, TNFα and IL-17a in the distal colon. 
Colon homogenates were prepared from the distal colons with mild and severe colitis and cytokine levels were 
measured. Data are expressed as mean ± SEM; n = 5 in colitis groups and n = 2 in control group. Local cytokine 
levels of (A): IL-6, (B): TNFα and (C): IL-17a in the distal colon of mice with mild and severe colitis. 
FIGURE 8 Treatment with hBM-MSCs affect local cytokine levels and monocyte composition in severe colitis. 
Data are expressed as mean ± SEM; n = 5 in all groups. (A): Colon homogenates were obtained from the distal 
colons after sacrifice at day 9 and local cytokine levels of IL-6, TNFα and IL-17a were measured. *, p = 0.05 hBM-
MSCs vs IFNγ-hBM-MSCs and **, p = 0.004 hBM-MSCs vs PBS. (B): Ratio Ly6Clo/Ly6Chi-monocytes in distal colon 











































































































































A.               





























































































FIGURE 6 DSS-induced colitis is alleviated by administration of hBM-MSCs after colitis induction. DSS was 
introduced in the drinking water for 7 days. Six hours after this introduction mice received 0.5x106 hBM-MSCs 
or PBS. Mice were sacrificed at day 9. Data are expressed as mean ± SEM; n = 5 in all groups. See figure 2 for 
study design. Body weight changes of mice with (A): mild and (B): severe colitis. The values of body weight 
change are expressed as a percentage of body weight at day 0. In mild colitis: *, p = 0.05 IFNγ-hBM-MSCs vs 
PBS and p = 0.051 hBM-MSCs vs PBS. In severe colitis: day 7 *, p = 0.05, day 8 *, p = 0.02 and day 9 *, p = 0.02 
hBM-MSCs vs PBS. (C): Microscopic images of H&E-stained paraffin slides of representative colons of mice with 
severe colitis. Magnification x20. (D): Histology scores of colons with mild and severe inflammation harvested 
on day 9. Scores were determined after microscopic analysis of the colon slides from each mouse. * p = 0.05 
hBM-MSCs vs PBS.  
geneic MSCs in moderate to severe refractory CD.18 Fifteen patients received four infusions 
of 2x106 cells/kg at weekly intervals. Three weeks after the last infusion of MSCs clinical 
response was observed in 80% of the patients and clinical remission in even 53% of the pati- 
  A.   B.Mild colitis





















































































































































MSCS IN DSS COLITIS 
113 
FIGURE 7 Adding DSS to the drinking water results in elevated levels of IL-6, TNFα and IL-17a in the distal colon. 
Colon homogenates were prepared from the distal colons with mild and severe colitis and cytokine levels were 
measured. Data are expressed as mean ± SEM; n = 5 in colitis groups and n = 2 in control group. Local cytokine 
levels of (A): IL-6, (B): TNFα and (C): IL-17a in the distal colon of mice with mild and severe colitis. 
FIGURE 8 Treatment with hBM-MSCs affect local cytokine levels and monocyte composition in severe colitis. 
Data are expressed as mean ± SEM; n = 5 in all groups. (A): Colon homogenates were obtained from the distal 
colons after sacrifice at day 9 and local cytokine levels of IL-6, TNFα and IL-17a were measured. *, p = 0.05 hBM-
MSCs vs IFNγ-hBM-MSCs and **, p = 0.004 hBM-MSCs vs PBS. (B): Ratio Ly6Clo/Ly6Chi-monocytes in distal colon 











































































































































A.               






























































































FIGURE 9 hBM-MSCs cluster at the serosal side of the colon. hBM-MSCs were transduced with GFP and injected 
at day 0. Mice were sacrificed at day 10. Immunohistochemistry showed that GFP-positive cells were found at 
the serosal side of the colon where they clustered to form spheroid-like structures. (A): Anti-GFP staining of 
the distal colon of a mouse with severe colitis. Magnification x20 and zoom in. (B): Histological image of same 
spheroid as in (A) but further in serial slides. Magnification x20. (C): Microscopic image of H&E-stained paraffin 
slide with matching anti-GFP staining. Magnification x20 and zoom in. 
ents. In contrast, a previous study from our group using a single dose of autologous MSC in 
CD was found to be relatively ineffective.19  
Earlier studies have shown that stimulation of human MSCs with proinflammatory cytokines 
such as IFNγ increases the immunosuppressive capacity of MSCs.16,17 On the other hand, 
MSCs can enhance immune responses when IFNɣ levels are not sufficient13-15 and they can 
even become antigen presenting cells by upregulating of MHC class II.29-31 In our hands, in 
vitro stimulation with IFNɣ before injection did not result in an increased efficacy of hBM-
MSCs compared to unstimulated hBM-MSCs. It could be that the optimal administration 
time point of immunostimulated MSCs is different from unstimulated MSCs and that 
therefore we were not able to increase the effectiveness of hBM-MSCs in DSS-induced 
colitis. 
Since Ly6Chi-monocytes are rapidly recruited from peripheral blood to the inflamed colon 
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and TNFα, Ly6Chi-monocytes may be crucial in the establishment of colitis.32,33 Moreover, 
DSS-induced colitis was attenuated when migration of these monocytes to the inflamed 
colon was hampered.33 In our hands, levels of IL-6, TNFα and IL-17a, produced by IL-23 
induced Th17-cells34, were elevated in the distal colons at sacrifice and reduced after 
treatment with hBM-MSCs. Interestingly, the relative number of Ly6Clo-monocytes in the 
colonic mucosa, responsible for promoting tissue repair processes and homeostasis in a 
non-inflammatory situation35, was increased after treatment with hBM-MSCs suggesting 
their contribution to the conversion of the proinflammatory milieu to a more regulatory one. 
Whether MSCs need to migrate to the colon to induce immunosuppression is not clear. We 
were able to trace hBM-MSCs ten days after intraperitoneal injection at the serosal side of 
the colon where they formed spheroids. Although MSCs are capable of transmigrating 
through endothelial cells36, we never observed transmigration into the colonic wall. In 
addition, in line with previously findings9,37, the amount of cells we found was very low as 
we did not observe spheroids in all mice that received GFP-positive MSCs. The importance 
of engraftment is therefore doubtful and recent data suggests that the secretion of soluble 
factors is the key factor in MSC-mediated immunosuppression.38,39 
In conclusion, we showed that injection of hBM-MSCs after but not prior to DSS-colitis 
induction alleviated severe colitis by reducing the production of proinflammatory cytokines 
resulting in less colonic damage. This was not observed in mild colitis. These findings 
suggests that the time of administration and an ongoing inflammation are crucial to achieve 
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ABSTRACT 
Mesenchymal stromal cells (MSCs) have gained much interest for use in cell-based 
treatment for various diseases. MSCs are potentially immunosuppressive and their capacity 
to migrate to the site of inflammation provides a possible mechanism for attenuating local 
immune responses. We evaluated the migratory ability of MSCs and their 
immunosuppressive effect after administration in a 2,4,6-trinitrobenzenesulfonic acid 
(TNBS)-induced experimental colitis model.  
Acute colitis was induced in BALB/c mice by skin sensitization and subsequent intraluminal 
infusion of TNBS. Murine MSCs that were transduced with an EF1α-FLuc-IRES-GFP lentiviral 
vector were administered intraperitoneally. The MSCs migrated towards the inflamed colon 
and ameliorated colitis upon infusion post-induction. The cells were detected as structured 
spheroids in the serosal fat surrounding the inflamed colon and in close proximity to immune 
cells. Vascular cell adhesion molecule (VCAM) is important for MSC migration as decreased 
cell migration and prolongation of colitis were observed after administration of MSCs with 
downregulated VCAM expression. Moreover, upon prestimulation in vitro with IFNɣ and 
TNFα, a condition that upregulates VCAM on the surface of MSCs, MSC migration towards 
the inflamed colon was further enhanced. IFNɣ and TNFα prestimulation also upregulates 
inducible nitric oxide synthase (iNOS) and TNF-inducible gene 6 protein (TSG-6) in MSCs. 
IFNɣ and TNFα prestimulated MSCs (i/tMSCs) silenced for iNOS or TSG-6 migrated to the 
colon at numbers similar to i/tMSCs. However, colitis was prolonged indicating a role for 
iNOS and TSG-6 in the immunosuppressive mechanism of MSCs in TNBS-induced colitis. 
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INTRODUCTION
The immunomodulatory capacity of mesenchymal stromal cells (MSCs) makes these cells a
promising treatment modality for various diseases.1 However, MSCs are not intrinsically
immunosuppressive and many studies have suggested that these cells need to be primed
with interferon-gamma (IFNɣ) to elicit their immunosuppressive capacities.2-5 This process is
tightly balanced, as MSCs that are insufficiently primed can enhance immune responses and
may participate in antigen presentation by upregulation of MHC class II molecules.6-11 To 
circumvent this potential problem, MSCs could be pretreated with inflammatory cytokines 
in vitro. Prestimulation of murine MSCs, with tumor necrosis factor alpha (TNFα) or
interleukin-1 (IL-1) has been reported to achieve full immunosuppression in vitro.12,13
Administration of prestimulated MSCs resulted in an increased therapeutic efficacy
compared to unstimulated MSCs in various animal models, such as experimental colitis,
cardiac ischemia, and graft versus-host disease.4,14,15
Upon tissue damage, inflammatory cytokines and chemokines are released. A possible
mechanism via which MSCs attenuate inflammation and contribute to the repair process is 
through migration to the site of injury after ‘sensing’ these signals that are released by the
damaged tissue.16-19 However, the number of systemically injected MSCs that specifically
migrate to the desired location is low,20-23 but was found to be increased after in vitro
pretreatment of MSCs with IFNɣ and TNFα.24-27
The mechanisms underlying the migration and subsequent immunosuppression mediated
by MSCs are not exactly understood. We used our TNBS-induced experimental colitis model
to study MSC migration by bioluminescence imaging (BLI). BLI is a non-invasive method to 
localize MSCs that were lentivirally transduced with a sensitive luciferase reporter gene as 
previously described.28 This allows us to repeatedly track MSCs in our colitis mouse model
to get a better understanding of their in vivo migratory capacity during the disease course.
The migratory capacity of MSCs was increased after prestimulation with IFNɣ and TNFα and
was, in part, VCAM-dependent. In addition, silencing of inducible nitric oxide synthase
(iNOS) and TNF-inducible gene 6 protein (TSG-6) in IFNɣ and TNFα prestimulated MSCs
(i/tMSCs) resulted in comparable migration of these cells to the inflamed colon as wild type
i/tMSCs. However, in the absence of either iNOS or TSG-6,  colitis was prolonged. This
suggests a role for iNOS and TSG-6 in immunosuppression by MSCs.
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colon at numbers similar to i/tMSCs. However, colitis was prolonged indicating a role for
iNOS and TSG-6 in the immunosuppressive mechanism of MSCs in TNBS-induced colitis.
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MATERIALS AND METHODS 
MSC isolation 
Murine bone marrow-derived MSCs were obtained from 8 to 12-week-old male 
BALB/cAnNCrl mice (Charles River Maastricht, The Netherlands). Mice were sacrificed by 
CO2 asphyxia and femurs and tibiae were removed, cleaned of tissue and flushed with 
RPMI (Invitrogen Corp., Paisley, UK) supplemented with 2% fetal calf serum (FCS; Greiner 
Bio-one), 3mM L-glutamine (Invitrogen Corp., Paisley, UK) and Penicillin/Streptomycin (P/S; 
Invitrogen Corp.) to retrieve bone marrow cells. Cells were plated in αMEM (Invitrogen 
Corp., Paisley, UK) supplemented with 10% FCS, 3mM L-glutamine and 
Penicillin/Streptomycin. After 24 hours, non-adherent cells were removed. MSC cultures 
were subsequently expanded in a 37°C humidified incubator at 5% CO2.The medium was 
refreshed every 3-4 days. When MSCs reached >80% confluence, cells were replated at a 
density of 4,000 cells per cm2. MSCs passage 1-2 were transduced with the EF1α-FLuc-IRES-
GFP lentiviral vector as described previously.28 Transduced MSC populations were ≥80% 
positive for the transgene expression either by direct transduction or upon cell sorting. 
MSC of passage 4-8 were used throughout all experiments. In indicated experiments, 
transduced MSCs were cultured in the presence of 10 ng/ml recombinant murine 
interferon-gamma (IFNɣ) and 10 ng/ml recombinant murine tumor necrosis factor-alpha 
(TNFα) (both from R&D Systems, Abingdon, UK) for 7 days to induce IFNɣ- plus TNFα-
stimulated MSCs (i/tMSCs). 
Gene Description Gene ID Accession/Ref Seq 
number* 
TRC number 
VCAM1 22329 NM_011693 TRCN0000094139 
TRCN0000094140 
TRCN0000094141 
TSG-6 21930 NM_009398 TRCN0000109490 
TRCN0000109491 
TRCN0000109492 




TABLE 1 Clones directed against VCAM, iNOS and TSG-6 from MISSION® shRNA Bacterial Glycerol Stock. 
Silencing of VCAM, iNOS and TSG-6 in MSCs  
To silence the expression of VCAM-1, iNOS or TSG-6 in mouse MSC, short hairpin RNA 
(shRNA) from the MISSION® shRNA library (Sigma-Aldrich. St. Louis, USA) were used. Three 
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different clones directed against VCAM-1, iNOS and TSG-6 from the MISSION® shRNA Library 
(table 1) were tested. Clones were provided as a frozen bacterial glycerol stocks. Each clone 
is constructed within the lentivirus plasmid vector, pLKO.1-puro or TRC2-pLKO-puro. In these 
plasmid vectors, the shRNA expression is driven by the U6 promoter. The plasmids contain 
the bacterial β-lactamase (ampicillin) and mammalian puromycin N-acetyl transferase, which 
confer resistance to ampicillin and puromycin in bacteria and mammalian cell, respectively. 
As a shRNA control the clone SHC002 was used from the MISSION® pLKO.1-puro library, 
which does not target any transcript in mammalian cells. Plasmids were propagated in E. coli 
and purified by standard techniques. Lentiviral particles were produced as described 
previously.28 Ten thousand MSC-EF1α-FLuc-IRES-GFP were transduced as previously 
described.28  
MSC characterization 
Characterization of the EF1α-FLuc-IRES-GFP-tranduced MSCs was performed as described 
previously.28 Briefly, immunophenotyping of transduced MSCs was performed using the 
following primary antibodies: CD44, CD29, CD106, CD105, Sca-1, major histocompatibility 
complex (MHC)-I and II, CD45 and CD31 (BD Biosciences, Erebodegem, Belgium). Samples 
were analyzed using a FACSCanto II flow cytometer with Diva Software (BD Biosciences) 
and the data were analyzed with FlowJo software (version 7.6.3., Tree Star Inc. Ashland, OR, 
USA).  
Measurement of iNOS and TSG-6 
TSG-6 was analyzed in MSC culture supernatants using the mouse Tumor Necrosis Factor-
inducible gene 6 protein ELISA kit (My Biosource, San Diego, US) according to the 
manufacturer’s instructions. iNOS was measured on MSC cell lysates that were obtained by 
repeated freeze/thawing cycles using the mouse Inducible nitric oxide synthase ELISA kit 
(My Biosource). 
Induction of colitis 
Acute colitis was induced in 8-week-old female BALB/c mice with trinitrobenzene sulfonate 
(TNBS, Sigma-Aldrich). Animal procedures were carried out in compliance with the 
Institutional Standards for the care and use of laboratory animals and approved by the 
Institutional Animal Welfare Committee. Animals were housed in individually ventilated 
cages and were given drinking water and food ad libitum. To induce acute colitis, mice were 
sensitized for TNBS through the skin on day 0 with 3.25 mg TNBS diluted in 40% ethanol. 
Seven days later 3.00 mg TNBS diluted in 40% ethanol was intraluminally injected with a 22 
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different clones directed against VCAM-1, iNOS and TSG-6 from the MISSION® shRNA Library 
(table 1) were tested. Clones were provided as a frozen bacterial glycerol stocks. Each clone 
is constructed within the lentivirus plasmid vector, pLKO.1-puro or TRC2-pLKO-puro. In these 
plasmid vectors, the shRNA expression is driven by the U6 promoter. The plasmids contain 
the bacterial β-lactamase (ampicillin) and mammalian puromycin N-acetyl transferase, which 
confer resistance to ampicillin and puromycin in bacteria and mammalian cell, respectively. 
As a shRNA control the clone SHC002 was used from the MISSION® pLKO.1-puro library, 
which does not target any transcript in mammalian cells. Plasmids were propagated in E. coli 
and purified by standard techniques. Lentiviral particles were produced as described 
previously.28 Ten thousand MSC-EF1α-FLuc-IRES-GFP were transduced as previously 
described.28  
MSC characterization 
Characterization of the EF1α-FLuc-IRES-GFP-tranduced MSCs was performed as described 
previously.28 Briefly, immunophenotyping of transduced MSCs was performed using the 
following primary antibodies: CD44, CD29, CD106, CD105, Sca-1, major histocompatibility 
complex (MHC)-I and II, CD45 and CD31 (BD Biosciences, Erebodegem, Belgium). Samples 
were analyzed using a FACSCanto II flow cytometer with Diva Software (BD Biosciences) 
and the data were analyzed with FlowJo software (version 7.6.3., Tree Star Inc. Ashland, OR, 
USA).  
Measurement of iNOS and TSG-6 
TSG-6 was analyzed in MSC culture supernatants using the mouse Tumor Necrosis Factor-
inducible gene 6 protein ELISA kit (My Biosource, San Diego, US) according to the 
manufacturer’s instructions. iNOS was measured on MSC cell lysates that were obtained by 
repeated freeze/thawing cycles using the mouse Inducible nitric oxide synthase ELISA kit 
(My Biosource). 
Induction of colitis 
Acute colitis was induced in 8-week-old female BALB/c mice with trinitrobenzene sulfonate 
(TNBS, Sigma-Aldrich). Animal procedures were carried out in compliance with the 
Institutional Standards for the care and use of laboratory animals and approved by the 
Institutional Animal Welfare Committee. Animals were housed in individually ventilated 
cages and were given drinking water and food ad libitum. To induce acute colitis, mice were 
sensitized for TNBS through the skin on day 0 with 3.25 mg TNBS diluted in 40% ethanol. 




FIGURE 1 Design of the in vivo experimental studies. On day 0, female Balb/c mice (8 weeks old) were sensitized 
for TNBS on the skin followed by an intraluminal TNBS infusion on day 7 to establish acute colitis. (A) On day 
7, mice were injected with 1x106 or 2x106 unstimulated or IFNγ- and TNFα-stimulated MSCs with or without 
shVCAM, shiNOS or shTSG-6, or PBS as indicated per experiment. Dorsal BLI scans were made at day 9 and 10, 
and colons were separately measured at sacrifice (day 10). (B) On day 8, mice were injected with 1x106 
unstimulated or IFNγ and TNFα-stimulated MSCs, or PBS as indicated per experiment. Dorsal BLI scans were 
performed at day 9 and 10, and colons were separately measured at sacrifice (day 10).  
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Gauge catheter (Abbocath, Hospira Benelux, Brussels, Belgium) approximately 3 cm from 
the anus. Ethanol breaks down the mucosa enabling TNBS to haptenize the colonic flora to
induce a mainly Th1-mediated immune response.29 MSCs were injected intraperitoneally
(i.p.) on day 7 (post-induction) or day 8 (treatment) (figure 1). PBS was used as a control.
Body weight was measured daily and disease progression and recovery were calculated as
a percentage of weight loss from body weight at the day of intraluminal injection of TNBS
(day 7). At sacrifice on day 10, colon length and weight were measured as an indicator of
disease-related intestinal shortening and wall thickening and colons were opened
longitudinally to calculate the disease score consisting of  the presence of loose stool, visible
faecal blood and macroscopic inflammation using a scale of 0-3 per item, resulting in a
maximum score of 9.30
Bioluminescence imaging
Bioluminescence imaging (BLI) was performed under isoflurane anesthesia using an IVIS
Lumina II in living mice at 10 minutes following luciferin injection as described previously
(figure 2A).28 Mice were scanned dorsally for 2 minutes. On day 10 mice were sacrificed
immediately after the dorsal BLI scans to be able to perform BLI on the colon, small intestine
and the carcass of the mice to trace MSCs in these organs (figure 2B). All images were
quantified by creating regions of interest (ROIs) using Living Image 4.0 software (Caliper)
and expressed as average radiance. Background average radiance of PBS mice was
subtracted from MSC-treated groups. Average radiance of mice with colitis were normalized
for their own healthy control and shown as fold difference in average radiance (FDAR).
The part of the colon and small intestine with the highest signal on BLI (figure 2B) were
either directly frozen in isopentane on dry ice for protein- and cytokine measurements or
stored in 4% formalin and embedded in paraffin for (immuno)histochemistry. In case of a
high signal in the carcass, the tissue was removed and plated in a 6-well culture plate to 
reharvest the i.p. injected MSCs. Swiss rolls were made from colons and stored in 4% formalin
and embedded in paraffin for (immuno)histological examination.31
As previously described, transduction with EF1α-FLuc-IRES-GFP did not change the growth
kinetics, phenotype, differentiation capacity or immunomodulatory capacity of MSCs
compared to untransduced MSCs of the same parental line and passage number.28 When
MSCs were stimulated with IFNɣ (iMSCs), the EF1α-FLuc-IRES-GFP-construct was partially
silenced in vitro and in vivo. Stimulation with IFNɣ plus TNFα slightly enhances the silencing
compared to stimulation with IFNɣ alone. Therefore, we used the FDAR to be able to
compare the migration of unstimulated MSCs with stimulated MSCs.
FIGURE 2 BLI of living mice and colon at day of sacrifice. (A) Ten minutes before BLI was performed, mice were 
subcutaneously injected with 150 mg/kg D-luciferin. BLI was performed with the IVIS Lumina II and mice were 
scanned ventrally and dorsally for 2 minutes. (B) At sacrifice small intestine and colon were scanned 
separately to trace the injected MSCs.
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FIGURE 1 Design of the in vivo experimental studies. On day 0, female Balb/c mice (8 weeks old) were sensitized 
for TNBS on the skin followed by an intraluminal TNBS infusion on day 7 to establish acute colitis. (A) On day 
7, mice were injected with 1x106 or 2x106 unstimulated or IFNγ- and TNFα-stimulated MSCs with or without 
shVCAM, shiNOS or shTSG-6, or PBS as indicated per experiment. Dorsal BLI scans were made at day 9 and 10, 
and colons were separately measured at sacrifice (day 10). (B) On day 8, mice were injected with 1x106 
unstimulated or IFNγ and TNFα-stimulated MSCs, or PBS as indicated per experiment. Dorsal BLI scans were 
performed at day 9 and 10, and colons were separately measured at sacrifice (day 10).  
FIGURE 2 BLI of living mice and colon at day of sacrifice. (A) Ten minutes before BLI was performed, mice were 
subcutaneously injected with 150 mg/kg D-luciferin. BLI was performed with the IVIS Lumina II and mice were 
scanned ventrally and dorsally for 2 minutes. (B) At sacrifice small intestine and colon were scanned separately 
to trace the injected MSCs. 
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Gauge catheter (Abbocath, Hospira Benelux, Brussels, Belgium) approximately 3 cm from 
the anus. Ethanol breaks down the mucosa enabling TNBS to haptenize the colonic flora to 
induce a mainly Th1-mediated immune response.29 MSCs were injected intraperitoneally 
(i.p.) on day 7 (post-induction) or day 8 (treatment) (figure 1). PBS was used as a control. 
Body weight was measured daily and disease progression and recovery were calculated as 
a percentage of weight loss from body weight at the day of intraluminal injection of TNBS 
(day 7). At sacrifice on day 10, colon length and weight were measured as an indicator of 
disease-related intestinal shortening and wall thickening and colons were opened 
longitudinally to calculate the disease score consisting of  the presence of loose stool, visible 
faecal blood and macroscopic inflammation using a scale of 0-3 per item, resulting in a 
maximum score of 9.30 
 
Bioluminescence imaging 
Bioluminescence imaging (BLI) was performed under isoflurane anesthesia using an IVIS 
Lumina II in living mice at 10 minutes following luciferin injection as described previously 
(figure 2A).28 Mice were scanned dorsally for 2 minutes. On day 10 mice were sacrificed 
immediately after the dorsal BLI scans to be able to perform BLI on the colon, small intestine 
and the carcass of the mice to trace MSCs in these organs (figure 2B). All images were 
quantified by creating regions of interest (ROIs) using Living Image 4.0 software (Caliper) 
and expressed as average radiance. Background average radiance of PBS mice was 
subtracted from MSC-treated groups. Average radiance of mice with colitis were normalized 
for their own healthy control and shown as fold difference in average radiance (FDAR). 
The part of the colon and small intestine with the highest signal on BLI (figure 2B) were 
either directly frozen in isopentane on dry ice for protein- and cytokine measurements or 
stored in 4% formalin and embedded in paraffin for (immuno)histochemistry. In case of a 
high signal in the carcass, the tissue was removed and plated in a 6-well culture plate to 
reharvest the i.p. injected MSCs. Swiss rolls were made from colons and stored in 4% formalin 
and embedded in paraffin for (immuno)histological examination.31 
As previously described, transduction with EF1α-FLuc-IRES-GFP did not change the growth 
kinetics, phenotype, differentiation capacity or immunomodulatory capacity of MSCs 
compared to untransduced MSCs of the same parental line and passage number.28 When 
MSCs were stimulated with IFNɣ (iMSCs), the EF1α-FLuc-IRES-GFP-construct was partially 
silenced in vitro and in vivo. Stimulation with IFNɣ plus TNFα slightly enhances the silencing 
compared to stimulation with IFNɣ alone. Therefore, we used the FDAR to be able to 






Organs stored in 4% neutral buffered formalin were serially dehydrated, cleared in xylene 
and embedded in paraffin. Serial sections of 4 µm were cut and stained with hematoxylin 
and eosin (H&E). Collagen deposition was stained with 0.1% Sirius Red (Klinipath BV, Duiven, 
The Netherlands) in saturated picric acid. MSCs in colons and small intestines embedded in 
paraffin were stained with an anti-GFP antibody (Invitrogen, Bleiswijk, The Netherlands). In 
brief, for endogen peroxidase blocking slides were incubated in 0.3% H2O2/methanol for 20 
minutes at room temperature. After antigen retrieval, slides were blocked with Teng-T (10 
mM Tris, 5 mM EDTA, 0.15 M NaCl, 0.25% gelatin, 0.05% (v/v) Tween-20, pH 8.0) for 30 
minutesto decrease a-specific binding, incubated overnight at 4°C with primary antibody in 
PBS containing 0.1% Triton X-100 and 1% bovine serum albumin (BSA) and followed by a 
peroxidase labelled polymer (EnVision+, Dako Netherlands BV, Heverlee, Belgium). 
Peroxidase activity was detected with 3,3’-diaminobenzidine tablets (DAB Fast Tablet, 
Sigma-Aldrich, St. Louis, MO). Sections were counterstained with hematoxylin, dehydrated, 
and mounted in Entellan (Merck KGaA, Darmstadt, Germany). T cells (anti-CD3 antibody, 
Dako Netherlands BV) were also stained following the above protocol. For the staining of 
regulatory T cells (anti-FoxP3 antibody, clone: FJK-16s, eBioscience, LTD, Hatfield, UK) and 
macrophages (anti-F4/80 antibody, clone: BM8, eBioscience) slides were incubated for 1 
hour with a rabbit anti-rat HRP conjugated secondary antibody (Dako Netherlands BV) 
diluted in PBS containing 0,1% Triton X-100 and 1% bovine serum albumin (BSA) instead of a 
peroxidase labelled polymer.  
In vitro spheroid formation 
Spheroid-formation was induced in 96-well culture plates (Round (U) bottom; Greiner Bio-
One BV, Alphen a/d Rijn, The Netherlands) by plating 2,500 MSCs, in MSC medium per well, 
containing 0.24% methyl cellulose (Sigma-Aldrich).  
Cytokine measurements 
Tissue homogenates were obtained from the parts of the colons and small intestines with 
the highest signal on BLI (n = 3-4 per treatment group) with a Potter-Elvehjem glass 
homogenizer at 4°C in Greenberger lysis buffer (150 mM NaCl, 15 mM Tris, pH 7.4, 1 mM 
MgCl2, and 1% Triton X-100). Total protein content was determined using the BCA Protein 
Assay (Thermo Scientific Pierce, Etten-Leur, The Netherlands) and cytokine levels of IL-2, IL-
4, IL-6, IL-10, IL17a, IFNɣ and TNFα were measured using the Cytometric Bead Array (BD 
Biosciences, San Diego, CA, USA) and FACSCalibur flow cytometer (BD Biosciences) 
following the manufacturer’s instructions. Data were analyzed with FlowJo software  
MIGRATION OF MSCS IN TNBS COLITIS 
129 
FIGURE 3 Intraluminal infusion of TNBS 
results in an acute colitis 
characterized by body weight loss 
with shortening and thickening of the 
colon and elevated local levels of IL-6 
and TNFα. Mice were sensitized for 
TNBS through the skin on day 0 
followed by an intraluminal injection 
with TNBS seven days later. (A) A 
severe distal colitis was induced after 
intraluminal infusion of TNBS at day 7. 
Data are expressed as mean ± SD; n = 
11 in TNBS+PBS group; n = 9 in No 
TNBS+PBS group (n = 1 experiments). 
(B) A higher disease score consisting 
of the presence of loose stool, visible 
faecal blood and macroscopic 
inflammation compared to healthy 
control, and (C) disease-related 
shortening and wall thickening of the 
colon as indicated by the 
weight/length ratio was observed in 
TNBS mice. (D) Local 
proinflammatory cytokines IL-6 and 
(E) TNFα were elevated compared to 
control. Data are expressed as mean 


















































































































































Organs stored in 4% neutral buffered formalin were serially dehydrated, cleared in xylene 
and embedded in paraffin. Serial sections of 4 µm were cut and stained with hematoxylin 
and eosin (H&E). Collagen deposition was stained with 0.1% Sirius Red (Klinipath BV, Duiven, 
The Netherlands) in saturated picric acid. MSCs in colons and small intestines embedded in 
paraffin were stained with an anti-GFP antibody (Invitrogen, Bleiswijk, The Netherlands). In 
brief, for endogen peroxidase blocking slides were incubated in 0.3% H2O2/methanol for 20 
minutes at room temperature. After antigen retrieval, slides were blocked with Teng-T (10 
mM Tris, 5 mM EDTA, 0.15 M NaCl, 0.25% gelatin, 0.05% (v/v) Tween-20, pH 8.0) for 30 
minutesto decrease a-specific binding, incubated overnight at 4°C with primary antibody in 
PBS containing 0.1% Triton X-100 and 1% bovine serum albumin (BSA) and followed by a 
peroxidase labelled polymer (EnVision+, Dako Netherlands BV, Heverlee, Belgium). 
Peroxidase activity was detected with 3,3’-diaminobenzidine tablets (DAB Fast Tablet, 
Sigma-Aldrich, St. Louis, MO). Sections were counterstained with hematoxylin, dehydrated, 
and mounted in Entellan (Merck KGaA, Darmstadt, Germany). T cells (anti-CD3 antibody, 
Dako Netherlands BV) were also stained following the above protocol. For the staining of 
regulatory T cells (anti-FoxP3 antibody, clone: FJK-16s, eBioscience, LTD, Hatfield, UK) and 
macrophages (anti-F4/80 antibody, clone: BM8, eBioscience) slides were incubated for 1 
hour with a rabbit anti-rat HRP conjugated secondary antibody (Dako Netherlands BV) 
diluted in PBS containing 0,1% Triton X-100 and 1% bovine serum albumin (BSA) instead of a 
peroxidase labelled polymer.  
In vitro spheroid formation 
Spheroid-formation was induced in 96-well culture plates (Round (U) bottom; Greiner Bio-
One BV, Alphen a/d Rijn, The Netherlands) by plating 2,500 MSCs, in MSC medium per well, 
containing 0.24% methyl cellulose (Sigma-Aldrich).  
Cytokine measurements 
Tissue homogenates were obtained from the parts of the colons and small intestines with 
the highest signal on BLI (n = 3-4 per treatment group) with a Potter-Elvehjem glass 
homogenizer at 4°C in Greenberger lysis buffer (150 mM NaCl, 15 mM Tris, pH 7.4, 1 mM 
MgCl2, and 1% Triton X-100). Total protein content was determined using the BCA Protein 
Assay (Thermo Scientific Pierce, Etten-Leur, The Netherlands) and cytokine levels of IL-2, IL-
4, IL-6, IL-10, IL17a, IFNɣ and TNFα were measured using the Cytometric Bead Array (BD 
Biosciences, San Diego, CA, USA) and FACSCalibur flow cytometer (BD Biosciences) 
following the manufacturer’s instructions. Data were analyzed with FlowJo software  
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(version 7.6.3., Tree Star Inc. Ashland, OR, USA). Cytokine levels measured were corrected 
for the total amount of protein of the sample. 
Statistical analysis 
To compare two groups, parametric and nonparametric analyses were performed using an 
unpaired t test or Mann-Whitney U test, respectively. Numerical values were expressed as 
means ± standard deviation (SD). All analyses were performed using GraphPad Prism 
software (GraphPad Software, version 5.01, San Diego, CA). P values ≤0.05 were 
considered statistically significant. 
RESULTS
Migration of MSCs is enhanced after in vitro prestimulation with IFNɣ and TNFα 
Colitis was induced by sensitization with TNBS through the skin on day 0 followed by an 
intraluminal injection with TNBS diluted in ethanol 7 days later. Ethanol breaks down the 
mucosa enabling TNBS to haptenize the colonic flora to induce colitis with a mainly Th1-
mediated immune response.29 TNBS-treatment resulted directly in an acute severe distal 
colitis reflected by a severe body weight loss compared to controls, higher disease scores 
(sum of the presence of loose stool, visible faecal blood and macroscopic inflammation) and 
shortening and wall thickening of the colon as indicated by the weight/length ratio (figure 
3A-C). Furthermore, the proinflammatory cytokines IL-6 and TNFα were elevated in colon 
homogenates compared to healthy controls (figure 3D and E). 
To evaluate whether IFN-ɣ and TNF-α stimulated MSCs (i/tMSCs) have increased capacity to 
attenuate colitis compared to unstimulated MSC in our model, mice were injected i.p. with 
1x106 unstimulated or i/tMSCs at day 8. Control TNBS mice received PBS instead of MSC 
(figure 1B). Colitis was accompanied by an average body weight loss of 16.5%±4.8% and 
19.7%±5.7% at day 9 and 10 respectively, in TNBS mice receiving PBS. Upon MSC 
administration, mice lost 14.5%±4.9% body weight at day 9 and 14.3%±7.9% at day 10 (p<0.05 
at day 10 compared to PBS-injected TNBS control mice). Mice that received i/tMSCs lost 
14.6%±5.5% and 13.3%±8.8% at respectively day 9 and 10 (p = 0.05 at day 10 compared to PBS-
injected TNBS controls; figure 4A). 
Next, we investigated whether migration is important for unstimulated- and i/tMSCs to 
attenuate colitis. Therefore, at day 9 and 10, mice were imaged dorsally to localize the MSCs 
in proximity of the distal colon. At day 9, administration of MSCs resulted in 2.5±1.5-fold more 
signal at the dorsal side of colitis mice compared to non-TNBS controls that received MSCs. 
This is reflected by a 2.5-fold difference in average radiance (FDAR) (figure 4A). At day 10, 
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the FDAR further increased to 3.8±2.9. Injection of i/tMSCs resulted in 3.4±1.4-FDAR at day 9
and 2.4±1.1-FDAR at day 10. No differences in disease score were observed between TNBS
mice receiving MSCs or i/tMSCs (figure 4B). Interestingly, at sacrifice on day 10, when the
colon was imaged separately, the FDAR in the colon was more than 10-fold increased after
i/tMSC administration compared to injection with unstimulated MSCs (79.3±89.3 versus
7.1±8.0; p<0.005). This suggests that stimulation with IFNɣ and TNFα enhances MSC
migration to the site of inflammation (figure 4B).
To evaluate whether the time of i/tMSC injection is important to further increase body
weight, 1x106 i/tMSCs were injected per mouse on day 7 or day 8 (figure 1). Administration
of i/tMSCs to TNBS mice at day 7 resulted in significantly less body weight loss at day 10
compared to administration of i/tMSCs at day 8 (7.9%±6.7% versus 15.9%±3.6% respectively; p
< 0.01; figure 5A). This difference in body weight loss cannot be explained by the fact that
i/tMSCs administered at day 7 were injected one day earlier than i/tMSCs administered at
day 8. When the body weights at two days after injection of i/tMSCs were compared (i.e. at
day 9 when i/tMSCs were injected at day 7 and at day 10 when i/tMSCs were injected at day
8), a significantly higher body weight was observed when i/tMSCs were injected at day 7
compared to day 8 (9.7%±4.7% versus 15.9%±3.6% body weight loss compared to day 7; p <
0.01). In addition, the disease score at the day of sacrifice was lower when i/tMSCs were
administered at day 7 compared to day 8 (2.1±1.6 versus 3.6±1.5; p = 0.06; figure 5B). The
FDAR at the dorsal side of the mice at two days after administration of i/tMSCs was
significantly higher in mice that received i/tMSCs at day 8 compared to administration at day
7 (11.7±4.5 versus 2.0±1.0; p < 0.0001; figure 5A). In contrast, more i/tMSCs were localized at
the colon at sacrifice when i/tMSCs were administered at day 7 compared to administration
on day 8 (48.6±34.0 versus 24.6±16.9; p = 0.07). These results indicate that the time of i/tMSC
administration and the subsequent migration of i/tMSCs towards the colon are important 
factors to attenuate colitis.
VCAM expression is involved in MSC localization to the inflamed colon
Following stimulation with IFNɣ and TNFα, VCAM is upregulated on the surface of MSCs 
(figure 6A). Therefore, we hypothesized that VCAM expression may be involved in the
adhesion of MSCs to the inflamed colon and in the amelioration of colitis. To address this
issue, we knocked down VCAM using shRNA (shVCAM) and injected 2x106 MSCs, shVCAM-
MSCs, i/tMSCs or shVCAM-i/tMSCs per mouse at day 7. Stimulation of shVCAM-MSC with
IFNɣ and TNFα resulted in upregulation of VCAM expression, compared to unstimulated
shVCAM-MSC and unstimulated MSC (figure 6A). Upon administration of cells with the




(version 7.6.3., Tree Star Inc. Ashland, OR, USA). Cytokine levels measured were corrected 
for the total amount of protein of the sample. 
 
Statistical Analysis 
To compare two groups, parametric and nonparametric analyses were performed using an  
unpaired t test or Mann-Whitney U test, respectively. Numerical values were expressed as 
means ± standard deviation (SD). All analyses were performed using GraphPad Prism 
software (GraphPad Software, version 5.01, San Diego, CA). P values ≤0.05 were 
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RESULTS 
Migration of MSCs is enhanced after in vitro prestimulation with IFNɣ and TNFα 
Colitis was induced by sensitization with TNBS through the skin on day 0 followed by an 
intraluminal injection with TNBS diluted in ethanol 7 days later. Ethanol breaks down the 
mucosa enabling TNBS to haptenize the colonic flora to induce colitis with a mainly Th1-
mediated immune response.29 TNBS-treatment resulted directly in an acute severe distal 
colitis reflected by a severe body weight loss compared to controls, higher disease scores 
(sum of the presence of loose stool, visible faecal blood and macroscopic inflammation) and 
shortening and wall thickening of the colon as indicated by the weight/length ratio (figure 
3A-C). Furthermore, the proinflammatory cytokines IL-6 and TNFα were elevated in colon 
homogenates compared to healthy controls (figure 3D and E). 
To evaluate whether IFN-ɣ and TNF-α stimulated MSCs (i/tMSCs) have increased capacity to 
attenuate colitis compared to unstimulated MSC in our model, mice were injected i.p. with 
1x106 unstimulated or i/tMSCs at day 8. Control TNBS mice received PBS instead of MSC 
(figure 1B). Colitis was accompanied by an average body weight loss of 16.5%±4.8% and 
19.7%±5.7% at day 9 and 10 respectively, in TNBS mice receiving PBS. Upon MSC 
administration, mice lost 14.5%±4.9% body weight at day 9 and 14.3%±7.9% at day 10 (p<0.05 
at day 10 compared to PBS-injected TNBS control mice). Mice that received i/tMSCs lost 
14.6%±5.5% and 13.3%±8.8% at respectively day 9 and 10 (p = 0.05 at day 10 compared to PBS-
injected TNBS controls; figure 4A). 
Next, we investigated whether migration is important for unstimulated- and i/tMSCs to 
attenuate colitis. Therefore, at day 9 and 10, mice were imaged dorsally to localize the MSCs 
in proximity of the distal colon. At day 9, administration of MSCs resulted in 2.5±1.5-fold more 
signal at the dorsal side of colitis mice compared to non-TNBS controls that received MSCs. 
This is reflected by a 2.5-fold difference in average radiance (FDAR) (figure 4A). At day 10, 
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the FDAR further increased to 3.8±2.9. Injection of i/tMSCs resulted in 3.4±1.4-FDAR at day 9 
and 2.4±1.1-FDAR at day 10. No differences in disease score were observed between TNBS  
mice receiving MSCs or i/tMSCs (figure 4B). Interestingly, at sacrifice on day 10, when the 
colon was imaged separately, the FDAR in the colon was more than 10-fold increased after 
i/tMSC administration compared to injection with unstimulated MSCs (79.3±89.3 versus 
7.1±8.0; p<0.005). This suggests that stimulation with IFNɣ and TNFα enhances MSC 
migration to the site of inflammation (figure 4B).  
To evaluate whether the time of i/tMSC injection is important to further increase body 
weight, 1x106 i/tMSCs were injected per mouse on day 7 or day 8 (figure 1). Administration 
of i/tMSCs to TNBS mice at day 7 resulted in significantly less body weight loss at day 10 
compared to administration of i/tMSCs at day 8 (7.9%±6.7% versus 15.9%±3.6% respectively; p 
< 0.01; figure 5A). This difference in body weight loss cannot be explained by the fact that 
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FIGURE 4 Migration of MSCs is enhanced after in vitro prestimulation with IFNγ and TNFα. Mice were sensitized 
for TNBS on the skin at day 0, followed by intraluminal TNBS at day 7 to establish acute TNBS-colitis. 
Subsequently, 1x106 MSCs, i/tMSCs or PBS was administered day 8. (A) BLI was performed at day 9 and 10. 
Average radiance of mice with colitis were normalized for their own non-TNBS control and shown as FDAR 
(left panel). Body weights at day 9 and 10 were assessed and expressed as the percentage of body weight of 
the same mouse measured at day 7 (right panel). (B) FDAR of colons was assessed at time of sacrifice (left 
panel). Disease scores consisting of the presence of loose stool, visible faecal blood and macroscopic 
inflammation were measured at sacrifice (day 10; right panel). Data are expressed as mean (± SD); n = 7-14 per 
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FIGURE 5 Time of i/tMSC administration is crucial to attenuated colitis. On day 0 mice were sensitized for TNBS
followed by an intraluminal TNBS infusion on day 7. On day 7 or 8, 1x106 i/tMSCs were injected i.p. (A) Dorsal
scans were made using BLI at day 9 and 10. Average radiance of mice with colitis were normalized for own
healthy controls and shown as FDAR (left panel). Body weights at day 9 and 10 were assessed and expressed
as the percentage of body weight of the same mouse measured at day 7 (right panel). (B) FDAR in the colons
were analyzed at day 10 (left panel). Disease scores consisting of the presence of loose stool, visible faecal
blood and macroscopic inflammation were measured at sacrifice (day 10; right panel). Data are expressed as
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3.4% versus 89.8%±7.9%; p<0.05; figure 6B) and lower disease scores (1.1±0.9 versus 2.9±2.0; 
p<0.05; figure 6C) at sacrifice compared to mice that received cells with the lowest 
expression of VCAM (shVCAM-MSCs). Administration of shVCAM-i/tMSCs resulted in a 
significantly decreased FDAR compared to i/tMSC when BLI was performed at day 9 (6.1±3.3 
versus 15.7±14.9; p = 0.01; figure 6D). At day 10, the FDAR in the dorsal scans of mice treated 
with i/tMSCs decreased to levels comparable to shVCAM-i/tMSCs (7.7±8.5 versus 6.1±2.8). 
Interestingly, the FDAR in the excised colons at sacrifice on day 10 coincided with increased 
VCAM expression (from 2.9±1.8 to 4.8±3.1 and 11.9±11.4) with the colon FDAR after i/tMSC 
administration as an exception (4.6±4.6; figure 6E). This may be due to the fact that mice 
treated with i/tMSCs had body weights of almost 100% and very low disease scores at time 
of sacrifice suggesting that MSCs may be cleared when the inflammation in the colon is 
cleared. 
To evaluate whether the downregulated migration of shVCAM-MSC was VCAM-specific and 
were not induced by the shRNA transduction procedure, 2x106 i/tMSCs with shRNA for  
inducible nitric oxide synthase (iNOS) or for tumor necrosis factor-inducible gene (TSG)-6 
were administered at day 7. These cells had similar expression levels of VCAM as i/tMSCs, 
but were silenced for iNOS or TSG-6. Interestingly, mice treated with shiNOS-i/tMSCs or 
shTSG-6-i/tMSCs had body weights and disease scores comparable to mice treated with low 
expression VCAM-cells (shVCAM-MSCs or MSCs; figure 6B and C). However, their ability to 
migrate to the dorsal side of the mice was at levels similar to i/tMSC (figure 6D) while specific 
migration towards the inflamed colon was increased (figure 6E).  
Injection of MSCs with a low expression of VCAM (shVCAM-MSCs or MSCs) or of MSCs in 
which iNOS or TSG-6 is downregulated impairs colitis attenuation. Therefore, we evaluated 
the levels of iNOS and TSG-6 after stimulation with IFNɣ and TNFα. Stimulation with IFNɣ 
and TNFα upregulated both intracellular iNOS and the secretion of TSG-6 (figure 6F). These 
data suggest that the immunosuppressive mechanism of MSCs is established via a concerted 
action between VCAM, iNOS and TSG-6. Prestimulation of MSCs with IFNɣ and TNFα induced 
high expression levels of VCAM, iNOS and TSG-6 and was the most effective in the 
attenuation of colitis. 
MSCs migrate specifically to the distal colon where the colitis is most severe 
Localization of the MSCs in the intestines was evaluated in mice injected with 2x106 
unstimulated or IFNɣ and TNFα stimulated MSCs at day 7. At day 10, mice were sacrificed 
and the exact location of the highest BLI signal in the small intestine and colon was 
determined, as this is the site where the highest number of MSCs is present (figure 2B). The 
highest signal in colitis mice was observed at the distal colon (figure 7A; left panel). Non-
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colitis colons did not have a specific site of MSC accumulation, but MSCs were 
predominantly observed in the small intestine (figure 7A; right panel). Since 
proinflammatory cytokines such as IL-6 and TNFα were elevated in TNBS-induced colitis 
(figure 3D and E) we evaluated whether the presence of MSCs influenced cytokine secretion 
at the site of inflammation. The spot with the highest signal was isolated from the colons, 
homogenized and levels of IL-6 and TNFα were determined. Administration of i/tMSCs 
resulted in IL-6 and TNFα levels comparable to healthy non-TNBS controls. In contrast, 
following shVCAM-MSCs administration, IL-6 and TNFα were still increased (IL-6: 3.5±3.5 vs 
345.8±495.6 pg/mg after administration of i/tMSCs and shVCAM-MSCs respectively; TNFα: 
2.3±0.2 vs 32.7±40.1 pg/mg after administration of i/tMSCs and shVCAM-MSCs respectively; 
figure 7B and C). 
MSCs form VCAM-dependent structured spheroids in the serosal fat surrounding the 
inflamed colon 
Clustered MSCs were occasionally observed by eye as a white spheroid (figure 8A). At the 
time of sacrifice, these clusters of MSC were harvested and subsequently cultured in vitro 
(figure 9A). Spindle shaped cells grew out of the harvested tissues around 4 days after 
isolation. Phenotypic analysis confirmed that these cells were MSCs as they expressed the 
same MSC markers as at the time of i.p. injection (figure 9B). In addition, all recultured MSCs 
were GFP-positive confirming that these cells were derived from the MSCs that we have 
injected previously (figure 9C). 
To further investigate these clusters, colons and small intestines were embedded in paraffin 
and slides were stained with an anti-GFP antibody to detect MSCs. In colitis mice, MSCs were 
detected in structured spheroids that were mostly located in the serosal fat surrounding the 
inflamed colon. In contrast, in control mice, spheroids were predominantly detected in the 
serosal fat surrounding the small intestines (figure 8B). All spheroids expressed collagen and 
contained F4/80+ macrophages. In approximately half of the spheroids of both colitis and 
non-colitis mice, CD3+ cells were detected. In contrast, FoxP3-positive regulatory T cells 
were not observed (figure 8B).  
To investigate the role of VCAM in spheroid formation we induced MSC-spheroids in vitro. 
All MSCs had the capacity to form spheroids in vitro, resembling the spheroids that we 
observed in vivo (figure 8C). However, shVCAM-MSCs formed significantly smaller spheroids 
and more ‘satellite spheroids’, containing few MSC, compared to MSCs and shCtrl-MSCs 
(figure 8D-F). These results suggest that shVCAM-MSCs form smaller spheroids in vivo and 
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FIGURE 6 VCAM expression is involved in MSC localization to the inflamed colon. On day 0 mice were sensitized for 
TNBS, followed by an intraluminal TNBS infusion on day 7. On day 7, 2x106 MSCs, shVCAM-MSCs, i/tMSCs, shiNOS-, 
shTSG-6- or shVCAM-i/tMSCs were administered. (A) VCAM-expression was analyzed by flow-cytometry following 
stimulation with IFNɣ and TNFα. (B) Body weights at day 9 and 10 were assessed and expressed as a percentage of 
body weight at day 7. (C) Disease score consisting of the presence of loose stool, visible faecal blood and 
macroscopic inflammation measured at sacrifice (day 10) was assessed. (D) BLI was performed at day 9 and 10. 
Average radiance of mice with colitis were normalized for own healthy control and shown as FDAR. (E) FDAR of 
colons was assessed at time of sacrifice. (F) Levels of iNOS and TSG-6are increased following stimulation with IFNɣ 
and TNFα. Data are expressed as mean (± SD); n = 7-8 per group (n = 2 experiments). See figure 1A for study design. 
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In the present study, we evaluated the migratory capacity and immunosuppressive effect of 
bone marrow-derived MSCs in a TNBS-induced experimental colitis model. The timing of 
MSC administration is crucial for the outcome of the colitis. MSC administration after 
induction of colitis resulted in specific migration to the serosa of the colon and amelioration 
of disease, with injection at day 7, i.e., shortly post colitis induction, resulting in the highest 
body weights and lowest disease scores at sacrifice on day 10. ‘Licensing’ of MSCs by 
proinflammatory stimuli in vivo is thought to be necessary to gain their full 
immunosuppressive properties.8,12,13 Prestimulation of MSCs in vitro with IFNɣ and TNFα 
upregulates the surface expression of VCAM and increases intracellular iNOS levels and TSG-
6 secretion. Furthermore, activation of MSCs with TNFα significantly promotes their 
migration to ischemic sites in experimental models.25,27 Upon injection, i/tMSCs migrated to 
the distal colon were the colitis is most pronounced and a decrease in i/tMSC was detected 
after establishing body weight gain and a decrease in disease scores to levels comparable 
to healthy controls without colitis. Interestingly, downregulation of VCAM abrogated this 
effect, as lower numbers of MSCs migrated to the colon when VCAM was downregulated, 
indicating a predominant role for VCAM in this process. VCAM expression levels strongly 
correlated with disease outcome. Mice that were treated with i/tMSCs, which have the 
highest expression levels of VCAM, had significantly higher body weights and lower disease 
scores than mice treated with shVCAM-MSCs that express the lowest levels of VCAM. Our 
observations were VCAM-specific as the migration in mice injected with i/tMSCs silenced for 
other factors using shRNA, such as iNOS- or TSG-6, was not altered. Interestingly, colitic mice 
treated with shiNOS-i/tMSCs or shTSG-6-i/tMSCs lost more body weight than i/tMSC treated 
mice, suggesting a role for iNOS and TSG-6 in our model. Both iNOS and TSG-6 have been 
suggested as key players in MSC-mediated immunosuppression.12,32 Therefore, we 
hypothesize that the immunosuppressive action of MSCs consists of both migration, which 
is, at least partially, dependent on VCAM, and upregulation of the immunosuppressive 
factors iNOS and TSG-6. Both VCAM, iNOS and TSG-6 are enhanced after stimulation with 
IFNɣ and TNFα explaining why i/tMSCs were most effective in alleviating TNBS-induced 
colitis. 
VCAM interacts with the α4β1-integrin (VLA-4) on multiple cell types, including T cells and is 
required for lymphocyte-MSC adhesion.26 α4β1-positive leukocytes have the capacity to 
adhere to VCAM-expressing cells such as a monolayer of endothelial cells and subsequently 
transmigrate through this layer into damaged tissues.33 In our hands, MSCs migrated more 
often to the inflamed colon when expression levels of VCAM were high but we never 
observed transmigration through the colonic wall towards the lamina propria or the 
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damaged mucosa. This may be explained by the distinct layers of cells of the colon compared 
to other tissues. Nonetheless, immunosuppression was still achieved, possibly by 
upregulation and local secretion of iNOS and TSG-6. MSCs formed collagen expressing 
spheroids in the serosal fat, containing T cells and macrophages. Analysis of the GFP-positive 
cells obtained from the spheroids at the time of sacrifice, indicated that these cells were 
phenotypically similar to the MSCs that were administered. This demonstrates that the 
injected MSCs did not differentiate into another cell type in the days after administration. In 
a DSS-induced colitis model was recently shown that MSCs form aggregates that produce 
TSG-6 in the peritoneal cavity.34 The authors reported that TSG-6 attenuated the colitis by 
decreasing the number of neutrophils in the intestinal mucosa and increasing FoxP3 positive 
cells. In addition, iNOS expressing regulatory macrophages were increased. These results 
suggest that spheroid formation by MSCs may be a mechanism to enhance their 
immunosuppressive abilities. In our hands, shVCAM-MSCs formed significantly smaller 
spheroids in vitro compared to MSCs and shCtrl-MSCs, instead significantly more ‘satellite 
spheroids’ were formed. These results may indicate that shVCAM-MSCs also form smaller 
spheroids in vivo. We hypothesize that large spheroids are more efficient in 
immunosuppression and that VCAM is involved in this process.  
In conclusion, we demonstrate that the migration of MSCs towards the inflamed colon is 
VCAM-dependent. MSCs pretreated with IFNɣ and TNFα expressed higher levels of VCAM 
resulting in increased MSC migration towards the inflamed colon where they subsequently 
ameliorated the colitis. We hypothesize that this is mediated by the VCAM-dependent 
formation of structured spheroids and the interaction with immune cells. In addition, iNOS 
and TSG-6 are upregulated after prestimulation with IFNɣ and TNFα and are possibly of 
importance in the immunosuppressive mechanism of MSCs in our model. 
FIGURE 8 MSCs form VCAM-dependent structured spheroids in the serosal fat surrounding the inflamed colon. 
BLI of the colon and small intestine at the time of sacrifice allowed us to trace i.p. injected MSCs. (A) BLI and 
matching macroscopic photo of a colon at sacrifice. MSCs clustered together at the serosal side of the colon 
forming a white spheroid (right black arrow). (B) MSCs were transduced with EF1α-FLuc-IRES-GFP and 
therefore could be traced with an anti-GFP staining. MSCs formed structured spheroids expressing collagen 
(Sirius Red). CD3-, FoxP3- and F4/80-staining were performed on slides and revealed F4/80+ macrophages and 
in approximately half of the spheroids CD3+ cells. No FoxP3+ cells were observed. Magnification, x20. (C) In 
vitro formed spheroids stained for GFP and Sirius Red resemble the in vivo phenotype. Magnification, x20. (D) 
In vitro formation of MSC-, shVCAM-MSC - and shCtrl-MSC-spheroids 48 hours after the start of spheroid 
culture. Magnification, x10. Quantification of spheroid size (E) and satellite spheroids (F). Data are expressed 
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importance in the immunosuppressive mechanism of MSCs in our model. 
FIGURE 8 MSCs form VCAM-dependent structured spheroids in the serosal fat surrounding the inflamed colon. 
BLI of the colon and small intestine at the time of sacrifice allowed us to trace i.p. injected MSCs. (A) BLI and 
matching macroscopic photo of a colon at sacrifice. MSCs clustered together at the serosal side of the colon 
forming a white spheroid (right black arrow). (B) MSCs were transduced with EF1α-FLuc-IRES-GFP and 
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In vitro formation of MSC-, shVCAM-MSC - and shCtrl-MSC-spheroids 48 hours after the start of spheroid 
culture. Magnification, x10. Quantification of spheroid size (E) and satellite spheroids (F). Data are expressed 
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FIGURE 9 (A): MSCs were harvested from mice at sacrifice and recultured in vitro. Spindle shaped cells grew out 
of the harvested tissues 4 days after reculture and were trypsinised and characterised 4 weeks later. (B): The 
cells that grew out of the harvested tissues had similar expression of MSC-markers as before i.p. injection. (C): 
Recultured cells were embedded in paraffin and stained with an anti-GFP antibody. All cells were GFP-positive 
confirming that these cells were expanded from the MSCs we injected in in vivo. Magnification, x20.  
A.
Tissue recultured in
6-Wells culture plate  
Spindle shaped cells grow out of the 
tissue 4 days after harvesting at sacrifice
The tissue harvested at sacrifice was 
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Background and Aim: In recent years mesenchymal stromal cells (MSCs) emerged as a 
promising therapeutic option for various diseases due to their immunomodulatory 
properties. We previously observed that intraperitoneally injected MSCs in experimental 
colitis form spherical shaped aggregates. Therefore, we aggregated MSCs in vitro into 
spheroids and injected them intraluminally in mice with established colitis to investigate 
whether these MSC spheroids could alleviate the colitis.  
Methods: We injected ‘0.5x106 MSCs in spheroids’, ‘2.0x106 MSCs in spheroids’, or PBS as a 
treatment control, via an enema in mice with established DSS-induced colitis. Body weight 
was measured daily and disease activity score was determined at sacrifice. Endoscopy was 
performed to evaluate mucosal healing. After sacrifice, both systemic and local 
inflammatory responses were evaluated.   
Results: Intraluminally injected MSC spheroids alleviated DSS-induced colitis resulting in 
significantly less body weight loss and lower disease activity score at sacrifice when a high 
dose of MSC spheroids was administered. However, the percentage of mucosal lesions in 
the distal colon and endoscopy scores were not significantly lower after treatment with 
2.0x106 MSCs in spheroids compared to PBS treated mice. Systemic inflammation marker 
SAA was significantly reduced after treatment with 2.0x106 MSCs in spheroids. In addition, 
local cytokine levels of IFN-ɣ, TNF-α, IL-6 and IL-17a, as well as numbers of macrophages and 
neutrophils, showed a clear decrease, though not always significant, after intraluminal 
injection of the MSC spheroids.  
Conclusion: Intraluminally injected MSC spheroids at least partially attenuate experimental 
colitis, accompanied by less phagocytes and proinflammmatory cytokines, when a high dose 
of MSCs in spheroids was administered.  
 
Keywords: mesenchymal stromal cell, spheroid, experimental colitis  




Due to their immunomodulatory properties and their ability to actively participate in tissue 
repair mesenchymal stromal cells (MSCs) emerged as a potential therapeutic alternative in 
the treatment of several diseases.1 Promising reports on the use of MSCs as a treatment for 
both experimental colitis as well as human inflammatory bowel disease (IBD) have been 
published in the last few years.2-6 Currently, their exact mode of action is under investigation. 
Previously it became clear that MSC-therapy is not beneficial under all conditions of an 
ongoing immune response and that the timing of administration is important to induce the 
full immunosuppressive and tissue regenerative properties of MSCs.7 In recent years, 
potentiating the therapeutic efficacy of MSCs, by priming with proinflammatory cytokines 
such as interferon-gamma (IFN-ɣ) and/or tumor necrosis factor-alpha (TNF-α) to create an 
immunostimulatory milieu in vitro before use in vivo was also evaluated.8, 9 Although 
encouraging results have been obtained in different preclinical studies using these primed 
MSCs10, 11, caution should be taken as MSCs can participate in antigen presentation by 
upregulation of major histocompatibility class (MHC) class II molecules when not primed 
sufficiently. This could finally result in a potential risk of rejection and exaggeration of an 
ongoing immune response, ultimately worsening the disease.7, 12-15 Therefore, new methods 
to increase the immunomodulatory effects of MSCs are relevant to be assessed. Recently, 
intraperitoneally injected MSCs were observed to cluster together to form aggregates 
which produced the anti-inflammatory protein tumor necrosis factor-inducible gene (TSG)-
6 leading to attenuated dextran sulphate sodium (DSS)-induced colitis.16 Remarkably, 
intravenously injected MSCs in experimental myocardial infarction entrapped within the 
lungs also formed clusters that produced TSG-6 thereby improving tissue damage.17 In our 
previously performed experiments, we also observed that intraperitoneally injected MSCs 
form spherical shaped aggregates. To investigate whether MSCs aggregated into spherical 
clusters, i.e. spheroids, could alleviate experimental colitis, we created MSC spheroids in 
vitro and injected them in mice with established DSS-induced colitis. Since the inflammation 
is in the mucosa of the distal colon, we injected the MSC spheroids intraluminally via an 
enema, hypothesizing that MSC spheroids might integrate into the mucosa or release 
soluble factors which contribute to the attenuation of experimental colitis. We observed 
that intraluminal injection of in vitro generated MSC spheroids alleviated DSS-induced colitis 
when given in a high dose, which was accompanied by a decreased invasion of distinct 
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MATERIAL AND METHODS 
MSC isolation 
Murine bone marrow MSCs were isolated from 8 to 12-week-old C57BL/6Jico mice (Charles 
River Maastricht, The Netherlands). Mice were sacrificed by cervical dislocation and femurs 
and tibiae were removed, cleaned of tissue and flushed to retrieve bone marrow cells. Cells 
were plated in αMEM (Lonza, Verviers, Belgium) supplemented with 10% fetal calf serum 
(Hyclone, Thermo Scientific, Landsmeer, The Netherlands), 3mM L-glutamine (Invitrogen, 
Bleiswijk, The Netherlands) and Penicillin/Streptomycin (Lonza, Verviers, Belgium) after a 
centrifugation step and expanded in a 37°C humidified incubator containing 5% CO2. After 24 
hours, non-adherent cells were removed and the medium was refreshed every 3-4 days. The 
protocol for the experiments was approved by the Committee on Animal Welfare of the 
Leiden University Medical Center. 
 
MSC spheroid formation 
Spheroids were formed in 96-wells culture plates (Greiner Bio-One BV, Alphen a/d Rijn, The 
Netherlands) of 2,500 MSCs per well. Thus, every spheroid consisted of 2,500 MSCs and 
0.24% methyl cellulose (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) which was 
added to the medium in each well to enhance spheroid formation. MSCs from passages 6 to 
8 were used to create spheroids for transplantation experiments. Spheroids were harvested 
after 2 days of culture. Before in vivo injection, MSC spheroids were thoroughly washed with 
PBS. Either 0.5x106 or 2.0x106 MSCs in spheroids were injected locally meaning 200 spheroids 
consisting of 2,500 MSCs per spheroid in case of ‘0.5x106 MSCs in spheroids’ and 800 
spheroids consisting of 2,500 MSCs per spheroid in case of ‘2.0x106 MSCs in spheroids’. 
In indicated in vitro experiments 500 U/ml recombinant mouse IL-6 (Life Technologies, 
Bleiswijk, The Netherlands) or recombinant mouse TNF-α (R&D systems, Abingdon, UK) was 
added to each well. In these experiments, in total 12-15 96-wells culture plates per time point 
were used to generate spheroids resulting in 1152-1440 spheroids per time point. 
 
MSC characterization 
Immunophenotyping of MSCs was performed using the following primary antibodies: CD44, 
CD105, CD106 (BD Biosciences, San Diego, CA, USA) CD29, Sca-1 and CD45 (eBioscience, 
Vienna, Austria). Samples were analyzed using a FACSCanto II flow cytometer with Diva 
Software (BD Biosciences, San Diego, CA, USA) and the data were analyzed with FlowJo 
software (version 8.7.1., Tree Star Inc. Ashland, OR, USA). In vitro differentiation was 
performed in 24-wells culture plates with MSCs at 80% confluency. MSC spheroids were 
transferred to 24-wells plates after 2 days of culture and 4 days before the start of 
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differentiation. For osteogenic differentiation MSCs and spheroids were stimulated for 21 
days in complete medium supplemented with 10-8 M dexamethason, 50 μg/ml ascorbic acid 
and 10 mM β-glycerophosphate (all from Sigma-Aldrich Chemie BV, Zwijndrecht, The 
Netherlands). Alkaline phosphatase activity was shown with Fast Blue and calcium deposit 
with Alizarin Red (both Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). For 
adipogenic differentiation, MSCs and spheroids were stimulated for 21 days in adipogenic 
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(10-6 M), insulin (5 µM), indomethacin (100 μM) and 3-isobutyl- 1-methylxanthine (0.5 mM) 
(all from Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). Formation of lipid 
droplets was visualized with Oil-red O staining (Sigma-Aldrich Chemie BV, Zwijndrecht, The 
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subsequent healing. The murine endoscopic index of colitis severity (MEICS) was used to 
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performed in 24-wells culture plates with MSCs at 80% confluency. MSC spheroids were
transferred to 24-wells plates after 2 days of culture and 4 days before the start of
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FIGURE 1 Intraluminally injected MSC spheroids in healthy mice. Mice received 0.5x106 or 2.0x106 MSCs in 
spheroids, PBS via enema or no treatment at day 5. Mice were sacrificed at day 10. Data are expressed as mean 
± SEM. n = 3 per group from 2 separate experiments. (A): Body weights were measured daily and expressed as 
the percentage of body weight at day 0. (B): Disease related shortening of the colon. (C): Disease activity score 
based on the presence of loose stool, fecal blood and macroscopic inflammation determined at sacrifice (day 
10). (D): Measurement of systemic inflammation marker serum amyloid A (SAA). 
larity of the mucosal surface and stool consistency.18 MEICS was scored blindly and 
independently by two researchers. At sacrifice, blood was collected by cardiac puncture and 
centrifuged (10,000g for 10 minutes) to collect serum which was stored in -20°C. Colon 
length was measured, as an indicator of disease-related intestinal shortening, and colons 
were opened longitudinally to calculate the disease activity score consisting of the presence 
of loose stool, visible fecal blood and macroscopic inflammation using a scale of 0-3 per item, 
resulting in a maximum score of 9.19 Colons were either stored in 4% neutral buffered  
A.
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FIGURE 2 Immunophenotypical characterization of single cell MSCs and MSC spheroids. Spheroids were created 
in 96-wells plates with 2,500 MSCs per well. (A): Macroscopic picture (left panel), histology (central panel) and 
cleaved caspase-3 staining (right panel) of spindle shaped MSCs and MSC spheroids. Magnification x20. (B): 
MSC surface markers CD29, CD44, CD105, CD106, Sca1 (positive) and CD45 (negative) as analyzed by flow 
cytometry. (C): Differentiation into adipocytes (lipid droplets) and osteoblasts (alkaline phosphatase activity 
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formalin as a ‘Swiss roll’20 and embedded in paraffin for (immuno)histological evaluation or 
the distal part of the colon was directly frozen in isopentane for protein extraction and 
cytokine measurements. 
 
Histological evaluation of disease activity 
The paraffin-embedded colons were cut into sections of 4 µm and stained with 
haematoxylin and eosin (HE) to evaluate the number of lesions in the distal 3 cm of the colon 
where DSS-induced colitis is most pronounced. A lesion was defined as a part of the colon 
without epithelium. Colon- and lesion length was measured with Olympus CellSens (version 
1.7.1, Zoeterwoude, The Netherlands). All colons were measured twice and the researcher 
was blind for the treatment mice had received. The average percentage of mucosal lesions 
is shown.  
 
Immunohistochemistry 
Apoptosis was shown in MSCs and MSC spheroids embedded in paraffin with an anti-cleaved 
caspase-3 antibody (1:800, Cell Signaling, Leiden, The Netherlands). Macrophages were 
detected with an anti-F4/80 antibody (1:800, eBioscience, LTD, Hatfield, UK) and T 
regulatory cells (Tregs) with an anti-FoxP3 antibody (1:500, eBioscience, LTD, Hatfield, UK). 
In brief, slides were deparaffinised, hydrated and incubated in 0.3% H2O2/methanol for 20 
minutes at room temperature. Slides were blocked with Teng-T (10 mM Tris, 5 mM EDTA, 
0.15 M NaCl, 0.25% gelatin, 0.05% (v/v) Tween-20, pH 8.0) for 30 minutes or proteinase K (50 
µg/ml) for 10 minutes at 37°C, and subsequently incubated overnight at 4°C with primary 
antibody in PBS containing 0.1% Triton X-100 and 1% bovine serum albumin (BSA) and 
followed by a peroxidase labelled polymer (EnVision+, Dako Netherlands BV, Heverlee, 
Belgium). For staining of macrophages and Tregs, slides were incubated for 1 hour (room 
temperature) with a rabbit anti-rat HRP secondary antibody conjugated secondary antibody 
(1:200, Dako Netherlands BV, Heverlee, Belgium) diluted in PBS containing 0,01% Triton X-100 
and 1% BSA instead of a peroxidase labelled polymer. Peroxidase activity was detected with 
3,3’-diaminobenzidine tablets (DAB Fast Tablet, Sigma-Aldrich, St. Louis, MO). Sections were 
counterstained with hematoxylin, dehydrated, and mounted in Entellan (Merck KGaA, 
Darmstadt, Germany). Microscopic images of the distal 3 cm of the colon were made with a 
magnification of x20. The F4/80-positive cells in these slides were counted using ImageJ 
software (version 1.45s, National Institutes of Health, USA) to quantify their number in the 
mucosa of the distal 3 cm of the colon.  
 
 
INTRALUMINAL INJECTION OF MSC SPHEROIDS IN DSS COLITIS 
155 
Serum amyloid A and cytokine measurements 
Serum amyloid A (SAA) levels were measured in the serum collected upon sacrifice using a 
solid phase sandwich ELISA kit (Life Technologies, Bleiswijk, The Netherlands). 
Homogenates were prepared from distal colon with a Potter-Elvehjem glass homogenizer 
at 4°C in Greenberger lysis buffer (150 mM NaCl, 15 mM Tris, pH 7.4, 1 mM MgCl2, and 1% 
Triton X-100). Samples were centrifuged for 15 minutes (11,000g at 4°C) and stored at -80°C. 
The BCA Protein Assay Kit (Thermo Scientific Pierce, Etten-Leur, The Netherlands) was used 
to determine the total concentration of protein in the colons and cytokine levels of IFN-ɣ, 
IL-2, IL-4, IL-6, IL-10, IL-17a and TNF-α were measured using the Cytometric Bead Array 
System (BD Biosciences, San Diego, CA, USA) following the manufacturer’s instructions. 
Data was analysed with FlowJo software (version 8.7.1., Tree Star Inc. Ashland, OR, USA). 
Cytokine levels measured were corrected for the amount of total protein.  
MPO determination 
Myeloperoxidase (MPO) activity in the homogenates of distal colon was measured as an 
index for neutrophil infiltration. In briefly, homogenates were sonicated and 0.5% 
hexadecyltrimethylammonium bromide (HTAB, Sigma-Aldrich Chemie BV, Zwijndrecht, The 
Netherlands) in 50 mM in phosphate buffer (pH 5.5) was added to the sonicated 
homogenates and incubated for 30 minutes at room temperature. Supernatants were 
mixed with 150 µl of phosphate buffer (pH 5.5; 37°C) containing 0.26 mg/ml o-dianisidine 
dihydrochloride (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) and 0.52 mM 30% 
H2O2. Colorimetric reaction was measured at 450 nm for 30 minutes using a 
spectrophotometer. One µmol H2O2 (= 1 unit of MPO) split, gives a change in absorbance of 
1.13x10-2/min. The number of MPO units was determined as ΔA450/(Δtime x 1.13x10-2) and 
corrected for the total amount of protein per sample. Samples were analysed in duplicate. 
RNA isolation and quantitative PCR 
RNA from MSC spheroids 1 to 5 days after the start of culture (n = 1152-1440 spheroids per 
time point) was extracted using RNeasy Mini Kit (Qiagen) according to the manufacturer’s 
instructions. cDNA synthesis was performed using RevertAid reverse transcriptase 
(Fermentas, St. Leon-Rot, Germany) and random primers (Promega, Leiden, The 
Netherlands). Quantitative PCR using SYBR green (QuantiFast SYBR Green PCR Kit, Qiagen) 
with a forward and reverse primermix for COX-2 (NM_011198) (QuantiTect Primer Assay, 
Qiagen) was performed. The household gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH, QiantiTect Primer Assay, Qiagen) was used to normalize the data. Samples were 
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FIGURE 3 Intraluminally injected MSC spheroids alleviate DSS-induced colitis. DSS was introduced in the drinking 
water for 7 days. Mice received 0.5x106 or 2.0x106 MSCs in spheroids or PBS via enema at day 5. Mice were 
sacrificed at day 10. Data are expressed as mean ± SEM. n = 7-14 per group from 2 separate experiments. The 
‘normal’ group consisted of 3 healthy mice that received 2.0x106 MSCs in spheroids. (A): Body weights were 
measured daily and expressed as the percentage of body weight at day 0. *, p = 0.02: 2.0x106 MSCs in spheroids 
vs both PBS and 0.5x106 MSCs in spheroids. (B): Disease related shortening of the colon. (C): Macroscopic 
images of representative colons at sacrifice (day 10). (D): Disease activity score based on the presence of loose 
stool, fecal blood and macroscopic inflammation determined at sacrifice (day 10). (E): Representative 
histological sections of mouse colons stained with HE. Magnification x20. (F): Quantification of mucosal lesions 
defined as parts in the colon without mucosa expressed as a percentage of total colon. n = 3-6 per DSS-group 
and n = 1 in healthy control group.  
PGE2 ELISA 
Prostaglandin E2 (PGE2) was measured in the supernatants of MSC spheroids 1 to 5 days 
after the start of culture using a competitive ELISA kit (Abcam, Cambridge, UK) following 
the manufacturer’s instructions. Samples were analysed in duplicate. 
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Statistical Analysis 
To compare two groups, parametric or nonparametric analyses were performed using an 
unpaired Student’s t-test or Mann-Whitney U-test, respectively. Numerical values were 
expressed as means ± standard error of the mean (SEM). All analyses were performed using 
GraphPad Prism software (GraphPad Software, version 5.01, San Diego, CA). P values ≤0.05 
were considered statistically significant. 
FIGURE 4 Endoscopic evaluation of colonic inflammation in mice with DSS-induced colitis. DSS was introduced 
in the drinking water for 7 days. Mice received 2.0x106 MSC spheroids or PBS via enema at day 5. Endoscopy 
was performed at day 0 before DSS introduction and at day 5, 8, 10 and 12. Mice were sacrificed after the 
endoscopy at day 12. Data are expressed as mean ± SEM. n = 9-10 per group. (A): Representative endoscopic 
images of mice with colitis treated with either 2.0x106 MSC spheroids or PBS via enema. (B): Endoscopic 
evaluation of the colonic inflammation using the murine endoscopic index of colitis severity (MEICS) based on 
the thickening of the colon, changes of the vascular pattern, fibrin deposit, granularity of the mucosal surface 
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FIGURE 3 Intraluminally injected MSC spheroids alleviate DSS-induced colitis. DSS was introduced in the drinking
water for 7 days. Mice received 0.5x106 or 2.0x106 MSCs in spheroids or PBS via enema at day 5. Mice were
sacrificed at day 10. Data are expressed as mean ± SEM. n = 7-14 per group from 2 separate experiments. The
‘normal’ group consisted of 3 healthy mice that received 2.0x106 MSCs in spheroids. (A): Body weights were
measured daily and expressed as the percentage of body weight at day 0. *, p = 0.02: 2.0x106 MSCs in spheroids
vs both PBS and 0.5x106 MSCs in spheroids. (B): Disease related shortening of the colon. (C): Macroscopic
images of representative colons at sacrifice (day 10). (D): Disease activity score based on the presence of loose
stool, fecal blood and macroscopic inflammation determined at sacrifice (day 10). (E): Representative
histological sections of mouse colons stained with HE. Magnification x20. (F): Quantification of mucosal lesions
defined as parts in the colon without mucosa expressed as a percentage of total colon. n = 3-6 per DSS-group
and n = 1 in healthy control group. 
PGE2 ELISA
Prostaglandin E2 (PGE2) was measured in the supernatants of MSC spheroids 1 to 5 days
after the start of culture using a competitive ELISA kit (Abcam, Cambridge, UK) following
the manufacturer’s instructions. Samples were analysed in duplicate.
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Statistical analysis 
To compare two groups, parametric or nonparametric analyses were performed using an 
unpaired Student’s t-test or Mann-Whitney U-test, respectively. Numerical values were 
expressed as means ± standard error of the mean (SEM). All analyses were performed using 
GraphPad Prism software (GraphPad Software, version 5.01, San Diego, CA). P values ≤0.05 
were considered statistically significant. 
FIGURE 4 Endoscopic evaluation of colonic inflammation in mice with DSS-induced colitis. DSS was introduced 
in the drinking water for 7 days. Mice received 2.0x106 MSC spheroids or PBS via enema at day 5. Endoscopy 
was performed at day 0 before DSS introduction and at day 5, 8, 10 and 12. Mice were sacrificed after the 
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evaluation of the colonic inflammation using the murine endoscopic index of colitis severity (MEICS) based on 
the thickening of the colon, changes of the vascular pattern, fibrin deposit, granularity of the mucosal surface 



























































Intraluminally injected MSC spheroids alleviate DSS-induced colitis 
The in vitro generated MSC spheroids had an average size of 148.9±3.8 µm (n = 6), a low 
expression of the apoptotic marker cleaved caspase-3 (figure 2A right panel) and every 
spheroid was constructed from 2,500 by flow cytometry characterized single cell MSCs 
(figure 2B). Similarly to single cell MSCs, MSC spheroids were able to differentiate into 
adipocytes and osteoblasts (figure 2C).  
Subsequently, we examined whether our in vitro generated MSC spheroids could attenuate 
DSS-induced colitis. Mice received either 0.5x106 or 2.0x106 MSCs in spheroids intraluminally 
via an enema at day 5 when colitis was established. Treatment with 2.0x106 MSCs in 
spheroids resulted in significantly reduced body weight loss at sacrifice compared to 
treatment with 0.5x106 MSCs in spheroids or PBS (9.2% vs 16.4% and 15.9% respectively; both 
p = 0.02; figure 3A). Moreover, disease related shortening of the colon was significantly 
reduced after treatment with 2.0x106 MSCs in spheroids compared to PBS (p < 0.05; figure 
3B and 3C) which was also reflected in the macroscopic disease activity score consisting of 
the presence of loose stool, visible fecal blood and macroscopic inflammation at sacrifice (p 
= 0.01 compared to PBS; figure 3D). In addition, histological evaluation of the distal colon 
revealed a clear but non-significant trend towards less mucosal lesions by injection with 
2.0x106 MSCs in spheroids compared to PBS (figure 3E and 3F).  
To quantify mucosal damage during the colitis, a second experiment was performed. Mice 
were treated with 2.0x106 MSCs in spheroids or PBS at day 5 when colitis was established 
and endoscopy was performed at day 0, 5, 8, 10 and 12 (figure 4A). The MEICS score was 
calculated to quantify the thickening of the colon, changes of the vascular pattern, fibrin 
deposit, granularity of the mucosal surface and stool consistency. The endoscope could be 
inserted in the colon up to approximately 3-4 cm from the anus. At day 0, endoscopy showed 
a smooth and translucent mucosal surface with a normal blood vessel architecture and solid 
stools as DSS was not yet introduced in the drinking water resulting in a MEICS score of 0 
(figure 4B). Five days after the start of DSS the colon transparency was reduced and the 
mucosa was vulnerable which in some mice resulted in bleedings. At day 8, signs of severe 
inflammation were present. Mice presented with diarrhea and intransparent mucosa with 
moderate granularity and fibrin deposit. The highest MEICS score was reached at day 10. At 
day 12, treatment with 2.0x106 MSCs in spheroids seemed to partially reduce the MEICS score 
compared to PBS treated mice (figure 4B). Body weight, disease activity and colonic TNF-α, 
IFN-ɣ, IL-6 and IL-17a at day 12 are shown in figure 5. 
INTRALUMINAL INJECTION OF MSC SPHEROIDS IN DSS COLITIS 
159 
FIGURE 5 Mice sacrificed at day 12 after endoscopy. DSS was introduced in the drinking water for 7 days. Mice 
received 2.0x106 MSCs in spheroids or PBS via enema at day 5. Mice were sacrificed at day 12 after endoscopic 
evaluation of colonic inflammation at day 0, 5, 8, 10 and 12. Data are expressed as mean ± SEM. n = 9-10 per 
group. (A): Body weights were measured daily and expressed as the percentage of body weight at day 0. (B): 
Disease activity score based on the presence of loose stool, fecal blood and macroscopic inflammation 
determined at sacrifice (day 12). Cytokine levels of (C) IFN-ɣ, (D) TNF-α, (E) IL-6 and (F) IL-17a. 
Local treatment with MSC spheroids results in reduction of some inflammatory mediators 
The systemic marker of inflammation SAA was drastically upregulated when DSS was 
induced indicating a severe colitis (figure 6A). Intraluminal treatment with 2.0x106 MSCs in 
spheroids resulted in a significant reduction of SAA in the serum at sacrifice compared to 
PBS treated mice (p = 0.04; figure 6A). Locally, the number of neutrophils, as reflected by 
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a smooth and translucent mucosal surface with a normal blood vessel architecture and solid 
stools as DSS was not yet introduced in the drinking water resulting in a MEICS score of 0 
(figure 4B). Five days after the start of DSS the colon transparency was reduced and the 
mucosa was vulnerable which in some mice resulted in bleedings. At day 8, signs of severe 
inflammation were present. Mice presented with diarrhea and intransparent mucosa with 
moderate granularity and fibrin deposit. The highest MEICS score was reached at day 10. At 
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FIGURE 5 Mice sacrificed at day 12 after endoscopy. DSS was introduced in the drinking water for 7 days. Mice 
received 2.0x106 MSCs in spheroids or PBS via enema at day 5. Mice were sacrificed at day 12 after endoscopic 
evaluation of colonic inflammation at day 0, 5, 8, 10 and 12. Data are expressed as mean ± SEM. n = 9-10 per 
group. (A): Body weights were measured daily and expressed as the percentage of body weight at day 0. (B): 
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determined at sacrifice (day 12). Cytokine levels of (C) IFN-ɣ, (D) TNF-α, (E) IL-6 and (F) IL-17a. 
Local treatment with MSC spheroids results in reduction of some inflammatory mediators 
The systemic marker of inflammation SAA was drastically upregulated when DSS was 
induced indicating a severe colitis (figure 6A). Intraluminal treatment with 2.0x106 MSCs in 
spheroids resulted in a significant reduction of SAA in the serum at sacrifice compared to 
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FIGURE 6 Attenuated colitis is accompanied by reduced systemic and local inflammatory responses. DSS was 
introduced in the drinking water for 7 days. Mice received 0.5x106 or 2.0x106 MSCs in spheroids or PBS via 
enema at day 5. Mice were sacrificed at day 10. Data are expressed as mean ± SEM. n = 4-8 per DSS-group and 
n = 2 in healthy control group that received 2.0x106 MSCs in spheroids from 2 separate experiments. (A): 
Measurement of systemic inflammation marker serum amyloid A (SAA). (B): Myeloperoxidase (MPO) activity 
was measured in homogenates of the distal colons to evaluate the amount of neutrophils. (C): Number of 
macrophages per mm in the distal colon. n = 2-3 per DSS-group, n = 1 in healthy control group. (D): 
Representative immunohistological sections of mouse colons stained with a F4/80-antibody to reveal 
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in spheroids compared to PBS (p = 0.03; figure 6B). In addition, lower numbers of 
macrophages were observed in the distal colon after MSC spheroids treatment (p = 0.06 for
0.5x106 MSCs in spheroids vs PBS and p = 0.08 for 2.0x106 MSCs in spheroids vs PBS; figure
6C and 6D).
Next, we measured the proinflammatory cytokines locally in the distal colon. In our hands,
the Th1 and Th17-skewing cytokines TNF-α, IFN-ɣ, IL-6 and IL-17a were upregulated in the
experimental colitis compared to normal controls. IFN-ɣ and to a lesser extent TNF-α were 
reduced in the distal colons in colitis after treatment with 2.0x106 MSCs in spheroids (IFN-ɣ,  
p < 0.05; figure 7A and 7B). In addition, the level of local IL-6 was significantly reduced after
treatment with MSC spheroids (p = 0.03 for both 0.5x106 and 2.0x106 MSCs in spheroids vs
PBS; figure 7C). IL-17a was, although not significant, also decreased after MSC spheroid
treatment compared to PBS (figure 7D). IL-2 and IL-4 were not upregulated compared to
healthy control, however treatment with 2.0x106 MSCs in spheroid significantly reduced
both cytokines compared to PBS (figure 7E and 7F). Although MSC spheroid treatment 
reduced inflammatory responses and thereby alleviated colitis, levels of the regulatory
cytokine IL-10 were not elevated compared to PBS or healthy controls (figure 7G). In
addition, FoxP3 staining of the distal colons did not reveal major differences between Tregs 
in the MSC spheroid treated groups and the PBS treated mice (figure 7H).
TNF-α-stimulation of MSC spheroids enhances COX-2 dependent PGE2 secretion in vitro
COX-2 expression and subsequent production of PGE2 in inflamed colons has been identified
as an important factor in the wound healing process in experimental colitis.21, 22 To evaluate
if MSC spheroids produce COX-2 dependent PGE2, we determined COX-2 RNA in MSC
spheroids and PGE2 levels in the supernatant. In addition, MSC spheroids were stimulated
with IL-6 or TNF-α at the start of culture (day -1 in figure 8) since these cytokines were 
significantly elevated in DSS-induced colitis. Adding IL-6 to MSCs at the start of spheroid
induction did not affect the expression of COX-2 RNA (figure 8A). In concordance with this
result, PGE2 levels in the supernatants were comparable to those in non-stimulated MSC
spheroids (figure 8B). When TNF-α was added at the start of spheroid induction, already 1
day later COX-2 RNA expression was increased compared to non- or IL-6 stimulated MSC
spheroids (figure 8A). Moreover, PGE2 levels in the supernatants of TNF-α-stimulated MSC 
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treatment with MSC spheroids (p = 0.03 for both 0.5x106 and 2.0x106 MSCs in spheroids vs 
PBS; figure 7C). IL-17a was, although not significant, also decreased after MSC spheroid 
treatment compared to PBS (figure 7D). IL-2 and IL-4 were not upregulated compared to 
healthy control, however treatment with 2.0x106 MSCs in spheroid significantly reduced 
both cytokines compared to PBS (figure 7E and 7F). Although MSC spheroid treatment 
reduced inflammatory responses and thereby alleviated colitis, levels of the regulatory 
cytokine IL-10 were not elevated compared to PBS or healthy controls (figure 7G). In 
addition, FoxP3 staining of the distal colons did not reveal major differences between Tregs 
in the MSC spheroid treated groups and the PBS treated mice (figure 7H). 
 
TNF-α-stimulation of MSC spheroids enhances COX-2 dependent PGE2 secretion in vitro 
COX-2 expression and subsequent production of PGE2 in inflamed colons has been identified 
as an important factor in the wound healing process in experimental colitis.21, 22 To evaluate 
if MSC spheroids produce COX-2 dependent PGE2, we determined COX-2 RNA in MSC 
spheroids and PGE2 levels in the supernatant. In addition, MSC spheroids were stimulated 
with IL-6 or TNF-α at the start of culture (day -1 in figure 8) since these cytokines were 
significantly elevated in DSS-induced colitis. Adding IL-6 to MSCs at the start of spheroid 
induction did not affect the expression of COX-2 RNA (figure 8A). In concordance with this 
result, PGE2 levels in the supernatants were comparable to those in non-stimulated MSC 
spheroids (figure 8B). When TNF-α was added at the start of spheroid induction, already 1 
day later COX-2 RNA expression was increased compared to non- or IL-6 stimulated MSC 
spheroids (figure 8A). Moreover, PGE2 levels in the supernatants of TNF-α-stimulated MSC 








FIGURE 7 Local treatment with MSC spheroids alters colonic cytokine production. DSS was introduced in the 
drinking water for 7 days. Mice received 0.5x106 or 2.0x106 MSCs in spheroids or PBS via enema at day 5. Mice 
were sacrificed at day 10. Data are expressed as mean ± SEM. n = 4-8 per DSS-group and n = 2 in healthy control 
group that received 2.0x106 MSCs in spheroids from 2 separate experiments. Cytokine levels of (A) IFN-ɣ, (B) 
TNF-α, (C) IL-6 and (D) IL-17a were upregulated after colitis induction with DSS. No differences between healthy 
controls and DSS-colitis mice were observed in the cytokine levels of (E) IL-2, (F) IL-4 and (G) IL-10. (H): 
Representative immunohistological sections of mouse colons stained with a FoxP3-antibody to reveal Tregs 
(arrows). Magnification x20.
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FIGURE 8 TNF-α-stimulation of MSC spheroids enhances COX-2 dependent PGE2 secretion in vitro. Spheroids 
were created in 12-15 96-wells plates with 2,500 MSCs per well resulting in 1152-1440 MSC spheroids per time 
point. Culture medium was centrifuged to get rid of debris and stored. RNA was isolated from the MSC 
spheroids and cDNA was prepared. COX-2 RNA expression was measured in triplicate and normalized to 
GAPDH and PGE2 levels in duplicate. Data are expressed as mean ± SEM. (A): MSC spheroids were created 
without stimulation, with IL-6-stimulation (500 U/ml) or TNF-α-stimulation (500 U/ml) at day -1. Every day MSC 
spheroids were harvested to evaluate COX-2 RNA expression in the MSC spheroids (day 0: *, p = 0.02 no 
stimulation vs TNF-α; *, p = 0.01 IL-6 vs TNF-α; day 1: **, p = 0.002 both no stimulation and IL-6 vs TNF-α; day 2: 
**, p = 0.003 no stimulation vs TNF-α; **, p = 0.002 IL-6 vs TNF-α; day 3: **, p = 0.007 no stimulation vs TNF-α; 
**, p = 0.003 IL-6 vs TNF-α; day 4: *, p = 0.02 no stimulation vs TNF-α; *, p = 0.01 IL-6 vs TNF-α). (B): PGE2-levels 
in culture medium of MSC spheroids stimulated with IL-6, TNF-α or without stimulation (day 0: ns; day 1: ***, 
p = 0.0001 both no stimulation and IL-6 vs TNF-α; day 2: *, p = 0.05 no stimulation vs TNF-α; *, p = 0.03 IL-6 vs 
TNF-α; day 3: **, p = 0.002 no stimulation vs TNF-α; *, p = 0.03 IL-6 vs TNF-α; day 4: ns no stimulation vs TNF-α; 
*, p = 0.05 IL-6 vs TNF-α).  
DISCUSSION 
Recently, MSCs were observed to form aggregates in the peritoneum which produced TSG-
6 and thereby attenuated DSS-induced colitis.16 In addition, in an experimental myocardial 
infarction model intravenously injected MSCs entrapped within the lungs where they also 
formed aggregates that produced TSG-6 resulting in less myocardial damage.17 Not only in 
experimental disease models, but also in healthy state, MSCs tend to spontaneously form 
spheroids.16, 23 Therefore, we hypothesized that the formation of spheroids is important for 
MSCs to gain their immunosuppressive effects. In this present study, we observed that 
intraluminal treatment with in vitro generated MSC spheroids alleviated moderately-severe 
DSS-induced colitis, however, only when a high dose of 2.0x106 MSCs in spheroids was given. 































































FIGURE 7 Local treatment with MSC spheroids alters colonic cytokine production. DSS was introduced in the 
drinking water for 7 days. Mice received 0.5x106 or 2.0x106 MSCs in spheroids or PBS via enema at day 5. Mice 
were sacrificed at day 10. Data are expressed as mean ± SEM. n = 4-8 per DSS-group and n = 2 in healthy control 
group that received 2.0x106 MSCs in spheroids from 2 separate experiments. Cytokine levels of (A) IFN-ɣ, (B) 
TNF-α, (C) IL-6 and (D) IL-17a were upregulated after colitis induction with DSS. No differences between healthy 
controls and DSS-colitis mice were observed in the cytokine levels of (E) IL-2, (F) IL-4 and (G) IL-10. (H): 
Representative immunohistological sections of mouse colons stained with a FoxP3-antibody to reveal Tregs 
(arrows). Magnification x20.
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DSS-induced colitis, however, only when a high dose of 2.0x106 MSCs in spheroids was given. 
































































treatment with 2.0x106 MSCs in spheroids. The percentage of mucosal lesions in the distal 
colon and endoscopy scores were not significantly reduced after MSC spheroid treatment 
which resembles human IBD: clinical remission does not per definition imply histological 
and/or endoscopic remission.24,25 In addition, a retrospective study showed that in patients 
with clinical remission, the presence of mucosal inflammation was not associated with more 
complications or exacerbations during a median follow-up of 6.8 years.26
Biochemically, the systemic marker of inflammation SAA was elevated after DSS-induced 
mucosal damage possibly as a result of bacterial invasion. Similarly to other acute phase 
proteins, SAA is mainly produced in the liver. In addition, SAA is also secreted into the lumen 
by colonic epithelial cells especially in case of inflammation and tissue destruction.27,28 
Locally, SAA can promote IL-6 and TNF-α production by macrophages.29,30 Indeed, both IL-6 
and TNF-α were drastically upregulated after DSS administration. Although not significantly, 
histological evaluation demonstrated that the number of macrophages in the mucosa of the 
distal colon was decreased after local MSC spheroid treatment compared to PBS. Moreover, 
SAA-, IL-6- and TNF-α-levels were reduced. We cannot ensure that IL-6- and TNF-α were only 
produced by macrophages as dendritic cells and T cells are also able to produce these 
cytokines, however, macrophages are identified to be of crucial importance in the innate 
intestinal immunity. Mice deficient for macrophages or depleted for local gut macrophages 
are less susceptibility to experimental colitis than wild type mice.31,32 Moreover, DSS 
administration to lymphocyte-deficient mice leads to the development of colitis, indicating 
that macrophages are the key players in establishing DSS-induced colitis and that 
lymphocytes are of less importance herein.33 In our experiments, IL-17a was elevated in DSS-
induced colitis and dose-dependently reduced after intraluminal treatment with MSC 
spheroids. Since secreted IL-17a is reported to regulate migration of neutrophils to the place 
of inflammation34,35, we examined the amount of neutrophils in the distal colons. The 
amount of neutrophils was significantly lower after intraluminal treatment with 2.0x106 
MSCs in spheroids.  
The exact mechanism of MSC spheroid-mediated attenuation of DSS-induced colitis remains 
partially unclear as no MSC spheroids were found in the colon of treated mice at sacrifice. 
Both MSCs as well as the supernatants from MSCs are reported to be able to reduce the 
levels of IL-6 and TNF-α secreted by activated macrophages and to increase the production 
of IL-10 resulting in the polarisation towards regulatory M2 macrophages.36-38 We observed 
that IL-6 and TNF-α levels, and the number of macrophages in the mucosa of the distal 
colons were reduced, suggesting that in this model at time of sacrifice no regulatory 
macrophages were induced but rather that the number of macrophages was decreased as 
a sign of reduced inflammation after MSC spheroid treatment. In line with these results, an 
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increased recruitment of macrophages to the place of acute myocardial infarction was 
found to facilitate cardiac muscle repair by MSCs as no attenuation of disease was observed 
when macrophage recruitment was diminished or MSCs were removed after local 
macrophage infiltration.39 This indicates that the interaction between MSCs and 
macrophages might be an important factor in restoring cardiac function suggesting that the 
number of local macrophages will be decreased as a sign of attenuated disease when cardiac 
function is restored.  
In our hands, IL-10 levels in homogenates of the distal colons at sacrifice were similar 
between MSC spheroids treated mice and mice that received PBS and not significantly 
elevated compared to healthy controls. Although IL-10 has been described to be of major 
importance in the homeostasis of the colonic milieu40,41, clinical trials using IL-10 as a 
treatment for Crohn’s disease have failed to show superiority of IL-10 therapy.42 In addition, 
MSCs cocultured in vitro with activated NK cells resulted in reduced levels of IL-10.43 On the 
other hand, when MSCs were cocultured in vitro with dendritic cells, IL-10 production was 
elevated.44 In DSS-induced colitis an abundance of distinct immune cells is present, likely 
resulting in more complex interactions between those cells and MSCs compared to the 
‘simple’ interaction of MSCs with only one type of immune cell in in vitro models. Another 
possible explanation for the lack of IL-10 elevation in MSC spheroid treated mice is the time 
of sacrifice. It is possible that IL-10 produced by either MSCs or Tregs is one of the main 
factors involved in the immunosuppressive process mediated by MSCs directly after 
injection. However, we have not sacrificed animals in the first 24 to 48 hours after MSC 
spheroid injection to evaluate this hypothesis. In line with the observed IL-10 levels in the 
homogenates of the distal colons at sacrifice, no apparent differences in the number of 
Tregs were found in the distal colons of mice treated with MSC spheroids compared to PBS 
treated mice.  
MSCs are reported to be able to inhibit Th17 cell differentiation and subsequent IL-17a 
production which was restored when COX-2 was inhibited or PGE2 secretion by MSCs was 
blocked, suggesting that COX-2 dependent PGE2 is at least one of the paracrine factors MSCs 
produce to gain their immunosuppressive effects.45-47 Whether or not direct cell-to-cell 
contact between MSCs and CD4-positive T cells is needed for the suppression of Th17 cell 
differentiation is doubtful as previous published papers are not consistent. In our present 
study, however, we do not assume that direct contact between IL-17a-producing cells and 
intraluminally injected MSC spheroids is the explanation of the alleviated colitis since even 
with scrutinous histological evaluation, we have never observed the intraluminally injected 
MSC-spheroids in the damaged or healed mucosa. In addition, we generated MSC spheroids 
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of sacrifice. It is possible that IL-10 produced by either MSCs or Tregs is one of the main 
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injection. However, we have not sacrificed animals in the first 24 to 48 hours after MSC 
spheroid injection to evaluate this hypothesis. In line with the observed IL-10 levels in the 
homogenates of the distal colons at sacrifice, no apparent differences in the number of 
Tregs were found in the distal colons of mice treated with MSC spheroids compared to PBS 
treated mice.  
MSCs are reported to be able to inhibit Th17 cell differentiation and subsequent IL-17a 
production which was restored when COX-2 was inhibited or PGE2 secretion by MSCs was 
blocked, suggesting that COX-2 dependent PGE2 is at least one of the paracrine factors MSCs 
produce to gain their immunosuppressive effects.45-47 Whether or not direct cell-to-cell 
contact between MSCs and CD4-positive T cells is needed for the suppression of Th17 cell 
differentiation is doubtful as previous published papers are not consistent. In our present 
study, however, we do not assume that direct contact between IL-17a-producing cells and 
intraluminally injected MSC spheroids is the explanation of the alleviated colitis since even 
with scrutinous histological evaluation, we have never observed the intraluminally injected 




with GFP-positive MSCs and injected them intraluminally in mice with DSS-induced colitis and 
these MSCs were not found in the mucosa (figure 9).  
FIGURE 9 MSC spheroids generated with GFP-
positive MSCs. (A): In vitro generated GFP-
positive MSC spheroids were embedded in 
paraffin and stained with an anti-GFP antibody 
(Invitrogen, Bleiswijk, The Netherlands). (B): At 
sacrifice (day 10), colons were embedded in 
paraffin and stained with an anti-GFP antibody. 
Representative images of the colons of mice with 
DSS-induced colitis treated with PBS (left) and 
2.0x106 MSCs in spheroids (right). 
Thus, engraftment of the MSC spheroids in the mucosa does not seem to have occurred. 
Interestingly, supernatants from co-cultures between Th17 cells and MSCs have been 
reported to contain elevated PGE2 levels compared to culture of only CD4-positive T cells or 
MSCs suggesting that this soluble factor is at least one of the key player in the suppressed 
differentiation.47 In addition, spheroid formation was reported to induce increased 
expression of COX-2-dependent PGE2 both in vitro as in vivo.23  In line with those results, we 
observed that MSC spheroids constantly produced considerable but relatively low levels of 
COX-2 and PGE2 in vitro which increased over time especially when stimulated with TNF-α. 
However, in our in vitro model, we started with the priming of MSCs before they aggregated 
into spheroids, whereas in vivo, if at all, stimulation took place after the formation of 
spheroids. Interestingly, TNF-α induces the expression of COX-2 in colonic epithelial cells of 
patients with IBD and mice with DSS colitis thereby promoting epithelial wound healing.48-51 
Wound healing was even impaired in COX-2-/- mice with DSS-induced colitis as a result of an 
inability to increase colonic PGE2.22 Moreover, intraperitoneal administration of PGE2 
restored DSS-induced decrease of proliferating epithelial cells indicating a key role for PGE2 
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inflamed colons possibly resulted in priming of intraluminally injected MSC spheroids to 
produce high amounts of PGE2 subsequently promoting colonic epithelial wound healing 
without engraftment of the spheroids within the damaged mucosa. Supporting our 
hypothesis, rectal administration of basic fibroblast growth factor ameliorated DSS-induced 
colitis by activating COX-2 RNA which resulted in accelerated mucosal healing rather than a 
direct immunosuppressive effect on T cells.21 However, all these hypotheses are made with 
utmost caution since we did not offer direct evidence that supports an interaction between 
the intraluminal injected spheroids and TNF-α and/or the colonic mucosa. In addition, we did 
not evaluate other possible mediators such as TSG-6 and transforming growth factor-beta. 
Taken together, our results demonstrate that intraluminal injection of in vitro generated 
MSC spheroids at least partially attenuate DSS-induced colitis. The dose is important since 
only 2.0x106 MSCs in spheroids resulted in significantly less body weight loss and lower 
disease activity score accompanied by a reduction of systemic inflammation, some colonic 
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Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract which 
can affect any part of the intestine. A frequent manifestation of CD is the formation of 
perianal fistulas which can greatly affect patient’s quality of life due to continuous pain, 
abscess formation and malodourous discharge from the fistula causing skin irritation.1,2,3 
Nowadays, a wide range of medical and surgical therapies for perianal fistulizing CD is 
available. However, achieving complete fistula healing is often a long process preceded by 
multiple relapses during the treatment. Currently, mesenchymal stromal cells (MSCs) have 
gained much interest as a potential therapeutic option for inflammatory disorders, including 
fistulizing CD, because they possess immunosuppressive and tissue regenerative properties. 
Therefore, in this thesis the focus is on the effects of current treatment strategies on fistula 
healing, the safety, feasibility and efficacy of locally injected MSCs in patients with perianal 
fistulizing CD, and the mechanisms by which systemically and locally injected MSCs 
attenuate colitis in experimental mouse models. 
 
CURRENT TREATMENT OPTIONS FOR PERIANAL FISTULIZING CD 
In most patients treatment of perianal fistulas is necessary and drugs, surgery or a 
combination of both is required to achieve fistula closure. Until now, anti-tumor necrosis 
factor (TNF) agents are the most effective medical treatment for the induction and 
maintenance of fistula remission.4-7 In combination with temporary antibiotics higher 
response rates are observed compared to monotherapy with anti-TNF.8,9 However, durable 
remission rates of initially healed fistulas are low after treatment with anti-TNF agents10 and 
surgery is often inevitable. Success rates of the different surgical options such as fibrin glue, 
fistula plug, mucosal advancement flap (MAF) and ligation of the intersphincteric fistula 
tract (LIFT) range from 38 - 71%.11-15 The majority of the included patients in these trials had 
perianal fistulas based on cryptoglandular disease. Perianal fistulas as a manifestation of CD 
have a different etiology than those caused by cryptoglandular disease and often evolve 
into in complex fistulas with presence of rectal inflammation. Therefore, the actual success 
rates of surgery for the closure of perianal fistulas may be lower in case of CD. Indeed, in the 
cohort of 232 patients with perianal fistulas based on CD more than three quarters of the 
patients had complex fistulas (chapter 3). After the conventional treatment strategies, 
simple fistulas healed significantly more often compared to complex fistulas which is in line 
with previous published papers.2,16 In addition, we observed that complex fistulas relapsed 
more often than simple fistulas after a median follow-up of 10 years resulting in a 
disappointing durable remission rate of only 37%. Interestingly, therapy with anti-TNF did not 
result in significantly higher fistula closure rates compared to patients who did not receive 
anti-TNF agents. In this retrospective study patients treated for perianal fistulizing CD from 
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1980 – 2000 were included and followed until 2010. Infliximab was available from 1999 in the 
hospital possibly resulting in a delayed time to treatment in patients with treated for 
perianal fistulas before 1999.  
 
MESENCHYMAL STROMAL CELLS 
A new experimental approach in the treatment of perianal fistulizing CD is cellular therapy 
with mesenchymal stromal cells (MSCs). MSCs have immunomodulatory and tissue 
regenerative capacities making them a potential new treatment option for perianal 
fistulizing CD. MSCs are present in the stroma of almost all solid organs and in the bone 
marrow, and are easily isolated and expanded in culture. An advantage of MSCs is their 
relatively immunological inertness meaning that allogeneic MSCs of healthy donors can be 
used creating the possibility of an ‘off-the-shelf’ treatment potential. In chapter 4 we 
describe the results of our early phase II randomized, double-blind, placebo-controlled 
clinical trial evaluating the use of allogeneic bone marrow-derived MSCs in the treatment of 
perianal fistulizing CD. Only patients refractory for the conventional treatment strategies 
were included. Local administration of MSCs additional to a standardized surgical treatment 
was safe and feasible. Interestingly, higher fistula healing rates were observed when a low 
dose of MSCs was given (1x107 or 3x107) compared to a high dose (9x107) or placebo. A 
similar inverted dose response was observed in both an experimental model and clinical trial 
when MSCs were injected in an ischemic heart.17,18 Whether immunogenicity resulting in 
faster clearance of the cells and/or a lower survival and function of a high dose of MSCs is 
the explanation for this inverted dose response has to be elucidated in further research. 
When 3x107 MSCs were locally administered, 85.7% of the fistulas healed already 6 weeks 
after the injection. Previously published phase I and II trials showed fistula closure rates of 
69-82%.19-23 However, comparison of the results of these studies is difficult as cell source, cell 
number and time of primary endpoint and evaluation were not similar. In addition, in some 
trials fibrin glue was added to the local MSC treatment and multiple injections of MSCs were 
given when fistulas were not healed after some weeks. Furthermore, the location of 
injection of MSCs differed between the studies. Therefore, standardization of the treatment 
procedures is of utmost importance to be able to reliably compare the effect of local MSC 
therapy observed in different clinical trials. In chapter 5 we propose standardized operating 
procedures (SOPs) for the classification of perianal fistulizing CD, the surgical intervention, 
the local therapy administration and follow-up based on the procedures which we applied 
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MSCS: MODE OF ACTION 
Although encouraging results have been obtained in almost all performed clinical trials on 
perianal fistulizing CD, the exact mode of action of MSCs is only partially known. Until now, 
only one animal model of perianal fistulas resembling human perianal fistulizing CD, has 
been described.24 However, only approximately 5% of these mice spontaneously developed 
perianal fistulas making this model unsuitable for evaluation of the mechanisms by which 
MSCs induce immunosuppression in perianal fistulizing disease. Fistulas usually arise at the 
site of distal intestinal inflammation and the effect of MSC treatment at the site of disease 
initiation still needs further exploration. Therefore, we induced experimental colitis in mice 
using dextran sulphate sodium (DSS) or 2,4,6-trinitrobenzenesulfonic acid (TNBS) to 
examine the mode of action of MSCs. Introduction of DSS to the drinking water for 7 days is 
toxic to the gut epithelial cells and breaks the mucosal barrier resulting in diarrhea, weight 
loss and visible fecal blood. This model is useful when studying the innate immune system 
as the adaptive immune system does not play a major role in establishing DSS-induced 
colitis.25 On the other hand, TNBS induces colitis via a Th1-mediated immune response 
resembling CD. TNBS is diluted in ethanol which affects the integrity of the mucosal barrier. 
TNBS then haptenizes the colonic microflora to become immunogenic resulting in 
segmental ulcerations with influx of macrophages and lymphocytes.25  
MSCs can alter cytokine production of distinct immune cells in order to induce an anti-
inflammatory milieu both in vitro and in vivo, however, whether or not MSCs need to be in 
contact with these immune cells to educate them to become tolerant or that the release of 
soluble factors without cell-to-cell contact is their main mechanism of inducing 
immunosuppression, is still under debate.26-29 In addition, various studies showed that MSCs 
are not intrinsically immunosuppressive and that priming with proinflammatory cytokines 
might be necessary to induce their full immunosuppressive capacities. However, ‘over’ or 
‘under’ priming can result in enhancement of the proinflammatory response.30-32 In chapter 
6 we elaborate on the importance of the time of MSC administration in an experimental 
colitis model. Only severe colitis was attenuated after MSC injection indicating the 
importance of an initiated/ongoing inflammation for MSCs to become immunosuppressive. 
The study described in chapter 7 we confirm these observations as MSCs only alleviated 
experimental colitis when injected 5 hours after the establishment of acute colitis, but not 
when mice had a ‘too’ severe colitis. In addition, attenuation of colitis was accelerated when 
MSCs were pretreated in vitro with interferon-gamma (IFNɣ) and TNFα to become i/tMSCs 
before injection in colitic mice. We hypothesize that MSCs have to be licensed in vitro with 
proinflammatory cytokines to gain their full immunomodulatory capacities when 
administrated in vivo. In addition, migration promoting vascular cell adhesion molecule 
SUMMARY AND DISCUSSION 
177 
 
(VCAM) is drastically upregulated after stimulation with IFNɣ and TNFα. Indeed, MSCs with 
downregulated VCAM migrated significantly less to the inflamed colon compared to i/tMSCs 
and were also significantly less capable of attenuating colitis. This is in line with previously 
published research as TNFα promoted migration to the site of tissue damage in different 
experimental models.33,34 In our hands, the addition of IFNɣ even increased the expression 
of VCAM on the surface of MSCs compared to prestimulation solely with TNFα. In addition, 
MSCs downregulated for intracellular inducible nitric oxide synthase (iNOS) or for TNF-
stimulated gene (TSG)-6 also resulted in prolonged colitis although migration capacity to the 
inflamed colon was not diminished. Previously, both iNOS and TSG-6 have been described 
to be highly important in the MSC-mediated immunosuppression.29,35 In conclusion, our 
results suggest that the combination of migration and the upregulation of anti-inflammatory 
factors iNOS and TSG-6 is, at least partially, the mode of action of MSCs in experimental 
colitis. In addition, MSCs were observed to form spherical shaped cell aggregates, i.e. 
spheroids, at the serosal site of the distal colon. Both macrophages and T cells were 
observed within these spheroids suggesting that MSCs were in contact with these immune 
cells. In addition, the MSC spheroids formed a niche by producing collagen. Similar 
observations were recently made by an Italian group.29 The aggregated MSCs they observed 
produced TSG-6 that attenuated colitis, e.g., by upregulating iNOS expressing regulatory 
macrophages. Taken together, MSCs appear to form spheroids that produce collagen to 
create their own niche which possibly increase their immunosuppressive capacities. In that 
niche MSCs are in contact with distinct immune cells possibly resulting in upregulation of 
anti-inflammatory factors iNOS and TSG-6. Increasing migration to the inflamed colon by 
prestimulation with proinflammatory cytokines may accelerate attenuation of colitis as 
increased amounts of MSCs at the place of inflammation may result in the formation of more 
spheroids. We confirmed that in vitro generated MSC spheroids, resembling the MSC 
spheroids observed in vivo, are able to alleviate experimental colitis, as described in chapter 
8. In this model we infused MSC spheroids locally via an enema in order to evaluate the 
effect of MSC administration directly at the place of inflammation. 
 
FUTURE PERSPECTIVES 
The results described in this thesis demonstrate the importance of the moment of MSC 
administration in experimental mouse models. An ongoing inflammation seems to be of 
importance to prime MSCs towards an immunosuppressive phenotype subsequently 
attenuating colitis. Indeed, the recently published phase III trial on autologous adipose-
derived MSCs as a treatment for complex cryptoglandular perianal fistulas (which excluded 
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fibrin glue alone, possibly because the pathogenesis of cryptoglandular fistulas is not based 
on a chronic inflammatory disease such as CD.36 In contrast, we observed that if mice had a 
‘too’ severe colitis, administration of MSCs did not had a therapeutic effect on the disease. 
The latter suggests that in human severe perianal fistulizing CD should possibly not be 
treated solely with MSCs. On the other hand, in our clinical trial, which resulted in a fistula 
healing rate of 85.7% 6 weeks after local injection of 3x107 allogeneic bone marrow-derived 
MSCs, as described in chapter 4, only patients with active perianal fistulizing CD refractory 
to conventional treatment strategies were included indicating that only patients with severe 
fistulas joined the study. Since biologicals such as infliximab, adalimumab and vedolizumab, 
are very expensive, studies to determine the long-term fistula healing rate after local MSC 
administration are needed. In addition, trials evaluating the most effective donor source 
(autologous vs allogeneic; bone marrow-derived vs adipose-derived; young donor vs old 
donor), MSC cell dose, frequency and interval of MSC administration, and treatment 
strategy (injection into the wall or into the lumen of the fistula; with or without addition of 
fibrin glue) are warranted. Currently, the department of Gastroenterology and Hepatology 
at the Leiden University Medical Center plans to initiate a trial using 3x107 allogeneic bone 
marrow-derived MSCs to evaluate the efficacy of this treatment in a larger group of patients 
with refractory perianal fistulizing CD. In addition, patients with refractory rectovaginal 
fistulas will probably be included. Furthermore, a multicenter, randomized, double-blind, 
placebo-controlled phase III trial to evaluate the safety and efficacy of allogeneic adipose-
derived MSCs as a treatment for complex perianal fistulizing CD has been conducted by 
TiGenix. The results of this study are expected to be published at the end of 2015.  
In all published trials MSCs were locally injected in perianal fistulas, probably to ensure a high 
dose of MSCs at the place of inflammation with a lower risk of systemic adverse events 
compared to intravenous (i.v.) injection. In addition, perianal fistulas are more easily 
accessible for local treatment compared to luminal CD. Until now, probably because of the 
latter reason, MSCs were only given i.v. in trials treating patients with luminal CD. Recently, 
Forbes et al.37 performed an open-label study evaluating the efficacy of allogeneic bone 
marrow-derived MSCs in moderate to severe refractory CD. Four i.v. infusions of 2x106 
cells/kg at weekly intervals were given to 15 patients. 53% of the patients were in clinical 
remission 3 weeks after the last injection of MSCs and 80% of the patients showed a clinical 
response to the treatment. In contrast, however, the phase I study from our group using a 
single dose of autologous bone marrow-derived MSC in CD was found to be relatively 
ineffective.38 Several studies have shown that the number of MSCs that specifically home to 
the site of inflammation after systemic injection is low.29,39-41 Therefore, in our preclinical 
study, as described in chapter 8, we infused MSCs locally via an enema at the site of 
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inflammation in mice with DSS-induced colitis. Although intraluminal infusion of MSCs 
resulted in attenuated colitis, we did not observe MSCs in the mucosa when the colons were 
histologically evaluated after sacrifice. Currently, we are examining if MSCs injected 
endoscopically into the wall of the inflamed colon leads to alleviated disease in mice with 
DSS-induced colitis. We hypothesize that by injecting MSCs into the wall of the colon, these 
cells will engraft into the mucosa and possibly enhance their efficacy at the site of 
inflammation. The next step would be to evaluate the safety, feasibility and preliminary 
efficacy of endoscopically injected MSCs into the inflamed areas of the colon in patients with 
localized luminal disease. 
As described in chapter 7, prestimulation of MSCs with proinflammatory cytokines to gain 
their full immunomodulatory abilities resulted in accelerated attenuation of TNBS-induced 
colitis compared to non-prestimulated MSCs. Recently, a case report on the treatment of a 
patient with refractory CD with IFNɣ-prestimulated MSCs was published.42 The patient 
received twice 2x106 cells/kg. Although the authors describe that the infusions were well 
tolerated, the patient had an exacerbation of CD 10 days after the second infusion. Several 
studies have suggested that MSCs can become antigen presenting cells when primed with 
IFNɣ by upregulating MHC class II.43-45 The possibility that these IFNɣ-MSCs had become 
immunogenic is not discussed in this case report except for the fact that an increased 
percentage of natural killer cells was found in the peripheral blood of the patient after the 
second infusion indicating lysis of MSCs by these cells. Methods to enhance the 
immunomodulatory abilities of MSCs other than by priming them with proinflammatory 
cytokines, must be investigated. Recently, MSCs were observed to spontaneously 
aggregate into spheroid-like structures after systemic infusion (chapter 7).29,46 In vitro, 
clustering of MSCs resulted in enhanced expression of immunomodulatory proteins such as 
PGE2 and TSG-6 which might lead to improved therapeutic efficacy.47,48 Therefore, more 
preclinical studies to investigate role of MSC aggregation in establishing the 
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ZIEKTE VAN CROHN 
De ziekte van Crohn is een chronische ontstekingsziekte van de darm.  Elk deel van de darm 
kan meedoen in de ontsteking: van mond tot kont. Patiënten kunnen klachten krijgen van 
buikpijn, diarree met of zonder bloed- en slijmbijmenging, misselijkheid, braken, koorts, 
gewichtsverlies en vermoeidheid. De oorzaak van de ziekte van Crohn is nog niet geheel 
duidelijk. Het is wel duidelijk dat het afweersysteem, dat ons beschermd tegen indringers 
als bacteriën en virussen, bij patiënten met de ziekte van Crohn overactief is en daardoor 
het eigen darmweefsel aanvalt waardoor een ontsteking ontstaat met als gevolg schade 
aan de darm. Ook spelen een aantal genen en omgevingsfactoren, zoals het wonen in een 
welvarend westers land, een belangrijke rol. De ziekte van Crohn wordt meestal vastgesteld 
als de patiënt een leeftijd van 15-30 jaar heeft. Een tweede piekleeftijd ligt rond de leeftijd 
van 60 jaar. Elk jaar krijgen naar schatting 6-15 op de 100.000 mensen de diagnose ziekte van 
Crohn in Europa. Er is geen verschil in voorkomen tussen mannen en vrouwen. De diagnose 
wordt vastgesteld door middel van endoscopisch onderzoek (van de dikke darm en begin 
van de dunne darm, en soms ook van de slokdarm, maag en twaalfvingerige darm) waarbij 
kleine hapjes uit de darm genomen kunnen worden. De diagnose wordt veelal tijdens de 
scopie vastgesteld. Soms kunnen hapjes uit de darm helpen bij het stellen van de diagnose. 
Helaas zijn er nog geen medicijnen die de ziekte van Crohn kunnen genezen. Wel zijn er 
medicijnen die de ziekte rustig kunnen maken en houden. In dat geval is de ziekte in remissie. 
 
PERIANALE FISTELS 
Een van de veel voorkomende complicaties van de ziekte van Crohn is het ontstaan van 
fistels. Een fistel, ook wel pijpzweer genoemd, is een abnormale gang tussen twee holle 
organen of een tussen een hol orgaan en de huid die er niet hoort te zijn. Ongeveer 35% van 
alle patienten met de ziekte van Crohn krijgt tenminste eenmaal een fistel. In meer dan de 
helft van deze patienten gaat het om een perianale fistel. Waarom sommige patienten wel 
een perianale fistel ontwikkelen en anderen niet is nog niet helemaal duidelijk. Wel weten 
we dat het hebben van bepaalde genen, de aanwezigheid van bepaalde bacteriën in de darm 
en het immuunsysteem belangrijke factoren zijn in het ontstaan van een perianale fistel. 
Patienten met een perianale fistel hebben klachten van pijn rond de anus, continue 
(stinkende) pus afvloed en/of ontlasting uit de fistel en ophoping van pus op één plek in de 
fistelgang (abces) met daarbij koorts. In het geval van een abces moet de patiënt direct naar 






BEHANDELING PERIANALE FISTELS 
Helaas is de kans dat een fistel spontaan dicht gaat heel klein. Daarom hebben de meeste 
patiënten medicijnen en/of een chirurgische behandeling nodig. Allereerst is het belangrijk 
dat de ziekte van Crohn in de darm rustig wordt. Hiervoor werkt het medicijn tegen tumor 
necrosis factor-alpha (TNFα) het beste. TNFα is een stofje dat zorgt voor het ontstaan en 
onderhouden van een ontsteking. In het geval van patiënten met de ziekte van Crohn is er 
veel meer TNFα in de darm aanwezig dan bij gezonde personen. Het medicijn anti-TNFα 
bindt zich aan TNFα in de darm en zorgt ervoor dat het niet meer actief is waardoor de 
ontsteking idealiter verminderd. Helaas werkt dit medicijn niet bij alle patiënten met de 
ziekte van Crohn. Ook heeft anti-TNFα een positief effect op de genezing van perianale 
fistels. Het tijdelijk combineren van anti-TNFα en antibiotica geeft soms een sneller resultaat 
dan anti-TNFα alleen. Helaas blijven veel perianale fistels na genezing niet langdurig 
gesloten en worden ze opnieuw actief. Dan is chirurgisch ingrijpen vaak niet te voorkomen. 
Een complicatie van chirurgie is dat de patiënt incontinent voor ontlasting kan raken omdat 
door de operatie de kringspieren van de anus beschadigd kunnen raken. Het is dus van 
belang om voorafgaand aan de operatie precies te weten wat de route van de fistel van 
endeldarm naar anus is en of de fistel door de kringspieren loopt. Het percentage fistels dat 
langdurig dicht blijft na operatie varieert, maar 100% wordt tot nu toe niet gehaald. In 
hoofdstuk 3 van dit proefschrift beschrijven we de resultaten van onze studie naar de 
langdurige genezing van perianale fistels bij patiënten met de ziekte van Crohn. Van de 232 
patiënten had 78% complexe perianale fistels. Dit betekent o.a., in tegenstelling tot simpele 
perianale fistels, dat er meerdere fistels aanwezig waren, de hoofdfistel aftakkingen had, de 
opening hoger in de endeldarm zat, de patiënten ook abcessen had en/of dat er ontsteking 
in de endeldarm aanwezig was. Deze factoren maken de behandeling van een perianale 
fistel lastiger dan de behandeling van een simpele fistel. In dit onderzoek hebben we gezien 
dat complexe perianale fistels die na gebruik van medicatie en/of een chirurgische 
behandeling in eerste instantie gesloten waren, na een mediane follow-up van 10 jaar nog 
maar in 37% van de gevallen genezen was. Daarom hebben wij onderzoek gedaan naar een 
potentieel nieuw medicijn voor de behandeling van perianale fistels bij de ziekte van Crohn: 
mesenchymale, bindweefsel-achtige, stamcellen. 
 
MESENCHYMALE STAMCELLEN (MSCS) 
MSCs zijn stamcellen die in bijna alle weefsels en in het beenmerg voorkomen. Deze 
stamcellen kunnen veranderen tot de belangrijkste cellen in het weefsel waarin ze zitten als 
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MSCs nog meer kunnen. Ze kunnen het afweersysteem onderdrukken en zo een ontsteking 
remmen en ze kunnen helpen met het repareren van beschadigd weefsel. Dit maakt MSCs 
mogelijk een interessante nieuwe optie voor de behandeling van perianale fistels bij de 
ziekte van Crohn. In hoofdstuk 4 staat de studie beschreven waarin we hebben gekeken of 
MSCs inderdaad perianale fistels bij de ziekte van Crohn kunnen genezen. We hebben 21 
patiënten in de studie opgenomen die niet hebben gereageerd op alle conventionele 
behandelmogelijkheden die er momenteel voor perianale fistels zijn. De fistels van deze 
patiënten hebben we tijdens een operatie uitgeschraapt met een scherp lepeltje en de 
opening in de endeldarm en op de bil omsneden zodat er een wond ontstaat die met behulp 
van de MSCs moet genezen. De opening in de endeldarm is dichtgemaakt met hechtingen, 
zodat er geen pus of ontlasting door de fistel naar buiten kan. In de darmwand rondom deze 
gesloten opening zijn de MSCs ingespoten. We hebben de patiënten ingedeeld in 4 groepen 
op basis van de dosis van de MSCs: 10 miljoen (groep 1; 5 patiënten), 30 miljoen (groep 2; 5 
patiënten) of 90 miljoen (groep 3; 5 patiënten) MSCs of placebo (groep 4; 6 patiënten). We 
hebben gezien dat de chirurgische behandeling en de lokale injectie met MSCs veilig was en 
dat 85.7% van de fistels dicht is gegaan na lokale behandeling met 30 miljoen MSCs ten 
opzichte van 33.3% na behandeling met placebo. Verrassend was dat meer niet altijd beter 
is: injectie van 90 miljoen MSCs resulteerde in een vergelijkbaar percentage gesloten fistels 
als injectie met placebo. Eerder gepubliceerde klinische studies laten genezing van perianale 
fistels zien in 69-82% van de patiënten na MSC toediening. Echter zijn niet alle studies 
hetzelfde uitgevoerd. Het aantal ingespoten MSCs, het weefsel waaruit de MSCs zijn 
geoogst en het tijdspunt van evaluatie waren niet gelijk in de verschillende studies. Ook de 
chirurgische procedure en de plaats van lokale injectie van MSCs verschilt per studie. 
Daarom hebben we in hoofdstuk 5 een gestandardiseerd protocol voor lokale behandeling 
van perianale fistels voorgesteld, op basis van onze studie beschreven in hoofdstuk 4. 
 
WERKINGSMECHANISME VAN MSCS 
Ondanks dat meerdere klinische studies positieve effecten van lokale MSC behandeling op 
de genezing van perianale fistels hebben laten zien, weten we nog niet precies wat het 
werkingsmechanisme van MSCs is. In hoofdstuk 6 laten we de resultaten van een studie in 
een experimenteel muismodel zien, dat lijkt op de ziekte van Crohn, waarin het moment van 
injectie en de ernst van de ontsteking belangrijke factoren zijn voor het slagen van MSC 
behandeling. In hoofdstuk 7 gaan we dieper in op de migratie van MSCs naar de ontstoken 
darm. We hebben gezien dat het aantal MSCs dat naar de darm migreert hoger is wanneer 
er een ontsteking is dan wanneer de darm gezond is. Als de MSCs voor het inspuiten in de 




stofjes die zorgen voor het ontstaan en onderhouden van een ontsteking, is het aantal MSCs 
dat migreert naar de ontstoken darm nog veel hoger dan wanneer ‘normale’ 
ongeactiveerde MSCs worden ingespoten. We denken dat dit is omdat deze MSCs al voordat 
ze in de zieke muis worden ingespoten, het idee hebben dat ze in een ontstekingsmilieu zijn 
en daarom bij injectie direct afweersysteem-onderdrukkend gaan werken. Daarbij komt dat 
de productie van de ontstekingsremmende factoren inducible nitric oxide synthase (iNOS) 
en TNF-stimulated gene (TSG)-6 door MSCs verhoogd is na activatie met IFNɣ en TNFα. Uit 
dit onderzoek blijkt dat de verhoogde expressie van vascular cell adhesion molecule (VCAM) 
op de oppervlakte van MSCs na activatie met IFNɣ en TNFα de verklaring is voor de 
verhoogde migratie naar de ontstoken darm. Door middel van histologisch onderzoek 
hebben we ontdekt dat de MSCs die naar de ontstoken darm zijn gemigreerd 
gestructureerde ‘bollen’ vormen, mogelijk om hun afweersysteem-onderdrukkende 
werking te verhogen. Deze bollen hebben we sferoïden genoemd. In hoofdstuk 8 staan de 
resultaten beschreven van een studie waarin we sferoïden, die lijken op de sferoïden die we 
in de muizen hebben gevonden, hebben gemaakt in het laboratorium. Deze sferoïden 
hebben we in een experimenteel muismodel, dat lijkt op de ziekte van Crohn, lokaal via een 
klysma ingebracht zodat de sferoïden precies daar waar de ontsteking zich bevindt, werden 
geïnfuseerd. We zagen dat MSC sferoïden de ontsteking in de darm verminderden. 
 
DE TOEKOMST 
Tot op heden zijn alle gepubliceerde studies met kleine aantallen patiënten en vaak weten 
de artsen en/of de patiënten of ze MSCs hebben gehad of een andere behandeling (open-
label). Onze studie zoals besproken in hoofdstuk 4 is dubbel-blind uitgevoerd: zowel de arts 
die de patiënt terug ziet na de operatie als de patiënt weet niet of de patiënt MSCs of 
placebo heeft gekregen. Het voordeel hiervan is dat de patiënt tijdens de follow-up 
bezoeken eerlijk vertelt hoe hij/zij zich voelt en de arts dit ook precies zo opschrijft zonder 
het bijvoorbeeld rooskleuriger te maken indien er MSCs gegeven zijn. Een ander pluspunt 
aan ons uitgevoerde onderzoek is dat dit de eerste studie is die een ‘echte’ placebo heeft 
meegenomen. Andere studies hebben vaak een andere bestaande behandeling voor 
perianale fistels als placebo gebruikt. Echter, voordat MSCs als standaard behandeling aan 
patiënten in het ziekenhuis gegeven kunnen worden, is het van belang dat er grotere 
klinische studies plaatsvinden waarin niet alleen moet worden uitgezocht hoe effectief 
MSCs zijn, maar ook hoeveel MSCs en hoe vaak MSCs geinjecteerd moeten worden. 
Momenteel zijn er bij de afdeling Maag-, Darm- en Leverziekten van het LUMC plannen tot 
een vervolgstudie en heeft TiGenix een grote dubbel-blinde, placebo-gecontrolleerde studie 
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is: injectie van 90 miljoen MSCs resulteerde in een vergelijkbaar percentage gesloten fistels 
als injectie met placebo. Eerder gepubliceerde klinische studies laten genezing van perianale 
fistels zien in 69-82% van de patiënten na MSC toediening. Echter zijn niet alle studies 
hetzelfde uitgevoerd. Het aantal ingespoten MSCs, het weefsel waaruit de MSCs zijn 
geoogst en het tijdspunt van evaluatie waren niet gelijk in de verschillende studies. Ook de 
chirurgische procedure en de plaats van lokale injectie van MSCs verschilt per studie. 
Daarom hebben we in hoofdstuk 5 een gestandardiseerd protocol voor lokale behandeling 
van perianale fistels voorgesteld, op basis van onze studie beschreven in hoofdstuk 4. 
 
WERKINGSMECHANISME VAN MSCS 
Ondanks dat meerdere klinische studies positieve effecten van lokale MSC behandeling op 
de genezing van perianale fistels hebben laten zien, weten we nog niet precies wat het 
werkingsmechanisme van MSCs is. In hoofdstuk 6 laten we de resultaten van een studie in 
een experimenteel muismodel zien, dat lijkt op de ziekte van Crohn, waarin het moment van 
injectie en de ernst van de ontsteking belangrijke factoren zijn voor het slagen van MSC 
behandeling. In hoofdstuk 7 gaan we dieper in op de migratie van MSCs naar de ontstoken 
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stofjes die zorgen voor het ontstaan en onderhouden van een ontsteking, is het aantal MSCs 
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DE TOEKOMST 
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die de patiënt terug ziet na de operatie als de patiënt weet niet of de patiënt MSCs of 
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patiënten in het ziekenhuis gegeven kunnen worden, is het van belang dat er grotere 
klinische studies plaatsvinden waarin niet alleen moet worden uitgezocht hoe effectief 
MSCs zijn, maar ook hoeveel MSCs en hoe vaak MSCs geinjecteerd moeten worden. 
Momenteel zijn er bij de afdeling Maag-, Darm- en Leverziekten van het LUMC plannen tot 
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